<html class="gs_el_sm gs_pfcs"><head><title>‪Nicola Curtin‬ - ‪Google Scholar‬</title><meta http-equiv="Content-Type" content="text/html;charset=UTF-8"><meta http-equiv="X-UA-Compatible" content="IE=Edge"><meta name="referrer" content="origin-when-cross-origin"><meta name="viewport" content="width=device-width,initial-scale=1,minimum-scale=1,maximum-scale=2"><meta name="format-detection" content="telephone=no"><link rel="shortcut icon" href="/favicon.ico"><link rel="canonical" href="https://scholar.google.co.uk/citations?user=FhFQsc8AAAAJ&amp;hl=en"><meta name="description" content="‪Newcastle University‬ - ‪‪Cited by 21,125‬‬ - ‪Oncology‬ - ‪DNA damage response‬"><meta property="og:description" content="‪Newcastle University‬ - ‪‪Cited by 21,125‬‬ - ‪Oncology‬ - ‪DNA damage response‬"><meta property="og:title" content="Nicola Curtin"><meta property="og:image" content="https://scholar.googleusercontent.com/citations?view_op=medium_photo&amp;user=FhFQsc8AAAAJ&amp;citpid=1"><meta property="og:type" content="website"><meta name="twitter:card" content="summary"><style>html,body,form,table,div,h1,h2,h3,h4,h5,h6,img,ol,ul,li,button{margin:0;padding:0;border:0;}table{border-collapse:collapse;border-width:0;empty-cells:show;}html,body{height:100%}#gs_top{position:relative;box-sizing:border-box;min-height:100%;min-width:964px;-webkit-tap-highlight-color:rgba(0,0,0,0);}#gs_top>*:not(#x){-webkit-tap-highlight-color:rgba(204,204,204,.5);}.gs_el_ph #gs_top,.gs_el_ta #gs_top{min-width:320px;}#gs_top.gs_nscl{position:fixed;width:100%;}body,td,input,button{font-size:13px;font-family:Arial,sans-serif;line-height:1.24;}body{background:#fff;color:#222;-webkit-text-size-adjust:100%;-moz-text-size-adjust:none;}.gs_gray{color:#777777}.gs_red{color:#dd4b39}.gs_grn{color:#006621}.gs_lil{font-size:11px}.gs_med{font-size:16px}.gs_hlt{font-weight:bold;}a:link{color:#1a0dab;text-decoration:none}a:visited{color:#660099;text-decoration:none}a:hover,a:hover .gs_lbl{text-decoration:underline}a:active,a:active .gs_lbl,a .gs_lbl:active{color:#d14836}.gs_el_tc a:hover,.gs_el_tc a:hover .gs_lbl{text-decoration:none}.gs_pfcs a:focus,.gs_pfcs button:focus,.gs_pfcs input:focus,.gs_pfcs label:focus{outline:none}.gs_a,.gs_a a:link,.gs_a a:visited{color:#006621}.gs_a a:active{color:#d14836}a.gs_fl:link,.gs_fl a:link{color:#1a0dab}a.gs_fl:visited,.gs_fl a:visited{color:#660099}a.gs_fl:active,.gs_fl a:active{color:#d14836}.gs_fl{color:#777777}.gs_ctc,.gs_ctu{vertical-align:middle;font-size:11px;font-weight:bold}.gs_ctc{color:#1a0dab}.gs_ctg,.gs_ctg2{font-size:13px;font-weight:bold}.gs_ctg{color:#1a0dab}a.gs_pda,.gs_pda a{padding:7px 0 5px 0}.gs_alrt{background:#f9edbe;border:1px solid #f0c36d;padding:0 16px;text-align:center;box-shadow:0 2px 4px rgba(0,0,0,.2);border-radius:2px;}.gs_spc{display:inline-block;width:12px}.gs_br{width:0;font-size:0}.gs_ibl{display:inline-block;}.gs_scl:after{content:"";display:table;clear:both;}.gs_ind{padding-left:8px;text-indent:-8px}.gs_ico,.gs_icm{display:inline-block;background:no-repeat url(/intl/en/scholar/images/1x/sprite_20161020.png);background-position:-23px -161px;background-size:169px;width:21px;height:21px;}@media(-webkit-min-device-pixel-ratio:1.5),(min-resolution:144dpi){.gs_ico,.gs_icm{background-image:url(/intl/en/scholar/images/2x/sprite_20161020.png);}}.gs_el_ta .gs_nta,.gs_ota,.gs_el_ph .gs_nph,.gs_oph{display:none}.gs_el_ta .gs_ota,.gs_el_ph .gs_oph{display:inline}.gs_el_ta div.gs_ota,.gs_el_ph div.gs_oph{display:block}.gs_sth_g{visibility:hidden;max-height:0;}.gs_sth_vis .gs_sth_g{max-height:1000px;}.gs_sth_vis .gs_sth_b{position:fixed;top:0;}@keyframes gs_anm_spin{0%{transform:rotate(0deg);}100%{transform:rotate(360deg);}}.gs_rimg{display:block;background-color:#e5e5e5;border-radius:50%;overflow:hidden;position:relative;z-index:1;}.gs_rimg>img{position:absolute;margin:auto;left:0;top:0;bottom:0;right:0;}.gs_in_txtw{display:inline-block;vertical-align:middle;}.gs_in_txtb{display:block;}.gs_in_txt{color:#000;background-color:#fff;font-size:16px;box-sizing:border-box;height:29px;line-height:23px;border:1px solid #d9d9d9;border-top-color:#c0c0c0;padding:3px 6px 1px 8px;border-radius:1px;outline:none;-webkit-appearance:none;-moz-appearance:none;}.gs_el_tc .gs_in_txt{font-size:18px;}.gs_in_txtb .gs_in_txt{width:100%;}.gs_in_txt:hover{border-color:#b9b9b9;border-top-color:#a0a0a0;box-shadow:inset 0 1px 2px rgba(0,0,0,.1);}.gs_in_txte .gs_in_txt{border-color:#dd4b39;}.gs_in_txt:focus{border-color:#4d90fe;box-shadow:inset 0 1px 2px rgba(0,0,0,.3);}.gs_in_txt:disabled{color:#b8b8b8;border-color:#f1f1f1;box-shadow:none;}.gs_in_txtm .gs_in_txt{font-size:13px;height:24px;line-height:16px;padding:3px 6px;}.gs_el_tc .gs_in_txtm .gs_in_txt{height:29px;line-height:21px;}.gs_in_txts{font-size:13px;line-height:18px;color:#666;}.gs_in_txte .gs_in_txts{color:#dd4b39;}button{position:relative;z-index:1;box-sizing:border-box;font-size:13px;cursor:pointer;height:29px;line-height:normal;min-width:72px;padding:0 8px;color:#444;border:1px solid rgba(0,0,0,.1);border-radius:3px;text-align:center;background-color:#f5f5f5;-webkit-user-select:none;user-select:none;}button.gs_btn_rnd{border-radius:14px;padding:0 12px;}button.gs_btn_rnd.gs_btn_rndci{padding-left:4px;}button.gs_btn_lrge{height:41px;min-width:82px;padding:0 9px;}button.gs_btn_lrge.gs_btn_rnd{border-radius:20px;padding:0 16px;}button.gs_btn_lrge.gs_btn_rnd.gs_btn_rndci{padding-left:10px;}button.gs_btn_cir{border-radius:14.5px;min-width:29px;}button.gs_btn_lrge.gs_btn_cir{border-radius:20.5px;min-width:41px;}button.gs_btn_mini{padding:0;border:0;}.gs_el_ph button.gs_btn_mph,.gs_el_ta button.gs_btn_mta{height:41px;}button .gs_wr{position:relative;display:inline-block;width:100%;height:100%;}button .gs_wr:before{content:"";width:0;height:100%;}button .gs_wr:before,button .gs_ico,button .gs_rdt,button .gs_lbl,button .gs_icm{display:inline-block;vertical-align:middle;}button .gs_wr{font-size:13px;text-transform:none;}.gs_btn_lrge .gs_wr{font-size:15px;}.gs_btn_lsb .gs_wr{font-size:11px;font-weight:bold;}.gs_btn_lsu .gs_wr{font-size:11px;text-transform:uppercase;}.gs_btn_lrge.gs_btn_lsb .gs_wr,.gs_btn_lrge.gs_btn_lsu .gs_wr{font-size:13px;}.gs_btn_half,.gs_el_ta .gs_btn_hta,.gs_el_ph .gs_btn_hph{min-width:36px;}.gs_btn_lrge.gs_btn_half,.gs_el_ta .gs_btn_lrge.gs_btn_hta,.gs_el_ph .gs_btn_lrge.gs_btn_hph,.gs_el_ta .gs_btn_mta,.gs_el_ph .gs_btn_mph{min-width:41px;}.gs_btn_slt{border-radius:3px 0 0 3px;}.gs_btn_srt{margin-left:-1px;border-radius:0 3px 3px 0;}.gs_btn_smd{margin-left:-1px;border-radius:0;}button:hover{z-index:2;color:#222;border-color:rgba(0,0,0,.2);background-color:#f8f8f8;}button.gs_sel{background-color:#dcdcdc;}button:active{z-index:2;background-color:#f1f1f1;}button:focus{z-index:2;}button::-moz-focus-inner{padding:0;border:0}button:-moz-focusring{outline:1px dotted ButtonText}.gs_pfcs button:-moz-focusring{outline:none}a.gs_in_ib{position:relative;display:inline-block;line-height:16px;padding:6px 0 7px 0;-webkit-user-select:none;user-select:none;}a.gs_btn_lrge{height:40px;padding:0;}a.gs_in_ib .gs_lbl{display:inline-block;padding-left:21px;color:#222;}a.gs_in_ib .gs_lbl:not(:empty){padding-left:29px;}button.gs_in_ib .gs_lbl:not(:empty){padding-left:4px;}a.gs_in_ib:active .gs_lbl,a.gs_in_ib .gs_lbl:active,a.gs_in_ib :active~.gs_lbl{color:#d14836;}.gs_el_ta .gs_btn_hta .gs_lbl,.gs_el_ph .gs_btn_hph .gs_lbl,.gs_el_ta .gs_btn_mta .gs_lbl,.gs_el_ph .gs_btn_mph .gs_lbl,.gs_el_ta .gs_btn_cta .gs_lbl,.gs_el_ph .gs_btn_cph .gs_lbl{display:none;}a.gs_in_ib .gs_ico{position:absolute;top:3px;left:0;}.gs_in_ib.gs_md_li .gs_ico{left:14px;}.gs_el_tc .gs_in_ib.gs_md_li .gs_ico{top:11px;}.gs_in_ib.gs_md_li.gs_md_lix .gs_ico{top:10px;left:16px;}a.gs_btn_lrge .gs_ico{top:50%;left:50%;margin:-10.5px 0 0 -10.5px;}.gs_in_ib .gs_ico{opacity:.55;}.gs_in_ib:hover .gs_ico{opacity:.72;}.gs_in_ib:active .gs_ico,.gs_in_ib .gs_ico:active,.gs_in_ib :active~.gs_ico{opacity:1;}.gs_in_ib:disabled .gs_ico,.gs_in_ib.gs_dis .gs_ico{opacity:.28;}.gs_in_ib.gs_btn_act .gs_ico,.gs_in_ib.gs_btn_cre .gs_ico{opacity:1;}.gs_btn_act:disabled .gs_ico,.gs_btn_cre:disabled .gs_ico{opacity:.72;}.gs_rdt{position:relative;width:0;height:21px;}.gs_rdt:before{content:"";position:absolute;top:2px;right:1px;width:5px;height:5px;border-radius:50%;background-color:#dd4b39;}button.gs_btn_flat{border-color:transparent;background-color:transparent;}button.gs_btn_flat:hover{background-color:rgba(0,0,0,.05);}button.gs_btn_flat:active{background-color:rgba(0,0,0,.1);}button.gs_btn_flat.gs_btn_flact{color:#1a0dab;}button.gs_btn_act{color:#fff;-webkit-font-smoothing:antialiased;background-color:#4d90fe;}button.gs_btn_act:hover{color:#fff;background-color:#3983fe;}button.gs_btn_act.gs_sel{background-color:#2f6bcc;}button.gs_btn_act:active{background-color:#357ae8;}button.gs_btn_cre{color:#fff;-webkit-font-smoothing:antialiased;background-color:#d14836;}button.gs_btn_cre:hover{color:#fff;background-color:#c53727;}button.gs_btn_cre.gs_sel{background-color:#992b1e;}html:not(.gs_pfcs) .gs_btn_act:focus:not(:active){box-shadow:inset 0 0 0 1px rgba(255,255,255,.5);}button.gs_btn_cre:active{background-color:#b0281a;}button:disabled,button:disabled:hover,button:disabled:active{cursor:default;color:#b8b8b8;border-color:rgba(0,0,0,.05);background-color:transparent;z-index:0;}button.gs_btn_flat:disabled{color:#b8b8b8;border-color:transparent;}button.gs_btn_act:disabled{color:#fff;background-color:#a6c8ff;}button.gs_btn_cre:disabled{color:#fff;background-color:#e8a49b;}a.gs_in_ib.gs_dis{cursor:default;pointer-events:none}a.gs_in_ib.gs_dis .gs_lbl{color:#b8b8b8;text-decoration:none}.gs_ttp{position:absolute;top:100%;right:50%;z-index:10;pointer-events:none;visibility:hidden;opacity:0;transition:visibility 0s .13s,opacity .13s ease-out;}button:hover .gs_ttp,button:focus .gs_ttp,a:hover .gs_ttp,a:focus .gs_ttp{transition:visibility 0s .3s,opacity .13s ease-in .3s;visibility:visible;opacity:1;}.gs_md_tb.gs_sel .gs_ttp{transition:none;visibility:hidden;}button.gs_btn_lrge.gs_btn_cir .gs_ttp{top:75%;}.gs_ttp .gs_aro,.gs_ttp .gs_aru{position:absolute;top:-2px;right:-5px;width:0;height:0;line-height:0;font-size:0;border:5px solid transparent;border-top:none;border-bottom-color:#595959;z-index:1;}.gs_ttp .gs_aro{top:-3px;right:-6px;border-width:6px;border-top:none;border-bottom-color:white;}.gs_ttp .gs_txt{display:block;position:relative;top:2px;right:-50%;padding:4px 6px;background:#595959;color:white;font-size:11px;font-weight:bold;line-height:normal;white-space:nowrap;border:1px solid white;border-radius:3px;box-shadow:inset 0 1px 4px rgba(0,0,0,.2);}.gs_press,.gs_in_se,.gs_tan{touch-action:none;}.gs_in_se .gs_lbl:not(:empty){padding-right:14px;}.gs_in_se .gs_icm{position:absolute;top:50%;margin-top:-5.5px;right:0;width:7px;height:11px;background-position:-21px -88px;opacity:.55;}.gs_in_se:hover .gs_icm{opacity:.72;}.gs_in_se:active .gs_icm{opacity:1;}.gs_in_se:disabled .gs_icm{opacity:.28;}.gs_el_ta .gs_btn_hta .gs_icm,.gs_el_ph .gs_btn_hph .gs_icm,.gs_el_ta .gs_btn_mta .gs_icm,.gs_el_ph .gs_btn_mph .gs_icm,.gs_el_ta .gs_btn_cta .gs_icm,.gs_el_ph .gs_btn_cph .gs_icm{display:none;}.gs_btn_mnu .gs_icm{margin-top:-3.5px;height:7px;background-position:0 -110px;}.gs_in_se.gs_btn_act .gs_icm,.gs_in_se.gs_btn_cre .gs_icm{margin-top:-3.5px;height:7px;background-position:-42px -44px;opacity:1;}.gs_btn_act:disabled .gs_icm,.gs_btn_cre:disabled .gs_icm{opacity:.72;}button.gs_btnG .gs_ico{width:21px;height:21px;background-position:-92px -253px;}button .gs_bs{position:absolute;top:50%;left:50%;margin-top:-10px;margin-left:-10px;box-sizing:border-box;width:20px;height:20px;border-radius:50%;border:2px solid #eee;border-top-color:#4d90fe;visibility:hidden;animation:gs_anm_spin .8s linear infinite;}button.gs_bsp .gs_bs{visibility:visible;transition:visibility 0s .4s;}.gs_md_d{text-transform:none;white-space:nowrap;position:absolute;top:0;left:0;border:1px solid #ccc;border-color:rgba(0,0,0,.2);background:#fff;box-shadow:0 2px 4px rgba(0,0,0,.2);z-index:1100;text-align:left;visibility:hidden;max-height:0;margin-top:-1000px;opacity:0;transition:opacity .13s,visibility 0s .13s,max-height 0s .13s,margin-top 0s .13s;}.gs_md_d.gs_vis{visibility:visible;max-height:10000px;margin-top:0;opacity:1;transition:all 0s;}.gs_el_tc .gs_md_d{transform-origin:100% 0;transform:scale(1,0);transition:opacity .218s ease-out,transform 0s .218s,visibility 0s .218s,max-height 0s .218s,margin-top 0s .218s;}.gs_el_ios .gs_md_d{-webkit-backface-visibility:hidden;}.gs_el_tc .gs_md_d.gs_ttzi{transform-origin:50% 50%;transform:scale(0,0);}.gs_el_tc .gs_md_d.gs_ttzr{transform:scale(0,0);}.gs_el_tc .gs_md_d.gs_vis{transform:scale(1,1);transition:transform .218s ease-out;}.gs_md_r{position:relative;display:inline-block;}.gs_md_rmb>.gs_md_d{top:29px}.gs_md_rmbl>.gs_md_d{top:41px}.gs_md_ul{list-style-type:none;word-wrap:break-word;display:inline-block;vertical-align:top;}.gs_md_ul.gs_md_ul_tb{display:block;}.gs_md_li,.gs_in_cb.gs_md_li,.gs_md_li:link,.gs_md_li:visited{display:block;padding:6px 44px 6px 16px;font-size:13px;line-height:16px;color:#222;cursor:pointer;text-decoration:none;position:relative;z-index:0;}a.gs_md_li:hover .gs_lbl,a.gs_md_li:active .gs_lbl{text-decoration:none}.gs_el_tc .gs_md_li{padding-top:14px;padding-bottom:10px;}.gs_md_li.gs_md_lix{font-size:16px;line-height:20px;padding:12px 16px 8px 16px;}.gs_md_li:before{content:"";background-color:#f1f1f1;position:absolute;left:0;right:0;top:0;bottom:0;opacity:0;transition:opacity .13s;z-index:-1;}.gs_md_li:hover:before,.gs_md_li:focus:before{opacity:1;transition:all 0s;}a.gs_in_ib.gs_md_li .gs_lbl{color:#222}a.gs_in_ib.gs_md_li.gs_in_gray .gs_lbl{color:#444}.gs_md_li:active:before{background-color:#ddd}.gs_md_li.gs_sel,a.gs_in_ib.gs_md_li.gs_sel .gs_lbl{color:#d14836}.gs_md_d:focus,.gs_md_li:focus{outline:none}a.gs_md_lix .gs_lbl,a.gs_md_lix .gs_lbl:not(:empty){padding:0 0 0 40px;}a.gs_in_cb:link,a.gs_in_cb:visited,a.gs_in_cb:active,a.gs_in_cb:hover{cursor:pointer;color:#222;text-decoration:none;}.gs_in_cb,.gs_in_ra{position:relative;line-height:16px;display:inline-block;-webkit-user-select:none;user-select:none;}.gs_in_cb.gs_md_li{padding:6px 44px 6px 16px;}.gs_in_cb input,.gs_in_ra input{position:absolute;top:1px;left:1px;width:15px;height:15px;margin:0;padding:0;opacity:0;z-index:2;}.gs_in_ra input{top:0;left:0}.gs_el_tc .gs_in_cb input{top:9px}.gs_el_tc .gs_in_ra input{top:8px}.gs_in_cb.gs_in_cbj input{top:15px;left:15px}.gs_in_cb label,.gs_in_cb .gs_lbl,.gs_in_ra label{display:inline-block;padding-left:21px;min-height:16px;}.gs_in_cb label:empty:before,.gs_in_cb .gs_lbl:empty:before,.gs_in_ra label:empty:before{content:"\200b";}.gs_el_tc .gs_in_cb label,.gs_el_tc .gs_in_cb .gs_lbl,.gs_el_tc .gs_in_ra label{padding-top:8px;padding-bottom:5px;}.gs_in_cb.gs_in_cbj label,.gs_in_cb.gs_in_cbj .gs_lbl{padding:13px 0 12px 41px;}.gs_in_cbb,.gs_in_cbb label,.gs_in_cbb .gs_lbl{display:block;}.gs_in_cb .gs_cbx,.gs_in_ra .gs_cbx{position:absolute}.gs_in_cb .gs_cbx{top:2px;left:2px;width:11px;height:11px;border:1px solid #c6c6c6;border-radius:1px;}.gs_md_li .gs_cbx{top:8px;left:18px}.gs_el_tc .gs_in_cb .gs_cbx{top:10px}.gs_el_tc .gs_md_li .gs_cbx{top:16px}.gs_in_cb.gs_in_cbj .gs_cbx{top:15px;left:15px}.gs_el_tc .gs_in_ra .gs_cbx{top:8px}.gs_in_ra .gs_cbx{top:0;left:0;border:1px solid #c6c6c6;width:13px;height:13px;border-radius:7px;}.gs_in_cb:hover .gs_cbx,.gs_in_ra:hover .gs_cbx{border-color:#666;box-shadow:inset 0 1px 1px rgba(0,0,0,.1);}button.gs_in_cb:hover .gs_cbx{border-color:#c6c6c6;}.gs_in_cb :focus~label,.gs_in_ra :focus~label{outline:1px dotted #222;outline:auto -webkit-focus-ring-color;}.gs_pfcs .gs_in_cb :focus~label,.gs_pfcs .gs_in_ra :focus~label{outline:none;}.gs_in_cb:active .gs_cbx,.gs_in_ra:active .gs_cbx,.gs_in_cb .gs_cbx:active,.gs_in_ra .gs_cbx:active,.gs_in_cb :active~.gs_cbx,.gs_in_ra :active~.gs_cbx{border-color:#666;background-color:#ebebeb;}button.gs_in_cb:active .gs_cbx{border-color:#a6a6a6;}.gs_in_cb :disabled~.gs_cbx,.gs_in_ra :disabled~.gs_cbx,button.gs_in_cb:disabled .gs_cbx{border-color:#f1f1f1;box-shadow:none;}.gs_in_cb :disabled~label,.gs_in_ra :disabled~label{color:#b8b8b8;}.gs_in_cb.gs_err .gs_cbx{border-color:#eda29b;}.gs_in_cb .gs_chk,.gs_in_ra .gs_chk{position:absolute;z-index:1;top:-3px;left:-2px;width:21px;height:21px;}.gs_md_li .gs_chk{top:3px;left:14px}.gs_el_tc .gs_in_cb .gs_chk{top:5px}.gs_el_tc .gs_md_li .gs_chk{top:11px}.gs_in_cb.gs_in_cbj .gs_chk{top:10px;left:11px}.gs_in_ra .gs_chk{top:4px;left:4px;width:7px;height:7px;border-radius:4px;}.gs_el_tc .gs_in_ra .gs_chk{top:12px}.gs_in_cb input:checked~.gs_chk,.gs_in_cb.gs_sel .gs_chk{background:no-repeat url(/intl/en/scholar/images/1x/sprite_20161020.png) -69px -67px;opacity:.62;}.gs_in_ra input:checked~.gs_chk{background-color:#666}.gs_in_cb.gs_par .gs_chk{background:no-repeat url(/intl/en/scholar/images/1x/sprite_20161020.png) -21px -44px;opacity:.55;}@media(-webkit-min-device-pixel-ratio:1.5),(min-resolution:144dpi){.gs_in_cb input:checked~.gs_chk,.gs_in_cb.gs_sel .gs_chk,.gs_in_cb.gs_par .gs_chk{background-image:url(/intl/en/scholar/images/2x/sprite_20161020.png);background-size:169px;}}.gs_in_cb input:checked:disabled~.gs_chk{opacity:.22}.gs_in_ra input:checked:disabled~.gs_chk{background-color:#f1f1f1}.gs_ico_x{background-position:-113px -22px;opacity:.55;}.gs_ico_x:hover{opacity:.72;}.gs_ico_x:active{opacity:1;}.gs_ico_X{background-position:-71px 0;opacity:.55;}.gs_ico_X:hover{opacity:.72;}.gs_ico_X:active{opacity:1;}.gs_el_tc .gs_ico_Xt{background-origin:content-box;background-clip:content-box;padding:10px 6px 10px 14px;}.gs_ico_P{background-position:0 0;opacity:.55;}.gs_ico_P:hover{opacity:.72;}.gs_ico_P:active{opacity:1;}.gs_btnP .gs_ico{background-position:-21px 0;}.gs_btnC .gs_ico{background-position:0 -66px;}.gs_btnL .gs_ico{background-position:-92px -44px;}.gs_ico_LB{background-position:-50px -44px;height:16px;}.gs_btnJ .gs_ico{background-position:-92px -22px;}.gs_btnM .gs_ico{background-position:-92px 0;}.gs_btnMW .gs_ico{background-position:-21px -22px;}.gs_btnSB .gs_ico{background-position:0 -44px;}.gs_btnTSB .gs_ico{background-position:-115px -253px;}.gs_btnPL .gs_ico{background-position:-148px -66px;}.gs_btnPR .gs_ico{background-position:-21px -66px;}.gs_btnPLW .gs_ico{background-position:-0 -230px;}.gs_btnPRW .gs_ico{background-position:-23px -230px;}.gs_btnZI .gs_ico{background-position:-148px -22px;}.gs_btnZO .gs_ico{background-position:-127px -44px;}.gs_btnDE .gs_ico{background-position:-134px 0;}.gs_btnFI .gs_ico{background-position:-50px -66px;}.gs_btnAD .gs_ico{background-position:-141px -88px;opacity:.55;}.gs_btnAD:hover .gs_ico{opacity:.72;}.gs_btnAD:active .gs_ico,.gs_btnAD .gs_ico:active,.gs_btnAD :active~.gs_ico{opacity:1;}.gs_btnBA .gs_ico{background-position:-50px -22px;}.gs_btnADD .gs_ico{background-position:-92px -66px;}.gs_btnMRG .gs_ico{background-position:-113px 0;}.gs_btnLBL .gs_ico{background-position:0 -161px;}.gs_btnCNCL .gs_ico{background-position:-71px 0;}.gs_btnDWL .gs_ico{background-position:-28px -88px;}.gs_btnMNU .gs_ico{background-position:0 -88px;}.gs_btnMNT .gs_ico{background-position:-46px -161px;}.gs_btnALT .gs_ico{background-position:-92px -161px;}.gs_btnART .gs_ico{background-position:-115px -161px;}.gs_btnGSL .gs_ico{background-position:-69px -161px;}.gs_btnCLS .gs_ico{background-position:-138px -161px;}.gs_btnXBLU .gs_ico{background-position:-138px -253px;}.gs_btnSSB .gs_ico{background-position:0 -276px;}.gs_btnSSW .gs_ico{background-position:-23px -276px;}.gs_btnFLT .gs_ico{background-position:0 -184px;}.gs_btnXT .gs_ico{background-position:-46px -184px;}.gs_btnPD .gs_ico{background-position:-69px -184px;}.gs_btnPU .gs_ico {background-position:-92px -276px;}.gs_btnCP .gs_ico{background-position:-92px -184px;}.gs_btnTP .gs_ico{background-position:-138px -184px;}.gs_btnML .gs_ico{background-position:-115px -276px;}.gs_btnCHK .gs_ico{background-position:-71px -66px;}.gs_btnDNB .gs_ico{background-position:-115px -230px;}.gs_btnDNW .gs_ico{background-position:0 -207px;}.gs_btnACA .gs_ico{background-position:-23px -207px;}.gs_btnAPT .gs_ico{background-position:-46px -207px;}.gs_btnAPTW .gs_ico{background-position:-92px -230px;}.gs_btnAFL .gs_ico{background-position:-69px -207px;}.gs_btnAN .gs_ico{background-position:-46px -276px;}.gs_btnAI .gs_ico{background-position:-69px -276px;}.gs_btnPBL .gs_ico{background-position:-92px -207px;}.gs_btnUCT .gs_ico{background-position:-115px -207px;}.gs_btnVRF .gs_ico{background-position:-138px -207px;}.gs_btnLSI .gs_ico{background-position:-46px -230px;}.gs_btnLSG .gs_ico{background-position:-69px -230px;}.gs_btnMOR .gs_ico{background-position:-23px -253px;}.gs_btnADV .gs_ico{background-position:-46px -253px;}.gs_btnPRO .gs_ico{background-position:-69px -253px;}.gs_ico_star{background-position:-71px -44px;width:13px;height:13px;}.gs_btnPLSW .gs_ico{background-position:-138px -230px;}.gs_btnPDF .gs_ico{background-position:0 -253px;}.gs_btnS .gs_ico{background-position:-138px -276px;}.gs_btnUNS .gs_ico{background-position:0 -299px;}.gs_btnMORR .gs_ico{background-position:-23px -299px;}.gs_btnTW .gs_ico{background-position:-46px -299px;}.gs_btnIN .gs_ico{background-position:-69px -299px;}.gs_btnFB .gs_ico{background-position:-92px -299px;}#gs_hdr_drs,#gs_hdr_drw{position:fixed;top:0;left:0;width:100%;height:100%;z-index:1200;visibility:hidden;}#gs_hdr_drs{opacity:0;background-color:#fff;transition:opacity .15s,visibility 0s .15s;}.gs_el_ta #gs_hdr_drs,.gs_el_ph #gs_hdr_drs{background-color:#666;}#gs_hdr_drs.gs_vis{visibility:visible;opacity:.5;transition:opacity .15s,visibility 0s;}.gs_el_tc #gs_hdr_drs{transition:opacity .218s,visibility 0s .218s;}.gs_el_tc #gs_hdr_drs.gs_vis{transition:opacity .218s,visibility 0s;}#gs_hdr_drw{overflow:auto;width:228px;background-color:#fff;box-shadow:2px 2px 4px rgba(0,0,0,.15);outline:none;transform:translate(-100%,0);transition:transform .15s ease-in-out,visibility 0s .15s;}#gs_hdr_drw.gs_vis{visibility:visible;transform:translate(0,0);transition:transform .15s ease-in-out,visibility 0s;}.gs_el_tc #gs_hdr_drw{transition:transform .3s cubic-bezier(.4,0,.6,1),visibility 0s .3s;}.gs_el_tc #gs_hdr_drw.gs_vis{transition:transform .225s cubic-bezier(0,0,.2,1),visibility 0s;}#gs_hdr_drw.gs_abt,.gs_el_tc #gs_hdr_drw.gs_abt{transition:none;}#gs_hdr_drw_in{position:relative;box-sizing:border-box;min-height:100%;padding:0 0 8px 0;}.gs_el_ta #gs_hdr_drw_in,.gs_el_ph #gs_hdr_drw_in{padding:0 0 65px 0;}#gs_hdr_drw_top{position:relative;height:63px;border-bottom:1px solid #e5e5e5;margin-bottom:8px;}.gs_el_ta #gs_hdr_drw_top,.gs_el_ph #gs_hdr_drw_top{height:57px;}#gs_hdr_drw_mnu,#gs_hdr_drw_lgo{position:absolute;top:0;height:100%;}#gs_hdr_drw_mnu{left:0;width:55px;}#gs_hdr_drw_lgo{left:56px;}.gs_hdr_drw_sec:before{display:block;content:" ";height:0;border-bottom:1px solid #e5e5e5;margin:8px 0;}.gs_hdr_drw_sec:first-child:before{display:none;}#gs_hdr_drw_bot{display:none;}.gs_el_ta #gs_hdr_drw_bot,.gs_el_ph #gs_hdr_drw_bot{display:block;position:absolute;left:0;bottom:0;width:100%;height:65px;}#gs_hdr_drw_bot .gs_md_li:before{opacity:0;}#gs_hdr_drw_bot .gs_hdr_pp{display:block;position:absolute;bottom:14px;left:15px;pointer-events:none;}#gs_hdr_drw_bot .gs_lbl{display:block;white-space:nowrap;overflow:hidden;text-overflow:ellipsis;}#gs_hdr{position:relative;height:63px;background-color:#f5f5f5;border-bottom:1px solid #e5e5e5;display:flex;}.gs_el_ta #gs_hdr,.gs_el_ph #gs_hdr{height:57px;}#gs_hdr_mnu,#gs_hdr_bck,#gs_hdr_lgo,#gs_hdr_lgt,#gs_hdr_md,#gs_hdr_sre,#gs_hdr_act{display:inline-block;vertical-align:top;position:relative;height:100%;flex:0 0 auto;}#gs_hdr_md{flex:1 1 auto;}#gs_hdr .gs_hdr_mbo,#gs_hdr .gs_hdr_mbo,.gs_el_ta #gs_hdr .gs_hdr_dso,.gs_el_ph #gs_hdr .gs_hdr_dso{display:none;}.gs_el_ta #gs_hdr .gs_hdr_mbo,.gs_el_ph #gs_hdr .gs_hdr_mbo{display:inline-block;}#gs_hdr_mnu,#gs_hdr_bck,#gs_hdr_sre{width:55px;margin-right:1px;}#gs_hdr_lgo,#gs_hdr_drw_lgo{width:149px;background:no-repeat url('/intl/en/scholar/images/1x/scholar_logo_24dp.png') 0% 50%;background-size:149px;}@media(-webkit-min-device-pixel-ratio:1.5),(min-resolution:144dpi){#gs_hdr_lgo,#gs_hdr_drw_lgo{background-image:url('/intl/en/scholar/images/2x/scholar_logo_24dp.png');}}#gs_hdr_lgo{margin-right:31px;}.gs_el_ph #gs_hdr_lgo{margin-right:0;}#gs_hdr_lgt{min-width:164px;margin-right:16px;}#gs_hdr_lgt:empty{display:none;}#gs_hdr_md{margin-right:16px;min-width:1px;}#gs_hdr_lgt,#gs_hdr_md h1{padding:19px 0 0 0;white-space:nowrap;overflow:hidden;text-overflow:ellipsis;font-size:20px;line-height:25px;font-weight:normal;color:#666;max-width:100%;text-align:left;}.gs_el_ta #gs_hdr_md h1,.gs_el_ph #gs_hdr_md h1{padding:16px 0 0 0;}#gs_hdr_srch{padding:14px 0 0 0;max-width:600px;}.gs_el_ta #gs_hdr_srch,.gs_el_ph #gs_hdr_srch{padding:10px 0 0 0;max-width:none;}#gs_hdr_frm{position:relative;padding-right:39px;}#gs_hdr_tsi{height:38px;border-radius:2px 0 0 2px;}#gs_hdr_tsi::-ms-clear{display:none;}#gs_hdr_tsc{display:none;position:absolute;top:3px;right:41px;width:21px;height:21px;padding:6px 10px 7px 10px;}.gs_in_acw[dir="rtl"]~#gs_hdr_tsc{right:auto;left:1px;}#gs_hdr_tsb{position:absolute;top:0;right:0;width:40px;height:38px;border-radius:0 2px 2px 0;}#gs_hdr_frm_ac{top:37px;right:40px;}.gs_el_ph #gs_hdr_frm_ac{right:0;}.gs_el_ph .gs_hdr_ifc #gs_hdr_mnu,.gs_el_ph .gs_hdr_ifc #gs_hdr_bck,.gs_hdr_src #gs_hdr_srch,.gs_hdr_src #gs_hdr_lgt,.gs_hdr_srx #gs_hdr_sre,.gs_hdr_srx #gs_hdr_md h1,.gs_hdr_srx #gs_hdr_md h1.gs_hdr_mbo,.gs_hdr_srx #gs_hdr_md h1.gs_hdr_dso,.gs_el_ta .gs_hdr_srx #gs_hdr_lgo,.gs_el_ph .gs_hdr_srx #gs_hdr_lgo,.gs_el_ph .gs_hdr_srx #gs_hdr_mnu,.gs_el_ph .gs_hdr_srx #gs_hdr_bck{display:none;}.gs_el_ph .gs_hdr_ifc #gs_hdr_md,.gs_el_ph .gs_hdr_srx #gs_hdr_md{margin-left:16px;}.gs_el_tc .gs_hdr_tsc #gs_hdr_tsi[dir="ltr"]{padding-right:41px;}.gs_el_tc .gs_hdr_tsc #gs_hdr_tsi[dir="rtl"]{padding-left:41px;}.gs_el_tc .gs_hdr_tsc .gs_in_acw~#gs_hdr_tsc{display:block;}#gs_hdr_act{min-width:64px;max-width:200px;text-align:right;float:right;}.gs_el_ta #gs_hdr_act,.gs_el_ph #gs_hdr_act{display:none;}#gs_hdr_act_i,#gs_hdr_act_s{display:inline-block;padding:23px 24px 23px 16px;max-width:100%;box-sizing:border-box;font-size:13px;line-height:17px;white-space:nowrap;overflow:hidden;text-overflow:ellipsis;color:#444;}#gs_hdr_act_s{text-transform:uppercase;}.gs_el_sm #gs_hdr_act_i,.gs_el_sm #gs_hdr_act_s{padding:23px 16px;}.gs_el_ta #gs_hdr_act_i,.gs_el_ta #gs_hdr_act_s,.gs_el_ph #gs_hdr_act_i,.gs_el_ph #gs_hdr_act_s{padding:20px 16px;}#gs_hdr_act_i:active,#gs_hdr_act_s:active{color:#d14836;}#gs_hdr_act_i,.gs_el_sm #gs_hdr_act_i{padding-top:15px;padding-bottom:16px;}.gs_el_ta #gs_hdr_act_i,.gs_el_ph #gs_hdr_act_i{padding-top:12px;padding-bottom:13px;}#gs_hdr_act_i .gs_hdr_pp{vertical-align:top;}#gs_hdr_act_d{top:63px;left:auto;right:24px;min-width:288px;max-width:400px;}.gs_el_sm #gs_hdr_act_d{right:16px;}.gs_el_ta #gs_hdr_act_d{top:57px;}.gs_el_ph #gs_hdr_act_d{top:57px;min-width:280px;max-width:280px;max-width:90vw;}/* Account dialog body. */#gs_hdr_act_aw,#gs_hdr_act_ap,.gs_hdr_act_am,#gs_hdr_act_ab{display:block;padding:10px 20px;word-wrap:break-word;white-space:normal;}#gs_hdr_act_aw{background-color:#fef9db;font-size:11px;}#gs_hdr_act_ap,.gs_hdr_act_am{border-bottom:1px solid #ccc;}#gs_hdr_act_ap{padding:20px;}.gs_el_ph #gs_hdr_act_ap{padding:10px;}#gs_hdr_act_apb{margin-top:12px;}#gs_hdr_act_aa:link,#gs_hdr_act_aa:visited{float:right;margin-left:8px;color:#1a0dab;}#gs_hdr_act_aa:active{color:#d14836}.gs_hdr_act_am:link,.gs_hdr_act_am:visited{color:#222;text-decoration:none;background:#fbfbfb;}.gs_hdr_act_am:hover,.gs_hdr_act_am:focus{background:#f1f1f1;}.gs_hdr_act_am:active{background:#eee;}#gs_hdr_act_ab{background:#fbfbfb;padding:10px 0;display:table;width:100%;white-space:nowrap;}#gs_hdr_act_aba,#gs_hdr_act_abs{display:table-cell;padding:0 20px;}#gs_hdr_act_abs{text-align:right;}.gs_el_ph #gs_hdr_act_aba,.gs_el_ph #gs_hdr_act_abs{display:block;padding:10px;text-align:center;}.gs_el_ph #gs_hdr_act_aba button,.gs_el_ph #gs_hdr_act_abs button{width:100%;}#gs_hdr_act_a1,#gs_hdr_act_a2{position:absolute;top:-9px;right:7.5px;width:0;height:0;z-index:1;border:8.5px solid transparent;border-top:none;border-bottom-color:#333;border-bottom-color:rgba(0,0,0,.2);}#gs_hdr_act_a2{top:-8px;border-bottom-color:#fff;}.gs_hdr_act_mw #gs_hdr_act_a2{border-bottom-color:#fef9db;}.gs_hdr_pp{border-radius:50%;overflow:hidden;}#gs_hdr_act_ap .gs_hdr_pp,.gs_hdr_act_am .gs_hdr_pp{float:left;}#gs_hdr_act_ap .gs_hdr_pm{margin-left:116px;}.gs_hdr_act_am .gs_hdr_pm{margin:6px 0 0 58px;}#gs_ab{position:relative;height:41px;border-bottom:1px solid #e5e5e5;display:flex;white-space:nowrap;background-color:#fff;z-index:1000;}.gs_el_ta #gs_ab.gs_nta,.gs_el_ph #gs_ab.gs_nph{display:none;}#gs_ab_g{height:42px;}.gs_sth_vis #gs_ab{position:fixed;}#gs_ab_ico,#gs_ab_ttl,#gs_ab_md,#gs_ab_btns{display:inline-block;vertical-align:top;position:relative;height:100%;flex:0 0 auto;}.gs_el_ph #gs_ab_md{display:block;}#gs_ab_ico{width:55px;margin-right:1px;}#gs_ab_ico .gs_ico{position:absolute;top:50%;left:50%;margin:-10.5px 0 0 -10.5px;}#gs_ab_ttl{min-width:172px;padding-right:8px;}.gs_el_sm #gs_ab_ttl{min-width:68px;}.gs_el_ta #gs_ab_ttl,.gs_el_ph #gs_ab_ttl{min-width:0;}#gs_ab_ttl,#gs_ab_ttll{font-size:18px;color:#666;text-transform:none;}.gs_el_sm #gs_ab_ttl,.gs_el_sm #gs_ab_ttll{font-size:16px;}#gs_ab_ttll{overflow:hidden;text-overflow:ellipsis;max-width:200px;}#gs_ab_md{flex:1 0 auto;}.gs_ab_st #gs_ab_md{flex:1 1 auto;font-size:13px;line-height:17px;padding:0 8px;color:#999;overflow:hidden;text-overflow:ellipsis;}.gs_el_ph .gs_ab_st #gs_ab_md{visibility:hidden;padding:0;}#gs_ab_btns{margin-right:8px;}.gs_el_sm #gs_ab_btns{margin-right:0;}.gs_el_ta #gs_ab_btns,.gs_el_ph #gs_ab_btns{margin-right:4px;}#gs_ab_ttl:before,#gs_ab_md:before,#gs_ab_btns:before{content:"";display:inline-block;width:0;height:100%;vertical-align:middle;}#gs_ab_md>button,#gs_ab_btns>button,#gs_ab_md>.gs_in_ib,#gs_ab_btns>.gs_in_ib,#gs_ab_md>.gs_md_r,#gs_ab_btns>.gs_md_r,#gs_ab .gs_ab_mdw,#gs_ab .gs_ab_btw{margin:0 8px;vertical-align:middle;}#gs_ab .gs_ab_mdw,.gs_ab_btw{display:inline-block;margin:0;}#gs_ab_btns>.gs_in_ib{margin:0 16px 0 8px;}#gs_ab .gs_ab_btw{margin:0 12px 0 16px;}.gs_el_ta .gs_ab_sel #gs_ab_ico,.gs_el_ph .gs_ab_sel #gs_ab_ico,.gs_el_ta .gs_ab_sel #gs_ab_ttl,.gs_el_ph .gs_ab_sel #gs_ab_ttl,.gs_el_ta .gs_ab_sel #gs_ab_btns,.gs_el_ph .gs_ab_sel #gs_ab_btns{display:none;}#gs_bdy{display:table;table-layout:fixed;width:100%;}#gs_bdy_sb{vertical-align:top;width:228px;word-wrap:break-word;display:none;}.gs_el_sm #gs_bdy_sb{}.gs_el_ta #gs_bdy_sb,.gs_el_ph #gs_bdy_sb{}.gs_bdy_sb_sec{margin:0 40px 0 56px;}.gs_bdy_sb_sec:before{display:block;content:" ";height:0;margin:13px 0;border-top:1px solid #eee;}.gs_bdy_sb_sec:first-child:before{margin:21px 0 0 0;border:none;}#gs_bdy_sb ul{list-style-type:none;}.gs_bdy_sb_sec a:link,.gs_bdy_sb_sec a:visited{color:#222;}.gs_bdy_sb_sec a:active{color:#d14836;}.gs_bdy_sb_sel a:link,.gs_bdy_sb_sel a:visited{color:#d14836;text-decoration:none;}.gs_el_tc .gs_bdy_sb_sec li.gs_ind,.gs_el_tc .gs_bdy_sb_sec li.gs_ind a{padding-top:8px;padding-bottom:5px;}.gs_el_tc .gs_bdy_sb_sec:first-child li.gs_ind:first-child{margin-top:-8px;}#gs_bdy_sb .gs_ind,#gs_bdy_sb .gs_inw{margin-bottom:4px;}.gs_el_tc #gs_bdy_sb .gs_ind,.gs_el_tc #gs_bdy_sb .gs_inw{margin-bottom:0;}#gs_bdy_ccl{display:table-cell;vertical-align:top;padding:0 24px 0 16px;}.gs_el_sm #gs_bdy_ccl{padding:0 16px;}.gs_el_ta #gs_bdy_ccl,.gs_el_ph #gs_bdy_ccl{padding:0 16px;}.gs_el_ph #gs_bdy_ccl{padding:0;}#gs_ftr_sp{height:62px;}.gs_el_sm #gs_ftr_sp{height:57px;}#gs_ftr{position:absolute;bottom:0;left:0;width:100%;white-space:nowrap;border-top:1px solid #e4e4e4;background-color:#f2f2f2;display:flex;}#gs_ftr_rt{box-sizing:border-box;max-width:100%;overflow-x:auto;margin-left:auto;padding:0 12px;}.gs_el_sm #gs_ftr_rt{padding:0 8px;}.gs_el_ph #gs_ftr_rt:after{content:" ";position:absolute;top:0;right:0;width:16px;height:100%;background-image:linear-gradient(to right,rgba(242,242,242,0),rgba(242,242,242,1) 80%);}#gs_ftr_rt a{display:inline-block;line-height:16px;padding:12px;white-space:nowrap;}.gs_el_sm #gs_ftr_rt a{padding:12px 8px;}#gs_ftr_rt a:link,#gs_ftr_rt a:visited{color:#666}#gs_ftr_rt a:active{color:#d14836}#gsc_a_t{width:100%;table-layout:fixed;}#gsc_a_tr0,#gsc_a_trh{box-sizing:border-box;}#gsc_a_tr0 th.gsc_a_x,#gsc_a_tr0 th.gsc_a_t,#gsc_a_tr0 th.gsc_a_c,#gsc_a_tr0 th.gsc_a_y{height:0;}#gsc_a_trh{z-index:700;background-color:#f5f5f5;height:42px;}.gs_el_ta #gsc_a_trh,.gs_el_ph #gsc_a_trh,.gs_el_ta #gsc_a_t td,.gs_el_ph #gsc_a_t td{background-color:#fff;border-bottom:1px solid #e5e5e5;}#gsc_a_t th.gsc_a_x,#gsc_a_t th.gsc_a_t,#gsc_a_t th.gsc_a_c,#gsc_a_t th.gsc_a_y{box-sizing:border-box;text-transform:uppercase;vertical-align:middle;padding-top:0;padding-bottom:0;}#gsc_x_all{z-index:1;}.gsc_a_x,.gsc_a_t,.gsc_a_c,.gsc_a_y,.gsc_a_e{font-weight:normal;padding:16px 16px 0 16px;vertical-align:top;text-align:right;}.gsc_a_c{padding:16px 8px 0 8px;}.gs_el_sm .gsc_a_x,.gs_el_sm .gsc_a_t,.gs_el_sm .gsc_a_c{padding:12px 8px 0 8px;}.gs_el_ta .gsc_a_x,.gs_el_ta .gsc_a_t,.gs_el_ta .gsc_a_c,.gs_el_ph .gsc_a_x,.gs_el_ph .gsc_a_t,.gs_el_ph .gsc_a_c{padding:12px 8px;}.gs_el_sm .gsc_a_y{padding:12px 8px 0 8px;}.gs_el_ta .gsc_a_y{padding-bottom:12px;}.gsc_a_x{width:41px;padding:4px 0 0 0;}.gs_el_sm .gsc_a_x{padding:0;}.gsc_a_t{text-align:left;}.gs_el_ph .gsc_a_t{padding-left:16px;}#gsc_a_ta{display:inline-block;vertical-align:middle;margin-right:16px;}.gs_el_ph #gsc_a_ta{display:none}.gs_el_ph .gsc_a_c{padding-right:16px;}th.gsc_a_c{width:64px;white-space:nowrap;}.gsc_art_sel #gsc_a_ta,.gsc_art_sel #gsc_a_ca,.gsc_art_sel .gsc_a_h{display:none;}.gsc_a_ac,.gsc_a_hc{margin-top:3px;}th.gsc_a_y{width:88px;white-space:nowrap;}.gs_el_sm th.gsc_a_y{width:58px;}.gs_el_ph th.gsc_a_y,.gs_el_ph td.gsc_a_y{width:0;padding:0;}.gs_el_ph .gsc_a_h{display:none}@media print{#gs_top th.gsc_a_y{width:58pt;}#gs_top #gsc_a_tr0{display:none}#gs_top #gsc_a_trh{position:static}}.gsc_a_e{padding:16px;text-align:center;}.gsc_a_a{padding:8px 0}.gsc_a_at{padding:8px 0;font-size:16px}a.gsc_a_acm{text-decoration:line-through;}a.gsc_a_acm:hover,a.gs_a_acm:active{text-decoration:underline;}.gsc_a_m{position:absolute;}.gs_el_ph .gsc_a_m{display:block;position:static;}.gsc_a_am{font-size:24px;position:absolute;top:-18px;left:-2px;padding:8px 12px 4px 8px;}.gs_el_ph .gsc_a_am{display:inline-block;position:static;padding:6px 16px;margin-bottom:-6px;}#gsc_a_sp{visibility:hidden;}#gsc_a_sp.gs_vis{visibility:visible;padding:16px 0;height:25px;border-bottom:1px solid #ccc;}#gsc_a_sp:after{display:block;height:100%;content:" ";background:url('/intl/en/scholar/images/spinner.gif') no-repeat 50% 50%;opacity:0;}#gsc_a_sp.gs_vis:after{opacity:1;transition:opacity 0s .4s;}#gsc_a_err{display:none;padding:28px 0;}#gsc_a_err.gs_vis{display:block;}#gsc_md_iad{width:800px;max-width:94%;}.gs_el_ph #gsc_md_iad{width:100%;max-width:100%;}#gsc_md_iad .gs_md_prg{min-height:400px;}.gs_el_ph #gsc_iads_res .gs_md_prg{margin:0 16px;}#gsc_iad_tart,.gsc_iad_tsel.gsc_iad_tart #gsc_iad_tart,.gsc_iad_tart #gsc_iad_tgrp,.gsc_iad_tsel #gsc_iad_tgrp,#gsc_iad_tsel,#gsc_napb_hdr #gsc_iad_tart,#gsc_napb_hdr #gsc_iad_tgrp{display:none;}#gsc_iad_tgrp,.gsc_iad_tart #gsc_iad_tart,.gsc_iad_tsel #gsc_iad_tsel,#gsc_napb_hdr #gsc_iad_tsel{display:inline-block;}#gsc_iad_t:not(.gsc_iad_tsel) #gsc_iad_tsel{pointer-events:none;color:#b5b5b5;}.gs_el_ph #gsc_napb #gsc_iads_frm{margin:0 16px;}#gsc_iads_res{position:relative;margin:8px 0 16px 0;min-height:80px;border-bottom:1px solid #e5e5e5;}.gs_el_ph #gsc_md_iad #gsc_iads_res{margin:8px -16px 16px -16px;}.gs_el_ph #gsc_napb #gsc_iads_pp{margin-right:16px;}#gsc_iadb_hdr{display:table;table-layout:fixed;width:100%;}#gsc_iadb_hdr_cb,#gsc_iadb_hdr_instr{display:table-cell;vertical-align:middle;height:41px;}#gsc_iadb_hdr_cb{width:41px;}#gsc_iadb_hdr_cb:empty{width:0;}.gs_el_ph #gsc_iadb_hdr_cb:empty{width:16px;}#gsc_iadb_hdr_instr{font-size:16px;}.gs_el_ph #gsc_iadb_hdr_instr{padding-right:16px;}.gsc_oic{position:relative;}.gsc_oic_cb{font-weight:normal;border-top:1px solid #e5e5e5;border-bottom:1px solid #e5e5e5;background-color:#fcfcfc;padding-right:16px;}.gsc_oict{display:block;overflow:hidden;}.gsc_oict_name{display:block;font-size:16px;line-height:20px;word-wrap:break-word;}.gsc_oict_inf{display:block;float:right;margin-left:16px;white-space:nowrap;}.gsc_oict_all,.gsc_oict_prf{font-size:13px;text-transform:uppercase;line-height:20px;}.gsc_oict_all[data-a]{color:#1a0dab;cursor:pointer;}.gsc_oict_all[data-a]:hover{text-decoration:underline;}.gsc_oict_all[data-a]:active{color:#d14836;}.gsc_oict_prf{padding-left:8px;margin-left:8px;border-left:1px solid #e0e0e0;}.gsc_oict_prf:empty{display:none;}.gs_el_ph .gsc_oict_all,.gs_el_ph .gsc_oict_prf{float:right;clear:both;margin:0;padding:0;border:none;}.gs_el_ph .gsc_oict_prf{margin-top:2px;}.gsc_oic_res{margin:8px 0 12px 41px;}.gs_el_ph .gsc_oic_res{margin-right:16px;}.gsc_oic_res h4{font-size:13px;font-weight:normal;}.gsc_oic_dis .gsc_oic_name,.gsc_oic_dis .gsc_oic_all,.gsc_oic_dis .gsc_oic_prf{color:#777;}.gsc_oic_dis .gsc_oict_all[data-a]{color:#1a0dab;opacity:.66;}.gsc_oic_dis .gsc_oic_res{opacity:.5;}.gsc_iadb_art{border-top:1px solid #e5e5e5;overflow:hidden;}.gsc_iadb_art_cb{float:left;}.gsc_iadb_art_added{float:right;margin:12px;font-size:11px;text-transform:uppercase;color:#777;}.gs_el_ph .gsc_iadb_art_added{display:block;float:none;text-align:right;margin:8px 16px;}.gsc_iadb_art_added:empty{display:none;}.gsc_iadb_art_body{margin:12px 0 12px 41px;}.gs_el_ph .gsc_iadb_art_body{margin:12px 16px 12px 41px;}.gsc_iadb_art_body h3{font-size:13px;font-weight:normal;}.gsc_iadb_art_dis .gsc_iadb_art_body{opacity:.5;}#gsc_md_mopt,#gsc_md_cbyd,#gsc_md_cbym{width:600px;}.gs_el_ta #gsc_md_mopt,.gs_el_ta #gsc_md_cbyd,.gs_el_ta #gsc_md_cbym{width:500px;}.gs_el_ph #gsc_md_mopt,.gs_el_ph #gsc_md_cbyd,.gs_el_ph #gsc_md_cbym{width:100%;}.gsc_mob_art{vertical-align:top;padding:8px 0;}.gs_el_tc .gsc_mob_art>.gs_in_ra{margin-top:-8px;}.gsc_mob_cby{vertical-align:top;text-align:right;padding:8px 12px;position:relative;}.gsc_mob_ttl,.gsc_mob_pub{display:block;}.gsc_mob_pub{color:#666;}.gsc_mob_cbym{text-decoration:line-through}.gsc_mob_cbm{font-size:24px;position:absolute;padding:4px 0 0 4px;line-height:16px;}.gs_fsvg line{stroke:#222222}a:link .gs_fsvg{fill:#1a0dab;}a:link .gs_fsvg line{stroke:#1a0dab;}a:visited .gs_fsvg{fill:#660099;}a:visited .gs_fsvg line{stroke:#660099;}a:active .gs_fsvg{fill:#d14836;}a:active .gs_fsvg line{stroke:#d14836;}a .gs_fsvg{border-bottom:1px solid transparent;}a:hover .gs_fsvg,a:focus .gs_fsvg{border-bottom-color:inherit;}.gs_fsml{font-size:13px}.gs_fscp{font-variant:small-caps}.gsh_clim{display:table-row}.gsh_clil,.gsh_clic{display:table-cell;padding-bottom:8px}.gsh_clil{padding-right:8px;}.gsh_lla{list-style-type:lower-alpha}.gsh_lua{list-style-type:upper-alpha}.gsh_llr{list-style-type:lower-roman}.gsh_lur{list-style-type:upper-roman}.gsh_l>li{margin-left:32px;}.gsh_h3{font-size:inherit;font-weight:normal}.gsh_h3,.gsh_csp{margin:16px 0}.gsh_h3+.gsh_csp{margin-top:-8px}.gsh_ovln{text-decoration:overline}.gsh_small .gsh_l .gsh_csp{margin:8px 0}.gsh_small .gsh_csp:first-child,.gsh_small .gsh_h3:first-child{margin-top:0}.gsh_small .gsh_csp:last-child{margin-bottom:0}.gsh_dspfr{text-align:center}.gsh_dspfr svg{margin:8px 0}.gs_pp_tn,.gs_el_ta .gs_pp_mo_tn,.gs_el_ph .gs_pp_mo_tn{width:32px;height:32px;}.gs_pp_sm,.gs_el_ta .gs_pp_mo_sm,.gs_el_ph .gs_pp_mo_sm{width:56px;height:56px;}.gs_pp_nm,.gs_el_ta .gs_pp_mo_nm,.gs_el_ph .gs_pp_mo_nm{width:128px;height:128px;}.gs_ai_pho{float:left;}.gs_ai_t{margin-left:72px;}.gs_ai_pho_pst+.gs_ai_t{margin-left:48px;}.gs_ai_t.gs_ai_pss{margin-left:64px;}.gs_ai_pho_pst+.gs_ai_t.gs_ai_pss{margin-left:40px;}.gs_ai_name{font-size:17px;font-weight:normal;margin-bottom:4px;}.gs_ai_name a{padding:6px 0 4px 0;}.gs_ai_name.gs_ai_name_nlsb{font-size:15px;}.gs_ai_name.gs_ai_name_nlsb a:link,.gs_ai_name.gs_ai_name_nlsb a:visited{padding:7px 0 5px 0; color:#222;}.gs_ai_name.gs_ai_name_nlsb a:active{color:#d14836;}.gs_ai_int{margin-top:5px;}.gs_ai_eml:empty,.gs_ai_int:empty,.gs_ai_cby:empty{display:none;}.gs_ai_one_int{vertical-align:top;font-size:13px;margin-right:8px;white-space:nowrap;display:inline-block;max-width:200px;text-overflow:ellipsis;overflow:hidden;}.gs_el_tc a.gs_ai_one_int{padding:8px 0 5px 0;}.gs_el_ph .gs_ai_eml,.gs_el_ph .gs_ai_cby{margin-top:8px;}.gs_ai_ilnl .gs_ai_int,.gs_ai_ilnl .gs_ai_cby{margin-top:8px;color:#666;}.gs_ai.gs_ai_chpr{position:relative;}.gs_ai_chpr .gs_ai_t{margin-right:276px;}.gs_el_sm .gs_ai_chpr .gs_ai_t{margin-right:156px;}.gs_el_ph .gs_ai_chpr .gs_ai_t{margin-right:0;}.gs_ai_chpr .gs_ai_cby{position:absolute;top:4px;right:0;text-align:right;}.gs_el_sm .gs_ai_chpr .gs_ai_cby,.gs_el_ta .gs_ai_chpr .gs_ai_cby{width:132px;word-wrap:break-word;}.gs_el_ph .gs_ai_chpr .gs_ai_cby{text-align:left;position:static;width:auto;}#gsc_bdy{position:relative;max-width:1200px;margin:0 auto;}.gs_el_ph #gsc_bdy,.gs_el_ta #gsc_bdy{display:flex;flex-flow:column;}.gsc_lcl{position:relative;margin:0 350px 0 0;order:3;}.gs_el_sm .gsc_lcl{margin-right:334px;}.gs_el_ta .gsc_lcl,.gs_el_ph .gsc_lcl{margin:0;}#gsc_prf_t_wrp{position:relative;order:2;overflow:hidden;}.gs_el_tc #gsc_prf_t_wrp:after{display:block;content:"";position:absolute;z-index:100;top:0;right:0;width:12px;height:100%;background-image:linear-gradient(to right,rgba(247,247,247,0),rgba(247,247,247,1) 80%);}#gsc_prf_t{width:100%;background-color:#f5f5f5;display:none;white-space:nowrap;overflow-x:auto;padding:0 4px;}.gs_el_ta #gsc_prf_t,.gs_el_ph #gsc_prf_t{display:block;}#gsc_prf_t:after{content:"\00A0";padding:0 4px;}.gsc_prf_tab,.gsc_prf_tab:link{font-size:13px;text-transform:uppercase;padding:13px 12px;display:inline-block;color:#666;cursor:pointer;}.gsc_prf_tab:hover{color:#000;text-decoration:none}.gsc_prf_tab:active{color:#4d90fe;}.gsc_prf_tab[aria-selected="true"]{border-bottom:2px solid #4d90fe;color:#0461f9;cursor:default;}.gs_el_ta #gsc_art,.gs_el_ph #gsc_art,.gs_el_ta #gsc_rsb_cit,.gs_el_ph #gsc_rsb_cit,.gs_el_ta #gsc_rsb_mnd,.gs_el_ph #gsc_rsb_mnd,.gs_el_ta #gsc_rsb_awd,.gs_el_ph #gsc_rsb_awd,.gs_el_ta #gsc_rsb_co,.gs_el_ph #gsc_rsb_co{display:none;}#gsc_bdy[data-tab="gsc_prf_t-art"] #gsc_art,#gsc_bdy[data-tab="gsc_prf_t-cit"] #gsc_rsb_cit,#gsc_bdy[data-tab="gsc_prf_t-mnd"] #gsc_rsb_mnd,#gsc_bdy[data-tab="gsc_prf_t-awd"] #gsc_rsb_awd,#gsc_bdy[data-tab="gsc_prf_t-ath"] #gsc_rsb_co{display:block;}.gsc_rsb{float:right;width:317px;order:4;border-left:1px solid #eee;margin-top:32px;}.gs_el_sm .gsc_rsb{margin-top:16px;}.gs_el_ph .gsc_rsb,.gs_el_ta .gsc_rsb{float:none;width:auto;border:none;margin:0;}.gsc_rsb_s{margin:0 0 48px 16px;position:relative;}.gs_el_sm .gsc_rsb_s{margin:0 0 32px 16px;}.gs_el_ph .gsc_rsb_s,.gs_el_ta .gsc_rsb_s{margin:0;}.gsc_rsb_s:last-child{margin-bottom:0;}.gsc_rsb_header{padding:8px 8px 12px 8px;border-bottom:1px solid #e5e5e5;font-weight:normal;font-size:15px;}.gs_el_sm .gsc_rsb_header{padding:4px 8px 9px 8px;}.gs_el_ph .gsc_rsb_header,.gs_el_ta .gsc_rsb_header{display:none;}.gsc_rsb_action{position:absolute;top:-3px;right:-2px;}.gs_el_sm .gsc_rsb_action{top:-8px;}.gsc_rsb_tap{display:block;position:absolute;right:2px;top:12px;opacity:.5;z-index:1;}.gs_el_ta .gsc_rsb_tap,.gs_el_ph .gsc_rsb_tap{top:24px;right:10px;}.gsc_rsb_hm{border-bottom:1px solid #e5e5e5;padding:3px 6px;}#gsc_rsb_gpl{display:block;margin-top:3px;padding:6px 16px;line-height:15px;color:#0461f9;border:1px solid #4d90fe;border-radius:2px;text-align:center;text-transform:uppercase;}.gs_el_sm #gsc_rsb_gpl{margin-top:0;}.gs_el_ta #gsc_rsb_gpl,.gs_el_ph #gsc_rsb_gpl{display:none;}#gsc_rsb_st{width:100%;}.gsc_rsb_std{text-align:right;padding-right:8px;}.gs_el_ta .gsc_rsb_std,.gs_el_ph .gsc_rsb_std{padding-right:16px;}.gsc_rsb_sc1{text-align:left;padding:2px 8px;}.gs_el_sm .gsc_rsb_sc1{padding:0 8px;}.gs_el_ta .gsc_rsb_sc1,.gs_el_ph .gsc_rsb_sc1{padding:4px 16px;}.gsc_rsb_sth{font-weight:normal;padding:8px 8px 8px 0;border-bottom:1px solid #e5e5e5;text-align:right;}.gs_el_sm .gsc_rsb_sth{padding:4px 8px 4px 0;}.gs_el_ta .gsc_rsb_sth,.gs_el_ph .gsc_rsb_sth{padding:16px 16px 16px 0;}#gsc_rsb_st tbody:before,#gsc_rsb_st tbody:after{content:'';display:block;height:8px;}.gs_el_sm #gsc_rsb_st tbody:before,.gs_el_sm #gsc_rsb_st tbody:after{height:4px;}.gs_el_ph #gsc_hist_opn,.gs_el_ta #gsc_hist_opn{display:none;}.gsc_rsb_f{max-width:118px;word-wrap:break-word;white-space:normal;}.gs_el_ta .gsc_rsb_f{max-width:none;}.gsc_rsb_f:link,.gsc_rsb_f:visited{color:#222;}.gsc_rsb_m_na{color:#dd4b39;}.gsc_rsb_m_a{color:#006621;float:right;position:relative;}.gsc_rsb_m_bar{width:100%;height:4px;margin:8px 0 8px 0;background:#006621;}.gsc_rsb_m_bar_na{background:#dd4b39;width:100%;height:100%;z-index:1;}.gsc_rsb_m{padding:8px;}.gs_el_ta .gsc_rsb_m,.gs_el_ph .gsc_rsb_m{padding:8px 16px;}.gsc_rsb_m_desc{padding-top:16px;color:#777;}.gsc_rsb_m_s{font-size:24px;position:absolute;line-height:0.3;}#gsc_lwp_mndt_lnk{text-transform:uppercase;margin-left:16px;margin-right:-9px;text-align:right;font-size:13px;padding:12px 9px;border-radius:3px;}#gsc_lwp_mndt_lnk:hover,#gsc_lwp_mndt_lnk:active,#gsc_lwp_mndt_lnk:visited{text-decoration:none;color:#1a0dab;}#gsc_lwp_mndt_lnk:hover{background-color:rgba(0,0,0,.05);}#gsc_lwp_mndt_lnk:active{background-color:rgba(0,0,0,.1);}.gsc_rsb_m_title{padding-bottom:12px;}.gsc_rsb_m_header{display:flex;align-items:flex-end;justify-content:space-between;padding:0 8px;}.gs_el_sm .gsc_rsb_m_header{padding:0 8px;}.gsc_rsb_hmv{text-align:center;padding-top:16px;}.gsc_rsb_a{list-style:none;}.gsc_rsb_a>li{position:relative;}.gs_el_ta .gsc_rsb_a>li,.gs_el_ph .gsc_rsb_a>li{border-bottom:1px solid #e5e5e5;}.gsc_rsb_a>li:first-child{margin-top:8px;}.gsc_rsb_a_pht{float:left;width:32px;height:32px;}.gsc_rsb_a_desc{margin:0 33px 0 48px;min-height:32px;display:block;}.gs_el_ph .gsc_rsb_a_desc,.gs_el_ta .gsc_rsb_a_desc{margin:0 33px 0 64px;min-height:56px;}.gsc_rsb_a_desc a{color:#222;}.gsc_rsb_a_ext{display:block;color:#777;font-size:13px;white-space:nowrap;overflow:hidden;text-overflow:ellipsis;}.gs_el_ph .gsc_rsb_a_ext,.gs_el_ta .gsc_rsb_a_ext{white-space:normal;}.gsc_rsb_a_ext2{display:none;}.gs_el_ph .gsc_rsb_a_ext2,.gs_el_ta .gsc_rsb_a_ext2{display:block;}.gsc_rsb_aa{display:block;padding:8px;line-height:normal;cursor:pointer;}.gs_el_ph .gsc_rsb_aa,.gs_el_ta .gsc_rsb_aa{font-size:17px;padding:12px 16px;}.gsc_rsb_aa:hover,.gsc_rsb_aa:active{text-decoration:none;background:#f1f1f1;}.gsc_rsb_aa a:hover{text-decoration:none;}#gsc_prf_w{order:1;padding:32px 0;overflow:hidden;}.gs_el_sm #gsc_prf_w{padding:16px 0;}#gsc_prf_pu{float:left;width:128px;height:128px;text-align:center;}.gs_el_ph #gsc_prf_pu{float:none;width:100%;margin:0 0 8px 0;}#gsc_prf_pua{line-height:0;width:128px;height:128px;}.gs_el_ph #gsc_prf_pua{margin:0 auto;}#gsc_prf_pufi{width:0;height:0;overflow:hidden;}.gsc_prf_pufo #gsc_prf_pufi{width:auto;height:auto;overflow:visible;position:relative;z-index:10;}.gsc_prf_pufo #gsc_prf_pufi2{display:inline-block;background:#fcfcfc;padding:8px 8px 8px 0;}.gsc_prf_puic{position:absolute;bottom:0;width:100%;padding:8px 0;background-color:#000;opacity:.6;}.gsc_prf_pel{cursor:pointer;}#gsc_prf_i{margin:0 16px 0 160px;}.gs_el_sm #gsc_prf_i{margin:0 16px 0 144px;}.gs_el_ph #gsc_prf_i{margin:0 16px;text-align:center;}#gsc_prf_btne{vertical-align:top;margin:-9px 4px;}.gs_el_ph #gsc_prf_btne{position:absolute;top:60px;right:8px;margin:0;}#gsc_prf_btnf{float:right;margin:3px 0 16px 16px;}.gs_el_sm #gsc_prf_btnf{margin-top:0;}.gs_el_ph #gsc_prf_btnf{float:none;margin:0;position:absolute;top:8px;right:8px;border-radius:50%;}#gsc_prf_btnf .gs_lbl{padding:0 4px;}#gsc_prf_in{font-size:24px;line-height:24px;padding:3px 0 12px 0;word-wrap:break-word;}.gs_el_sm #gsc_prf_in{font-size:22px;padding:3px 0 8px 0;}.gs_el_ph #gsc_prf_in{font-size:20px;padding:0 0 2px 0;}.gsc_prf_il{font-size:15px;line-height:18px;padding:1px 0;}.gs_el_ph .gsc_prf_il{font-size:13px;line-height:16px;}.gsc_prf_ila:link,.gsc_prf_ila:visited{text-decoration:underline;color:#222;}#gsc_prf_int{margin-top:5px;}#gsc_prf_int:empty{display:none;}.gsc_prf_inta{margin-right:16px;white-space:nowrap;max-width:200px;text-overflow:ellipsis;overflow:hidden;vertical-align:top;}.gsc_prf_inta:last-child{margin:0}.gs_el_tc .gsc_prf_ila,.gs_el_tc .gsc_prf_inta{padding:8px 0 5px 0;}.gsc_md_pro_tt,.gsc_md_pro_ch #gsc_md_pro_lgtm,#gsc_md_pro_save{display:none;}.gsc_md_pro_ed #gsc_md_pro_ted,.gsc_md_pro_aa #gsc_md_pro_taa,.gsc_md_pro_ra #gsc_md_pro_tra,.gsc_md_pro_an #gsc_md_pro_tan,.gsc_md_pro_ai #gsc_md_pro_tai,.gsc_md_pro_ch #gsc_md_pro_save{display:inline-block;}.gsc_md_pro_el{color:#777;}.gsc_md_pro_ev{padding:4px 0 16px 0;}#gsc_dd_add-d,#gsc_dd_exp-d,#gsc_dd_sort-d,#gsc_dd_mor-d{top:42px;}#gsc_dd_add-d,#gsc_dd_mor-d,#gsc_dd_sort-d{white-space:normal;word-wrap:break-word;width:208px;width:-webkit-max-content;width:max-content;min-width:100px;max-width:208px;}.gs_el_ph #gsc_dd_add-d{left:-9px;}.gs_el_ph #gsc_dd_exp-d{left:auto;right:12px;}.gs_el_ph #gsc_dd_mor-d{left:-58px;}.gs_el_ph #gsc_dd_sort-d{left:10px;}.gs_el_ph #gsc_dd_sort-r{margin-left:-10px;}.gsc_dd_sec,#gsc_dd_exp-d{padding:8px 0;}.gs_el_tc .gsc_dd_sec,.gs_el_tc #gsc_dd_exp-d{padding:4px 0 8px 0;}.gsc_dd_sep{border-top:1px solid #ebebeb;}#gsc_dd_mor-s .gsc_dd_mor-sel,#gsc_dd_sort-s .gsc_dd_sort-sel{color:#dd4b39;}#gsc_dd_mor-p{padding:14px 44px 14px 16px;color:#777;}.gs_el_tc #gsc_dd_mor-p{padding:18px 44px 18px 16px;}.gsc_art_sel #gsc_dd_add-r,.gsc_art_sel #gsc_dd_mor-r,#gsc_btn_mer,#gsc_btn_del,#gsc_dd_exp-r{display:none;}#gsc_dd_mor-r,.gsc_art_sel #gsc_btn_mer,.gsc_art_sel #gsc_btn_del,.gsc_art_sel #gsc_dd_exp-r{display:inline-block;}html:not(.gs_el_ph) #gsc_dd_sort-r{display:none;}#gsc_lwp{margin:24px 0;text-align:center;}.gs_el_sm #gsc_lwp{margin:16px 0;}#gsc_bpf{display:inline-block;verticle-align:middle;}#gsc_a_nn{display:inline-block;vertical-align:middle;padding-right:16px;font-size:13px;}.gs_el_ph #gsc_a_nn{display:none;}@media print{#gs_top #gs_md_s,#gs_top #gs_md_w,#gs_top #gs_hdr,#gs_top #gs_hdr_drs,#gs_top #gs_hdr_drw,#gs_top #gs_ftr,#gs_top #gsc_nag,#gs_top #gsc_prf_nbar_btns,#gs_top #gsc_prf_btne,#gs_top #gsc_prf_btnf,#gs_top #gsc_prf_ivh,#gs_top #gsc_prf_puf,#gs_top #gsc_rsb_co,#gs_top #gsc_bdy #gsc_rsb_co,#gs_top .gsc_g_hist_wrp,#gs_top #gsc_prf_t_wrp,#gs_top .gsc_rsb_header,#gs_top .gsc_a_tb,#gs_top .gsc_a_x,#gs_top #gsc_lwp,#gs_top .gsc_prf_puic,#gs_top #gsc_dd_add-r,#gs_top #gsc_dd_mor-r,#gs_top #gsc_dd_sort-r{display:none;}#gs_top,#gs_top #gsc_bdy,#gs_top #gsc_prf_w,#gs_top #gsc_prf,#gs_top #gsc_prf_pu,#gs_top #gsc_prf_pua,#gs_top #gsc_prf_i,#gs_top .gsc_rsb_s,#gs_top .gsc_lcl,#gs_top .gsc_rsb,#gs_top #gsc_a_tw,#gs_top #gsc_a_t,#gs_top .gsc_prf_il,#gs_top .gsc_prf_ila,#gs_top .gsc_prf_inta,#gs_top #gsc_rsb_st{background:none;border:none;padding:0;margin:0;height:auto;width:auto;min-width:0;max-width:none;float:none;display:block;position:static;color:black;font-weight:normal;font-size:12pt;text-decoration:none;}#gs_top .gsc_a_ac,#gs_top .gsc_a_a,#gs_top #gsc_a_ca,#gs_top .gsc_a_at,#gs_top .gsc_rsb_sc1,#gs_top .gsc_rsb_sth,#gs_top .gsc_rsb_std,#gs_top #gsc_bdy .gsc_a_x,#gs_top #gsc_bdy .gsc_a_t,#gs_top #gsc_bdy .gsc_a_c,#gs_top #gsc_bdy .gsc_a_y,#gs_top #gsc_a_trh,#gs_top .gsc_a_m,#gs_top .gsc_a_am{color:black;font-weight:normal;font-size:12pt;padding:0;margin:0;background:none;border:none;}#gs_top #gsc_a_trh,#gs_top #gsc_a_trh th{height:0;}#gs_top #gsc_a_ta,#gs_top #gsc_a_ca,#gs_top #gsc_a_ha,#gs_top .gsc_a_a{font-size:11pt;}#gs_top .gsc_a_ac{font-size:10pt}#gs_top #gsc_prf_pu{width:80pt;height:auto;float:left;margin:0 7pt 7pt 0;}#gs_top #gsc_prf_pua{left:auto;transform:none;border-radius:0;}#gs_top #gsc_prf_pua>img{position:static;}#gs_top #gsc_prf_i{margin:0 7pt 7pt 87pt;text-align:left;}#gs_top #gsc_prf_in{font-size:18pt;line-height:18pt;padding:0 0 4pt 0;}#gs_top .gsc_prf_il{padding:2pt 0;}#gs_top #gsc_prf_w{float:left;width:64%;}#gs_top .gsc_rsb{float:right;width:35%;}#gs_top #gsc_art{clear:both;}#gs_top #gsc_rsb_st{display:table;width:100%;max-width:none;margin-top:3pt;}#gs_top .gsc_rsb_sc1,#gs_top .gsc_rsb_sth,#gs_top .gsc_rsb_std{font-size:10pt;}#gs_top th.gsc_rsb_sc1,#gs_top .gsc_rsb_sth{border-bottom:1pt solid #ccc;}#gs_top .gsc_rsb_f{max-width:60pt;}#gs_top .gsc_rsb_sth{padding-left:14pt;}#gs_top #gsc_bdy .gsc_a_x,#gs_top #gsc_bdy .gsc_a_t,#gs_top #gsc_bdy .gsc_a_c,#gs_top #gsc_bdy .gsc_a_y,#gs_top #gsc_a_trh{padding:6pt 0;}#gs_top #gsc_a_trh{border-bottom:1pt solid #ccc;}#gs_top #gsc_a_ca{display:block;width:auto;}#gs_top #gsc_a_ta{display:inline-block;vertical-align:middle;margin-right:12pt;}#gs_top .gsc_a_h{display:inline;font-size:10pt;}#gs_top .gsc_a_at{color:#008;}#gs_top .gsc_a_m,#gs_top .gsc_a_am{display:inline;position:absolute;}#gs_top .gsc_a_am{padding: 11pt 0 0 8pt;}#gs_top .gsc_a_t .gs_gray{color:black;font-size:10pt;}}.gsc_lwpds_frm{position:relative;height:29px;}.gsc_lwpds_tsiw{position:absolute;top:0;left:0;right:38px;}.gsc_lwpds_tsiw input{border-radius:3px 0 0 3px;}.gsc_lwpds_tsbw{position:absolute;top:0;right:0;}.gsc_lwpds_tsbw button{border-radius:0 3px 3px 0;}.gsc_pgn{text-align:right;font-weight:bold;line-height:29px;}.gsc_pgn_ppn{margin:0 8px;}.gsc_ccb_ck{padding:11px 10px 9px 10px;}.gsc_ccb_svg{stroke:#666;stroke-width:2px;fill:#fff;width:21px;height:21px;vertical-align:top;}.gsc_ccb_lim .gsc_ccb_svg,.gsc_ccb_dis .gsc_ccb_svg{fill:#e2e2e2;stroke:#fff;}.gsc_ccb_lim .gsc_ccb_svg>circle,.gsc_ccb_dis .gsc_ccb_svg>circle{stroke:#e2e2e2;}.gsc_ccb_on .gsc_ccb_svg{fill:#4d90fe;stroke:#fff;}.gsc_ccb_on .gsc_ccb_svg>circle{stroke:#4d90fe;}.gsc_ccb_del:active .gsc_ccb_svg>circle,.gsc_ccb_add:active .gsc_ccb_svg>circle{fill:#2f6de1;}#gsc_md_cod{width:800px;max-width:94%;}.gs_el_ph #gsc_md_cod{width:100%;max-width:100%;}#gsc_md_cod .gs_md_prg{min-height:400px;}.gsc_codb_instr{font-size:16px;margin:1em 0;}#gsc_cods_res{position:relative;margin-bottom:24px;min-height:80px;border-bottom:1px solid #e5e5e5;}.gs_el_ph #gsc_cods_res{margin-bottom:16px;}.gsc_cods_hide,.gsc_cod_sugg #gsc_cod_tedit,.gsc_cod_sugg #gsc_cods_frm,.gsc_cod_sugg #gsc_cods_pp,.gsc_cod_lc #gsc_cod_tadd,.gsc_cod_changed #gsc_cod_tedit,.gsc_cod_changed #gsc_cod_tadd,.gsc_cod_lim #gsc_cod_tedit,.gsc_cod_lim #gsc_cod_tadd{display:none;}#gsc_cods_frm{margin:0 0 24px 0;}.gs_el_ph #gsc_cods_frm{margin:0 0 16px 0;}.gsc_ucoar{padding:24px 0;border-bottom:1px solid #eee;}.gs_el_ph .gsc_ucoar{padding:16px 0px;}.gsc_ucoar:first-child{padding-top:0;}.gsc_ucoar:last-child{border-bottom:none;}.gsc_ucoar_cb{float:right;margin-top:-8px;}#gsc_cod_trev{display:none;color:#666;pointer-events:none;}.gsc_cod_changed #gsc_cod_trev,.gsc_cod_lim #gsc_cod_trev{display:inline-block;}.gsc_cod_changed #gsc_cod_trev{color:#1a0dab;pointer-events:auto;}.gsc_fol_cr{margin:0 0 8px 0;}.gs_el_tc .gsc_fol_cr{margin:0;}.gs_el_tc .gsc_fol_cr:first-child{margin-top:-8px;}#gsc_fol_ml{display:block;color:#777;padding:12px 0 4px 0;}</style><script>!function(GSP){/*

 Copyright The Closure Library Authors.
 SPDX-License-Identifier: Apache-2.0
*/
var aa="function"==typeof Object.create?Object.create:function(a){var b=function(){};b.prototype=a;return new b},ba;if("function"==typeof Object.setPrototypeOf)ba=Object.setPrototypeOf;else{var da;a:{var ea={a:!0},fa={};try{fa.__proto__=ea;da=fa.a;break a}catch(a){}da=!1}ba=da?function(a,b){a.__proto__=b;if(a.__proto__!==b)throw new TypeError(a+" is not extensible");return a}:null}
var ha=ba,ia=function(a,b){a.prototype=aa(b.prototype);a.prototype.constructor=a;if(ha)ha(a,b);else for(var c in b)if("prototype"!=c)if(Object.defineProperties){var d=Object.getOwnPropertyDescriptor(b,c);d&&Object.defineProperty(a,c,d)}else a[c]=b[c];a.na=b.prototype},ja=function(){},ka=function(a,b){var c=Array.prototype.slice.call(arguments,1);return function(){var d=c.slice();d.push.apply(d,arguments);return a.apply(this,d)}};var g=function(){this.o=this.o;this.F=this.F};g.prototype.o=!1;g.prototype.isDisposed=function(){return this.o};g.prototype.T=function(){this.o||(this.o=!0,this.H())};g.prototype.H=function(){if(this.F)for(;this.F.length;)this.F.shift()()};function la(a){var b=[],c=0,d;for(d in a)b[c++]=d;return b};function l(a,b){a.classList.add(b)}function n(a,b){a.classList.remove(b)}function p(a,b){return a.classList?a.classList.contains(b):!1}function q(a,b,c){c=void 0!==c?c:!p(a,b);(c?l:n)(a,b)};function r(a){return 0<=(navigator.userAgent||"").indexOf(a)}var ma=r("iPhone")||r("iPad")||r("iPod"),na=r("iPhone")||r("Android")&&r("Mobile");function oa(){if(void 0===b){var a=window.screen;a={width:window.innerWidth,height:window.innerHeight,ma:a.width,la:a.height}}else a=b;var b=a;a=b.width;var c=b.height,d=b.ma;b=b.la;var e=4;if(600>a||48E4>d*b||na)e=1;else if(982>a)e=2;else if(1136>a||590>c)e=3;return e}var pa,qa=/[?&]tc=([01])/.exec(location.search||"");
pa=qa?0<+qa[1]:r("Android")?!0:window.matchMedia&&window.matchMedia("(pointer)").matches?window.matchMedia("(pointer:coarse)").matches:!r("Firefox")||r("Mobile")||r("Tablet")?ma||"ontouchstart"in window||0<(navigator.msMaxTouchPoints||0):!1;function ra(){if(void 0==sa){sa=!1;try{var a=Object.defineProperty({},"passive",{get:function(){sa=!0}});window.addEventListener("testPassive",ja,a);window.removeEventListener("testPassive",ja,a)}catch(b){}}return sa}var sa;var ta=function(a){this.Y=a},ua=new ta("INPUT"),va=new ta("TABLE");function t(a){return document.getElementById(a)}function x(a){return a.id||(a.id="gs_id"+wa++)}function xa(a){a=(void 0===a?null:a)||document.body;return"rtl"==(a?window.getComputedStyle(a,null):null).direction}
function ya(a){var b=[];a=a.elements;for(var c=a.length,d=0;d<c;d++){var e=a[d],f=encodeURIComponent(e.name||""),h=e.type;!f||e.disabled||!("checkbox"!=h&&"radio"!=h||e.checked)||b.push(f+"="+encodeURIComponent(e.value||""))}return b.join("&")}function za(a,b){var c=a.elements[b];c||(c=document.createElement(ua.Y),c.type="hidden",c.name=b,a.appendChild(c));return c}function Aa(a){t("gsc_md_cbyd_c").href=a&&a.match(Ba)?a:"javascript:void(0)"}function Ca(a){a.match(Ba)&&(window.location.href=a)}
var wa=100,Da=/\S+/g,Ba=/^(?:https?:|[^:/?#]*(?:[/?#]|$))/i,Ea=/^(?:#|\/[a-z0-9_-]*(?:[?].*)?$)/i;function y(a){return a.hasOwnProperty("gs_uid")?a.gs_uid:a.gs_uid=++Fa}var Fa=0;var z=function(){this.i=[];this.A={};this.O=this.v=0};z.prototype.add=function(a){var b=y(a);this.A[b]||(this.i.push(a),this.A[b]=this.i.length,++this.v)};z.prototype.remove=function(a){a=y(a);var b=this.A[a];b&&(this.i[b-1]=null,delete this.A[a],2*--this.v<this.i.length&&!this.O&&Ga(this))};z.prototype.notify=function(a){var b=this.i;try{++this.O;for(var c=0;c<b.length;c++){var d=b[c];d&&d.apply(null,arguments)}}finally{!--this.O&&2*this.v<b.length&&Ga(this)}};
var Ga=function(a){var b=a.i,c=b.length;a=a.A;for(var d=0,e=0;e<c;e++){var f=b[e];f&&(b[d]=f,a[y(f)]=++d)}b.length=d};function B(a,b,c,d,e){Ha(a,b,c,void 0===d?!1:d,void 0===e?!1:e,Ia)}function C(a,b,c,d){Ha(a,b,c,void 0===d?!1:d,!1,Ja)}function Ka(a,b,c,d){function e(h){C(f,a,e,c);b(h)}var f=document;c=void 0===c?!1:c;B(f,a,e,c,void 0===d?!1:d)}function D(a){La?La.add(a):a()}var Ma=window.requestAnimationFrame?function(a){window.requestAnimationFrame(a)}:function(a){setTimeout(a,33)};function Na(a){a.stopPropagation();a.preventDefault()}
function Oa(a){return(a.ctrlKey?1:0)|(a.altKey?2:0)|(a.metaKey?4:0)|(a.shiftKey?8:0)}function Ia(a,b,c,d,e){var f=a.addEventListener;e=e&&ra();f.call(a,b,c,e?{passive:e,capture:d}:d)}function Ja(a,b,c,d){a.removeEventListener(b,c,d)}function Ha(a,b,c,d,e,f){if("string"===typeof b)f(a,b,c,d,e);else for(var h=b.length,k=0;k<h;k++)f(a,b[k],c,d,e)}function Pa(){La.notify();La=null}function Qa(){"complete"==document.readyState&&(C(document,"readystatechange",Qa),Pa())}
var La,Ra=!!document.attachEvent,Sa=document.readyState;if(Ra?"complete"!=Sa:"loading"==Sa)La=new z,Ra?B(document,"readystatechange",Qa):Ka("DOMContentLoaded",Pa);function Ta(){Ka(["mousedown","touchstart"],function(){q(document.documentElement,"gs_pfcs",!0);B(document,"keydown",Ua,!0)},!0,!0)}function Ua(a){9==a.keyCode&&(q(document.documentElement,"gs_pfcs",!1),C(document,"keydown",Ua,!0),Ta())}Ta();function Va(a,b,c,d,e){var f=t(a);Wa(f,function(){l(f,"gs_vis");b&&b()},function(){n(f,"gs_vis");c&&c()},d,e)}function Wa(a,b,c,d,e){var f=x(a);if(!E[f]){var h=document.activeElement;Xa(Ya(a),!0);b&&b();G.push(function(k){delete E[f];try{k||(e||h).focus()}catch(m){}c&&c()});E[f]=G.length;h&&a.contains(h)||setTimeout(function(){var k=d,m=k&&"text"==k.type;if(!k||m&&pa)k=a;try{k.focus(),m&&(k.value=k.value)}catch(w){}},0)}}function H(a){Xa((E[a]||1E6)-1,!1)}
function Za(a){a=void 0===a?!1:a;G.pop()(a)}function Xa(a,b){for(b=void 0===b?!1:b;G.length>a;)Za(b||G.length>a+1)}function Ya(a){for(var b=0;a&&!(b=E[a.id]||0);)a=a.parentNode;return b}var G=[],E={};B(document,"click",function(a){var b=G.length;b&&!Oa(a)&&b>Ya(a.target)&&Za(!0)});B(document,"keydown",function(a){27==a.keyCode&&!Oa(a)&&G.length&&Za()});
B(document,"focus",function(a){var b=G.length;if(b)for(var c=Ya(a.target);c<b;){var d="",e;for(e in E)if(E[e]==b){d=e;break}a:{d=(t(d).getAttribute("data-wfc")||"").match(Da)||[];for(var f=0;f<d.length;f++){var h=t(d[f]);if(h&&h.offsetWidth){d=h;break a}}d=void 0}if(d){Na(a);d.focus();break}else Za(!0),--b}},!0);var $a={},ab={},bb;try{bb=window.sessionStorage}catch(a){};function J(a){return"object"==typeof a?a:null}function cb(a,b){b=db(b);a=eb(a);a=fb(a)||"#";gb=J(b);hb?window.history.pushState(b,"",a):window.location.assign(a)}function ib(a,b){b=db(b);a=eb(a);a=fb(a)||"#";gb=J(b);hb?window.history.replaceState(b,"",a):window.location.replace(a)}function fb(a){var b=[],c;for(c in a)b.push(encodeURIComponent(c)+"="+encodeURIComponent(a[c]));return(a=b.sort().join("&"))?"#"+a:""}
function jb(a){var b={};a=a.split("&");for(var c=0;c<a.length;c++){var d=a[c],e=d.indexOf("=");if(e+1){var f=d.substr(0,e);d=d.substr(e+1)}else f=d,d="";f&&(b[decodeURIComponent(f)]=decodeURIComponent(d))}return b}function kb(a){var b=a.indexOf("#")+1;return jb(b?a.substr(b):"")}function lb(a){var b=a.indexOf("?")+1;a=b?a.substr(b):"";b=a.indexOf("#");return jb(b+1?a.substr(0,b):a)}function mb(a,b){for(var c in b){var d=b[c];void 0!==d?a[c]=d:delete a[c]}}
function eb(a){var b=kb(window.location.hash);mb(b,a);return b}function db(a){var b=gb||J(window.history.state),c={},d;for(d in b)c[d]=b[d];mb(c,a);return c}function nb(){setTimeout(function(){if(!ob){var a=window.history.state;ob=!0;gb=J(a);rb.notify()}sb=!1},0)}var rb=new z,gb,ob=!1,sb=!0,hb="pushState"in window.history,tb;
if("undefined"==typeof GSP)tb=!1;else{var ub=.001*Date.now(),vb=GSP.eventId,wb=!1,K,xb=bb;if(!("nh"in $a)){var yb=xb&&xb.getItem("nh"),zb;if(yb)try{zb=JSON.parse(yb)}catch(a){}ab.nh=zb}K=ab.nh;K instanceof Array||(K=[]);for(var Ab=K.length,Bb=0,Cb=0;Cb<Ab;Cb++){var Db=K[Cb];if(Db instanceof Array&&2==Db.length){var Eb=Db[1]==vb;wb=wb||Eb;10>=Ab-Cb&&+Db[0]>ub-86400&&!Eb&&(K[Bb++]=Db)}}K.length=Bb;K.push([ub,vb]);var Fb=K,Gb=bb;ab.nh=Fb;try{Gb&&Gb.setItem("nh",JSON.stringify(Fb))}catch(a){}tb=wb}
var Hb=tb;"onpageshow"in window?B(window,"pageshow",nb):D(nb);B(window,hb?"popstate":"hashchange",function(a){"loading"!=document.readyState&&(a=a.state,ob=!0,gb=J(a),rb.notify())});function Ib(){Jb&&(C(t("gs_alrt_l"),"click",Jb),Jb=void 0)}function Kb(){var a=Lb();l(a,"gs_anm");l(a,"gs_vis");B(document,"click",Mb);clearTimeout(Nb);Nb=setTimeout(Mb,4E3);++Ob;setTimeout(Pb,0)}function Mb(){Ob||(C(document,"click",Mb),clearTimeout(Nb),Nb=void 0,Ib(),n(Lb(),"gs_vis"))}function Lb(){return t("gs_alrt")}function Pb(){Ob=0}var Nb,Ob=0,Jb;D(function(){var a=t("gs_alrt_m");a&&(a.innerHTML&&!Hb&&Kb(),B(window,"pagehide",function(){Ob=0;Mb();n(Lb(),"gs_anm")}))});function Qb(a,b,c){var d=new XMLHttpRequest;d.onreadystatechange=function(){if(4==d.readyState){var e=d.status,f=d.responseText,h=d.responseURL,k=window.location,m=k.protocol;k="//"+k.host+"/";h&&h.indexOf(m+k)&&h.indexOf("https:"+k)&&(e=0,f="");c(e,f)}};d.open(b?"POST":"GET",a,!0);d.setRequestHeader("X-Requested-With","XHR");b&&d.setRequestHeader("Content-Type","application/x-www-form-urlencoded");b?d.send(b):d.send();return d}function Rb(a){a&&(a.onreadystatechange=ja,a.abort())};var Sb=function(a,b,c){this.type=a;this.currentTarget=this.target=b;this.g=void 0===c?null:c;this.P=!1};Sb.prototype.stopPropagation=function(){this.g&&this.g.stopPropagation();this.P=!0};var L=function(a){a.g&&Na(a.g);a.P=!0};var M=function(a,b){this.R=a;this.ka=b},Tb=function(a,b,c){this.R=a;this.types=b;this.listener=c};function Ub(a,b){var c=b.length;if(c){var d=y(a),e=Vb[d];if(!e){e=Vb[d]=[];d=Wb(b[0].R);for(var f in d){var h=Xb[f];h||(h=Xb[f]=Object.create(null));for(var k in d[f]){var m=h[k];m||(m=h[k]=[]);m.push(a)}}Yb(a,e,b[0],Zb);for(f=1;f<c;f++)Yb(a,e,b[f],$b)}}}function O(a,b,c){ac(new Sb(a,b,void 0===c?null:c))}
function P(a,b,c){var d=bc;"string"===typeof b&&(cc[0]=b,b=cc);var e=b.length;a=Wb(a);for(var f in a)for(var h in a[f])for(var k=0;k<e;k++)d(f,h,b[k],c)}function Wb(a){"string"===typeof a&&(dc[0]=a,a=dc);for(var b=a.length,c=Object.create(null),d=0;d<b;d++){var e=a[d],f=e.charAt(0),h=e.substr(1);if("#"!=f&&"."!=f||!h)throw Error("bad selector: "+e);(e=c[f])||(e=c[f]=Object.create(null));e[h]=!0}return c}
function bc(a,b,c,d){var e=ec[c];e||("touchstart"!=c&&"mouseover"!=c&&"mouseout"!=c&&B(document,c,fc,"focus"==c||"blur"==c),e=ec[c]=Object.create(null));(c=e[a])||(c=e[a]=Object.create(null));(a=c[b])||(a=c[b]=new z);a.add(d)}function fc(a){var b=a.target;b&&3==b.nodeType&&(b=b.parentNode);ac(new Sb(a.type,b,a))}
function ac(a){for(var b=a.target;b&&b!=document&&!b.disabled&&!p(b,"gs_dis");){a.currentTarget=b;var c=b.id;if(c&&!gc("#",c,a))break;c=b.classList||[];for(var d=c.length,e=0;e<d;e++)if(!gc(".",c[e],a))return;b=b.parentNode}}function gc(a,b,c){var d=ec[c.type];(b=(a=d&&d[a])&&a[b])&&b.notify(c);return!c.P}function Yb(a,b,c,d){var e=c.R;c=c.ka;for(var f in c){var h=ka(d,a,c[f]);P(e,f,h);b.push(new Tb(e,f,h))}}function Zb(a,b,c){var d=c.currentTarget;a=hc(a,d)||a;a=ic(a,d);b.call(a,c)}
function $b(a,b,c){a:{for(var d=c.currentTarget;d&&d!=document;){var e=hc(a,d);if(e){a=ic(e,d);break a}d=d.parentNode}a=void 0}a&&b.call(a,c)}function ic(a,b){var c=jc(b),d=kc[c];d||(d=kc[c]=[]);for(var e=d.length,f=0;f<e;f++){var h=d[f];if(h instanceof a)return h}b=new a(b);d.push(b);a=y(a);(d=lc[a])||(d=lc[a]=[]);d.push(c);return b}function hc(a,b){var c,d=b.id;d&&(c=mc(a,c,"#",d));b=b.classList||[];d=b.length;for(var e=0;e<d;e++)c=mc(a,c,".",b[e]);return c}
function mc(a,b,c,d){c=(d=(c=Xb[c])&&c[d])?d.length:0;for(var e=0;e<c;e++){var f=d[e];!(f===a||f.prototype instanceof a)||b&&!(f===b||f.prototype instanceof b)||(b=f)}return b}function jc(a){var b=a.getAttribute("data-duid");b||a.setAttribute("data-duid",b=""+nc++);return b}var ec=Object.create(null),dc=[""],cc=[""],Xb=Object.create(null),Vb=Object.create(null),lc=Object.create(null),kc=Object.create(null),nc=100;window.gs_evt_dsp=fc;function oc(){var a=".gs_md_li";if("string"===typeof a){var b=a.charAt(0),c=a.slice(1);if("#"==b)a=function(d){return d.id==c&&0<d.offsetWidth};else if("."==b)a=function(d){return p(d,c)&&0<d.offsetWidth};else throw Error("bad selector: "+a);}return a}function pc(a,b){return a&&((void 0===b?0:b)?a.lastElementChild:a.firstElementChild)}function qc(a,b){return a&&((void 0===b?0:b)?a.previousElementSibling:a.nextElementSibling)}function rc(a,b,c){c=void 0===c?!1:c;return sc(a,b,oc(),c,!1)}
function sc(a,b,c,d,e){for(var f;b&&a;){if(c(b)){if(e)return b}else for(f=pc(b,d);f;f=qc(f,d))if(e=sc(f,f,c,d,!0))return e;for(e=!0;;){if(b==a)return null;f=b.parentNode;if(b=qc(b,d))break;b=f}}return null};function tc(a){return!!p(a,"gs_sel")+2*!!p(a,"gs_par")}function uc(a){return+a.getAttribute("data-s")}function vc(a,b,c){c=void 0===c?!1:c;q(a,"gs_sel",1==b);q(a,"gs_par",2==b);a.setAttribute("aria-checked",wc[b]);c||a.setAttribute("data-s",""+b)}var wc=["false","true","mixed"];var Q=function(){this.j=Object.create(null);this.l=0};Q.prototype.clear=function(){this.j=Object.create(null);this.l=0};Q.prototype.has=function(a){return a in this.j};Q.prototype.get=function(a){return this.j[a]};Q.prototype.set=function(a,b){this.has(a)||this.l++;this.j[a]=b};Q.prototype.delete=function(a){this.has(a)&&(delete this.j[a],this.l--)};var xc=function(a){var b=window,c=this;this.i=new z;this.V=0;this.S=[b,a,function(){c.V++||Ma(d)},!1];var d=function(){c.V=0;c.i.notify()}};xc.prototype.addListener=function(a){this.i.v||B.apply(null,this.S);this.i.add(a)};xc.prototype.removeListener=function(a){this.i.remove(a);this.i.v||C.apply(null,this.S)};var yc=new xc("scroll"),zc=new xc("resize");var Ac=new z;function Bc(){var a=document.documentElement,b=oa();b={gs_el_ph:1==b,gs_el_ta:2==b,gs_el_sm:4!=b,gs_el_tc:pa||1==b};var c;for(c in b){var d=b[c];if(p(a,c)!=d){var e=!0;q(a,c,d)}}e&&Ac.notify()}q(document.documentElement,"gs_el_ios",ma);Bc();zc.addListener(Bc);B(window,["pageshow","load"],Bc);function R(a,b,c,d){function e(){var u=ca&&p(h,"gs_el_ph");q(F,"gs_vis",!u);h.style.overflowY=Yd&&!u?"scroll":""}function f(){var u=h.clientHeight,I=+A.getAttribute("data-h");I||(w.style.maxHeight="none",I=m.offsetHeight);I=Math.max((u-I)/2,10);u=Math.max(u-48-2*I,10);var Jc=ca&&p(h,"gs_el_ph");m.style.top=Jc?"auto":I+"px";w.style.maxHeight=Jc?"none":u+"px";Cc(w)}b=void 0===b?"":b;c=void 0===c?"":c;d=void 0===d?"":d;var h=document.documentElement,k=t("gs_top"),m=t(a),w=t(a+"-bdy"),v=t(m.getAttribute("data-cid")||
m.id+"-bdy")||m,F=t(m.getAttribute("data-shd")||"gs_md_s"),A=Dc(m),ca=!!A&&p(A,"gs_md_wmw"),N=window.pageYOffset,Yd=k.scrollHeight>h.clientHeight,pb=!!E[a],qb=pb?"":S,Lc=b&&"#"!=b[0]&&!d,$d=a==S&&b==Ec&&c==T;Fc=b;Lc?(pb?q(v,"gs_md_ldg",!0):Gc(m,v,'<div class="gs_md_prg">'+t("gs_md_ldg").innerHTML+"</div>"),O("gs-md-ldin",v)):(d&&Gc(m,v,d),O("gs-md-lded",v));qb&&(++Hc,H(qb),--Hc);S=a;Ec=b;T=c;Ic=d;$d||Hc||(Kc+=1,(qb?ib:cb)(Mc(),Nc()));pb||Wa(m,function(){A&&l(A,"gs_vis");l(m,"gs_vis");q(m,"gs_abt",
sb);Oc(a);Ac.add(e);e();A&&w&&(f(),zc.addListener(f));l(k,"gs_nscl");k.style.top=-N+"px"},function(){Ac.remove(e);zc.removeListener(f);A&&n(A,"gs_vis");n(m,"gs_vis");n(m,"gs_abt");n(F,"gs_vis");h.style.overflowY="";n(k,"gs_nscl");k.style.top="auto";Rb(U);U=null;window.scrollTo(0,N);S=Ec=T=Ic="";var u=Kc;Kc=0;Hc||(0<u?window.history.go(-u):ib(Mc(),Nc()))},Pc(m),Qc(m));Lc&&(Rb(U),U=null,U=Qb(b,c,function(u,I){U=null;u=200==u;Gc(m,v,u?I:Rc());u&&a==S&&b==Ec&&c==T&&(Ic=I,ib(Mc(),Nc()));O("gs-md-lded",
v)}))}function Dc(a){a=a.parentNode;return p(a,"gs_md_wnw")?a:null}function Pc(a){return(a=a.getAttribute("data-ifc"))?t(a):null}function Qc(a){return(a=a.getAttribute("data-cfc"))?t(a):null}
function Gc(a,b,c){q(b,"gs_md_ldg",!1);for(var d=b.querySelectorAll("[data-duid]"),e=d.length,f={},h=0;h<e;h++){for(var k=jc(d[h]),m=kc[k],w=m?m.length:0,v=0;v<w;v++){var F=m[v],A=y(F.constructor),ca=f[A];ca||(ca=f[A]={});ca[k]=!0;F&&"function"==typeof F.T&&F.T()}delete kc[k]}for(var N in f){N=+N;d=f[N];h=(e=lc[N])?e.length:0;for(m=k=0;m<h;m++)w=e[m],w in d||(e[k++]=w);k?e.length=k:delete lc[N]}b.innerHTML=c;Oc(a.id);Rb(U);U=null}
function Oc(a){if(a=document.querySelector("#"+a+">.gs_md_bdy"))a.scrollTop=a.scrollLeft=0,Cc(a)}function Cc(a){var b=a.style,c="padding"+(xa(a)?"Left":"Right");b[c]="";var d=a.offsetWidth-a.clientWidth;2<d&&(a=parseInt(window.getComputedStyle(a,null)[c],10)||0,b[c]=Math.max(a-d,0)+"px")}function Rc(){return'<div class="gs_md_prg"><div class="gs_alrt">'+t("gs_md_err").innerHTML+"</div></div>"}function Mc(){return{d:S||void 0,u:Ec||void 0,p:T?"1":void 0}}function Nc(){return{n:Kc,p:T,h:Ic}}
var U=null,Fc="",S="",Ec="",T="",Ic="",Kc=0,Hc=0;rb.add(function(){var a=kb(window.location.hash),b=a.d||"",c=b?t(b):null;++Hc;if(c){c=a.u||"";a=0<+a.p;var d=gb||J(window.history.state)||{},e=+d.n||0,f=""+(d.p||"");d=""+(d.h||"");c.match(Ea)||(c="");a!=!!f?R(b,"","",Rc()):b==S&&c==Ec&&f==T&&d==Ic||R(b,c,f,d);Kc=e}else S&&H(S);--Hc});var Sc=function(a){g.call(this);this.D=a;this.K=Object.create(null);this.C=null;a=a.querySelectorAll(".gs_in_txtw>input[type=text]");for(var b=a.length;b--;){var c=a[b],d=c.parentNode.querySelector(".gs_in_txts");c=c.name;d&&c&&(this.K[c]=d.innerHTML)}};ia(Sc,g);Sc.prototype.H=function(){Rb(this.C);this.D=this.C=null;g.prototype.H.call(this)};
Sc.prototype.ga=function(a){var b=this;L(a);if((a=this.D)&&!this.C){var c="json=&"+ya(a);Tc(this,!0);this.C=Qb(a.action,c,function(d,e){b.C=null;Tc(b,!1);var f=b.D,h=f.getAttribute("data-alrt");if(h=h?t(h):null)h.innerHTML="";try{var k=200==d&&JSON.parse(e)}catch(A){}k&&"object"==typeof k||(Uc(h,t("gs_md_err").innerHTML),k={});if(d=k.L)Ca(""+d);else{(d=k.M)&&Uc(h,d);d=1E6;if(h&&h.innerHTML){var m=h;d=h.getBoundingClientRect().top}f=f.elements;k=k.E;"object"==typeof k||(k=Object.create(null));for(var w in b.K){h=
f[w];e=void 0;var v=""+(k[w]||""),F=h.parentNode.querySelector(".gs_in_txts");q(h.parentNode,"gs_in_txte",!!v);F&&(F.innerHTML=v||b.K[w]||"");v&&(e=h.getBoundingClientRect().top)<d&&(m=h,d=e)}m&&m.scrollIntoView&&(0>d||d+20>window.innerHeight)&&m.scrollIntoView()}})}};
var Tc=function(a,b){a=a.D;var c=a.getAttribute("data-bsel");a=c?document.querySelectorAll(c):a.querySelectorAll("button");for(c=a.length;c--;){var d=a[c];d.disabled=b;q(d,"gs_bsp",b)}},Uc=function(a,b){if(a)a.innerHTML=b;else{var c=void 0===c?"":c;var d=void 0===d?"":d;var e=void 0===e?[]:e;t("gs_alrt_m").innerHTML=b;Lb().action=d.match(Ba)?d:"";a=t("gs_alrt_l");a.textContent=c;c=t("gs_alrt_h");c.innerHTML="";for(var f in e)b=document.createElement("input"),b.type="hidden",b.name=f,b.value=e[f],
c.appendChild(b);Ib();q(a,"gs_fm_s",!0);Kb()}};Ub(Sc,[new M(".gs_ajax_frm",{submit:Sc.prototype.ga})]);var Vc=[[1,0,1],[2,0,1]];P(".gs_cb_gen","click",function(a){var b=a.currentTarget,c=tc(b),d=2==+b.getAttribute("data-s");vc(b,Vc[+d][c],!0);O("gs-change",b,a.g)});P(".gs_cb_gen",["keydown","keyup"],function(a){var b=a.currentTarget,c=a.g.keyCode;"BUTTON"!=b.tagName||13!=c&&32!=c||(L(a),"keydown"==a.type&&b.click())});P([".gs_cb_gen",".gs_md_li"],"keydown",function(a){var b=a.currentTarget,c=b.tagName,d=a.g.keyCode;"BUTTON"!=c&&(32==d||13==d&&"A"!=c)&&(L(a),b.click())});var Wc=["click","contextmenu","mouseup"].concat(navigator.sendBeacon?[]:["mousedown","touchstart"]),Xc="",Yc=null;function Zc(){Yc=null}function $c(a){navigator.sendBeacon?navigator.sendBeacon(a):Yc&&a==Yc.src||((Yc=new Image).src=a,setTimeout(Zc,1E3))}function ad(){var a=lb(document.location.href).hl||"";a="/scholar_bfnav?url="+encodeURIComponent(document.location.href)+"&hl="+encodeURIComponent(a)+"&ei="+GSP.eventId;$c(a)}D(function(){Xc=Hb?"&bn=1":"";Hb&&ad()});
B(window,"pageshow",function(a){a.persisted&&(Xc="&bn=1",ad())});
B(document,Wc,function(a){if(!("click"==a.type&&a.button||"mouseup"==a.type&&1!=a.button)){var b,c;a:{for(a=a.target;a;){var d=a.nodeName;if("A"==d)break a;if("SPAN"==d||"B"==d||"I"==d||"EM"==d||"IMG"==d)a=a.parentNode;else break}a=null}a&&(b=a.getAttribute("href"))&&(c=a.getAttribute("data-clk"))&&(b="/scholar_url?url="+encodeURIComponent(b)+"&"+c+"&ws="+window.innerWidth+"x"+window.innerHeight+"&at=",c=encodeURIComponent,a=(a=a.getAttribute("data-clk-atid"))&&t(a),b=b+c(a&&a.innerText||"")+Xc,$c(b))}},
!1,!0);P(".gs_fm_s","click",function(a){a=a.currentTarget.getAttribute("data-fm")||"";(a=t(a))&&a.submit()});var V=function(a){this.m=x(a.querySelector(".gs_md_d"));this.G=x(a.querySelector(".gs_md_tb"))};V.prototype.I=function(a){var b=t(this.m);return void 0!==a?rc(b,b,a):null};V.prototype.open=function(a){a=this.I(a);if(p(t(this.G),"gs_sel"))try{a&&a.focus()}catch(c){}else{var b=t(this.G);Va(this.m,function(){l(b,"gs_sel")},function(){n(b,"gs_sel")},a,b)}};V.prototype.close=function(){H(this.m)};V.prototype.Z=function(a){L(a);p(t(this.G),"gs_sel")?this.close():this.open("keydown"==a.g.type?!1:void 0)};
V.prototype.U=function(a){var b=a.g.keyCode;if(38==b||40==b)L(a),this.open(38==b)};V.prototype.aa=function(a){a.target.id==this.m&&this.U(a)};Ub(V,[new M(".gs_md_rmb",{}),new M(".gs_md_tb",{"gs-press":V.prototype.Z,keydown:V.prototype.U}),new M(".gs_md_d",{keydown:V.prototype.aa})]);var W=function(a){V.call(this,a);this.ia=x(a.querySelector(".gs_md_in"));this.ja=x(a.querySelector(".gs_md_tb .gs_lbl"))};ia(W,V);W.prototype.I=function(){return t(this.m).querySelector(".gs_md_li[aria-selected]")};W.prototype.ba=function(a){bd(this,a)};W.prototype.J=function(a){var b=a.g.keyCode;13!=b&&32!=b||bd(this,a)};
var bd=function(a,b){var c=b.currentTarget,d=t(a.ia),e=a.I();c!=e&&(d.value=c.getAttribute("data-v"),t(a.ja).innerHTML=c.innerHTML,e&&cd(e,!1),cd(c,!0));L(b);a.close();O("gs-change",d,b.g)},cd=function(a,b){q(a,"gs_sel",b);b?a.setAttribute("aria-selected","true"):a.removeAttribute("aria-selected")};Ub(W,[new M(".gs_md_ris",{}),new M(".gs_md_li",{click:W.prototype.ba,keydown:W.prototype.J})]);P("#gs_lp","click",function(a){L(a);R("gs_lp_d")});P("#gs_lp_cur","click",function(a){L(a);H("gs_lp_d")});var dd=function(a){this.W=x(a)};dd.prototype.J=function(a){var b=a.currentTarget,c=a.g.keyCode;if(38==c||40==c){var d=t(this.W);d=rc(d,b,38==c)||rc(d,d,38==c)}else if(37==c||39==c)a:{c=!!(37==c^xa(b.parentNode));d=b.parentNode;var e=d.children,f=e.length;if(d.id!=this.W){for(;e[--f]!=b;);d=qc(d,c)||pc(d.parentNode,c);e=d.children;if(f=Math.min(f+1,e.length))if(d=e[f-1],p(d,"gs_md_li")&&d.offsetLeft!=b.offsetLeft)break a}d=void 0}d&&(L(a),d.focus())};
Ub(dd,[new M(".gs_md_ulr",{}),new M(".gs_md_li",{keydown:dd.prototype.J})]);P("#gs_hdr_mnu","click",function(a){L(a);R("gs_hdr_drw")});P("#gs_hdr_drw_mnu","click",function(a){L(a);H("gs_hdr_drw")});P("#gs_hdr_act_i","click",function(a){L(a);1==oa()?Ca(document.querySelector("#gs_hdr_drw_bot>a").href):Va("gs_hdr_act_d")});P("#gs_hdr_drw","keydown",function(a){var b=a.g.keyCode;if(38==b||40==b){var c=a.currentTarget;if(b=rc(c,c,38==b))L(a),b.focus()}});
P("#gs_hdr_tsi",["focus","blur"],function(a){function b(){var h=d.getBoundingClientRect().top-10;10<Math.abs(h)&&window.scrollBy(0,h);clearTimeout(e);c()}function c(){C(window,f,b)}var d=a.target;a="focus"==a.type;q(t("gs_hdr"),"gs_hdr_ifc",a);if(a&&pa&&!(749<window.innerHeight)){var e=setTimeout(c,1E3),f=["scroll","resize"];B(window,f,b)}});P("#gs_hdr_tsi",["input","gs-change"],function(a){q(t("gs_hdr_frm"),"gs_hdr_tsc",!!a.currentTarget.value)});
P("#gs_hdr_tsc","mousedown",function(a){L(a);var b=t("gs_hdr_tsi");b.value="";b.focus();O("input",b,a.g)});P("#gs_hdr_sre","click",function(a){L(a);var b=t("gs_hdr");Va("gs_hdr_frm",function(){n(b,"gs_hdr_src");l(b,"gs_hdr_srx")},function(){l(b,"gs_hdr_src");n(b,"gs_hdr_srx")},t("gs_hdr_tsi"))});P(".gs_md_x","click",function(a){(a=a.currentTarget.getAttribute("data-mdx"))&&H(a)});var X=function(){},ed,fd;X.prototype.$=function(a){a.g.button||(L(a),gd(a))};X.prototype.ca=function(a){hd(a)&&(L(a),gd(a))};X.prototype.da=function(a){hd(a)&&L(a)};X.prototype.ea=function(a){if(!a.g.button){L(a);var b=a.g;b&&(id=b.clientX||0,jd=b.clientY||0,B(document,kd,ld,!0),clearTimeout(ed),ed=setTimeout(md,2E3));gd(a)}};X.prototype.ha=function(a){L(a);if(nd){var b=a.g;if(b=(b=b&&b.touches)&&1==b.length&&b[0])od=b.clientX,pd=b.clientY,B(document,qd,rd,!0),clearTimeout(fd),fd=setTimeout(sd,2E3)}gd(a)};
var hd=function(a){a=a.g.keyCode;return 32==a||13==a},gd=function(a){O("gs-press",a.currentTarget,a.g)},md=function(){C(document,kd,ld,!0);clearTimeout(ed);ed=void 0},ld=function(a){"mousedown"!=a.type&&10>Math.abs(a.clientX-id)&&10>Math.abs(a.clientY-jd)?(Na(a),"click"==a.type&&md()):md()},sd=function(){C(document,qd,rd,!0);clearTimeout(fd);fd=void 0},rd=function(a){"touchstart"!=a.type&&10>Math.abs(a.clientX-od)&&10>Math.abs(a.clientY-pd)?(Na(a),"click"==a.type&&sd()):sd()},id=0,jd=0,kd=["mousedown",
"mouseup","click"],nd=r("Android")&&!r("Chrome"),od=0,pd=0,qd=["touchstart","mousedown","mouseup","click"];Ub(X,[new M(".gs_press",{click:X.prototype.$,keydown:X.prototype.ca,keyup:X.prototype.da,mousedown:X.prototype.ea,touchstart:X.prototype.ha})]);function td(){var a=0>ud.getBoundingClientRect().top;vd!=a&&(vd=a,q(wd,"gs_sth_vis",a),a?xd():(yd.style.left="",yd.style.width="",zd()))}function xd(){if(vd){var a=ud.getBoundingClientRect();yd.style.left=a.left+"px";yd.style.width=a.width+"px";zd()}}function zd(){O("gs-sth-change",t("gs_sth"))}var wd,ud,yd,vd=!1;D(function(){if(wd=t("gs_sth"))ud=wd.querySelector(".gs_sth_g"),yd=wd.querySelector(".gs_sth_b"),yc.addListener(td),zc.addListener(xd),td()});function Ad(){var a=t("gsc_rsb_co");if(a){a=a.querySelectorAll("img.gs_pp_df");for(var b=0;b<a.length;b++){var c=a[b];c.getAttribute("data-srcset")&&(c.setAttribute("srcset",c.getAttribute("data-srcset")),c.removeAttribute("data-srcset"));c.getAttribute("data-src")&&(c.setAttribute("src",c.getAttribute("data-src")),c.removeAttribute("data-src"))}}};var Bd=/\S+@\S+\.\S+/;function Cd(a){return p(a,"gsc_ccb_dis")||p(a,"gsc_ccb_lim")}function Dd(){for(var a=0>=Ed(),b=t("gsc_cods_res").querySelectorAll(".gsc_ccb_add"),c=b.length;c--;){var d=b[c];p(d,"gsc_ccb_on")||q(d,"gsc_ccb_lim",a)}};var Fd=function(a){this.X=a};Fd.prototype.fa=function(a){L(a);a=a.currentTarget.getAttribute("data-a");this.X.setAttribute("data-a",a||"");O("gsc-navigate",this.X)};var Gd=[new M(".gsc_pgn",{}),new M([".gsc_pgn_ppr",".gsc_pgn_pnx"],{click:Fd.prototype.fa})];function Hd(a,b){b=void 0===b?"":b;var c=t("gsc_md_cod");a+=fb({t:Id});R(c.id,a,"",b)}function Jd(a){if(Id!=a){var b=t("gsc_md_cod");n(b,Id);l(b,a);Id=a}}function Kd(){var a=kb(Fc).t;"gsc_cod_sugg"!=a&&"gsc_cod_lc"!=a||Jd(a)}function Ld(){var a=Md();a=a?a.value:"";var b=(t("gsc_cods_urls").getAttribute("data-sa")||"").replace(Nd,"$1"+encodeURIComponent(a));a=a?b:t("gsc_cods_urls").getAttribute("data-lc")||"";Hd(a)}
function Od(a){var b=t("gsc_cods_frm");if(b){b=b.elements;var c=b[1];b[0].disabled=c.disabled=a;q(c,"gs_bsp",a)}a=a?null:t("gsc_codb_data");if(c=t("gsc_cods_pp")){var d=a&&a.getAttribute("data-prev");b=a&&a.getAttribute("data-next");var e=a&&a.getAttribute("data-start"),f=a&&a.getAttribute("data-end");c.querySelector(".gsc_pgn_ppn").textContent=e&&f?e+" - "+f:"";e=c.querySelector(".gsc_pgn_ppr");e.disabled=!d;e.setAttribute("data-a",d||"");c=c.querySelector(".gsc_pgn_pnx");c.disabled=!b;c.setAttribute("data-a",
b||"")}a&&(Pd=+a.getAttribute("data-max")||0,za(t("gsc_cods_save"),"xsrf").value=a.getAttribute("data-xsrf")||"")}function Qd(){var a=0<Y.l||0<Z.l,b=Ed(),c=0>=b;t("gsc_cod_done").disabled=!a||0>b;q(t("gsc_cod_t"),"gsc_cod_changed",a);a=t("gsc_cod_trev");a.textContent=a.getAttribute(c?"data-lim":"data-txt")||"";q(t("gsc_cod_t"),"gsc_cod_lim",c)}function Ed(){return Pd-Y.l+("gsc_cod_sugg"==Id?0:Z.l)}function Md(){return t("gsc_cods_tsi")}
function Rd(a){for(var b="",c=la(a.j),d=c.length;d--;)b+=a.get(c[d]);return b}var Id="gsc_cod_lc",Pd=0,Nd=/([?&]mauthors=)([^&]*)/,Y=new Q,Z=new Q;function Sd(a){q(t("gsc_a_sp"),"gs_vis",0==a);q(t("gsc_a_err"),"gs_vis",2==a)}function Td(){return document.querySelectorAll("#gsc_a_t input[type=checkbox]")}function Ud(){O("gsc-works-change",t("gsc_a_t"))}function Vd(){var a=t("gsc_x_all");if(a){var b=document.querySelectorAll("#gsc_a_t input[type=checkbox]:checked");var c=b.length;var d=Td().length;c=c?c==d?1:2:0;vc(a,c);2==c&&(Wd=b)}Ud()}var Wd=[];var Xd="",Zd=0,ae=0;function be(a){for(var b=[!1,!1,!1],c=0;c<b.length;c++){var d=t(ce[c]);d&&(b[c]=!!a(d))}return b}function de(){var a=t("gsc_fol_m");if(a){var b=t("gsc_fol_b");if(!(a=!Bd.test(a.value))){a:{a=be(tc);for(var c=be(uc),d=0;d<a.length;d++)if(a[d]!=c[d]){a=!0;break a}a=!1}a=!a}b.disabled=a}}var ce=["gsc_fol_a","gsc_fol_c","gsc_fol_r"],ee=["follow_articles_btn","follow_citations_btn","follow_related_btn"];function fe(){p(document.documentElement,"gs_el_ph")||p(document.documentElement,"gs_el_ta")||Ad()};function ge(a){if(a){a.id&&a.removeAttribute("id");for(var b=0;b<a.children.length;b++)ge(a.children[b])}};function he(){var a=t("gsc_prf_pufii");if(r("MSIE ")){var b=t("gsc_prf_puf");Va("gsc_prf_pufi",function(){l(b,"gsc_prf_pufo")},function(){n(b,"gsc_prf_pufo")},a)}else a.click()};function ie(){var a=document.querySelectorAll(".gsc_prf_pnl"),b=document.documentElement;b=p(b,"gs_el_ph")||p(b,"gs_el_ta");for(var c=0;c<a.length;c++)a[c].setAttribute("role",b?"tabpanel":"region")};var je=kb(window.location.hash),ke=je.u||"";"gs_md_cita-d"==je.d&&ke.match(Ea)&&0<=ke.indexOf("view_citation")&&Ca(ke);P("#gsc_md_cod","gs-md-ldin",function(){Kd();Od(!0)});P("#gsc_md_cod","gs-md-lded",function(){Kd();Od(!1);for(var a=t("gsc_cods_res").querySelectorAll(".gsc_ccb_ck"),b=a.length;b--;){var c=a[b];if(!Cd(c)){var d=c.getAttribute("data-authorid")||"";d=(p(c,"gsc_ccb_add")?Y:Z).has(d);q(c,"gsc_ccb_on",d)}}Dd();Qd();a=lb(Fc);(b=Md())&&(b.value=a.mauthors||"")});
P("#gsc_cods_frm","gsc-lwpds-submit",Ld);P("#gsc_cods_pp","gsc-navigate",function(a){(a=a.currentTarget.getAttribute("data-a"))&&Hd(a)});
P([".gsc_ccb_add",".gsc_ccb_del"],"click",function(a){a=a.currentTarget;if(!Cd(a)){var b=!p(a,"gsc_ccb_on");q(a,"gsc_ccb_on",b);var c=p(a,"gsc_ccb_add")?".gsc_ccb_del":".gsc_ccb_add",d=a.parentNode;(c=d&&d.querySelector(c))&&n(c,"gsc_ccb_on");c=a.getAttribute("data-authorid")||"";Y.delete(c);Z.delete(c);b&&(p(a,"gsc_ccb_add")?Y:Z).set(c,t("gsc_ucoar-"+c).outerHTML);Dd();Qd()}});
P("#gsc_cod_trev","click",function(){var a=t("gsc_cods_res").cloneNode(!0),b=a.querySelector("#gsc_codb_content");b||(b=document.createElement("div"),b.id="gsc_codb_content",a.appendChild(b));var c=Rd(Y)+Rd(Z);b.innerHTML=c;(b=Md())&&(b.value="");Hd("",a.innerHTML)});P("#gsc_cod_done","click",function(){var a=t("gsc_cods_save");za(a,"colleague_add").value=la(Y.j).join(",");za(a,"colleague_del").value=la(Z.j).join(",");a.submit()});
P(["#gsc_coauth_opn",".gsc_rsb_btne",".gsc_rsb_btnv"],"click",function(){Jd("gsc_cod_lc");Pd=0;Y.clear();Z.clear();var a=Md();a&&(a.value="");Ld()});P(".gsc_rsb_aa",["click","keydown"],function(a){if("keydown"!=a.type||a.g&&!Oa(a.g)&&13==a.g.keyCode)a.g&&Na(a.g),(a=(a=a.currentTarget.querySelector("a"))?a.getAttribute("href"):"")&&Ca(a)});P("#gsc_prf_t-ath","click",function(){Ad()});D(function(){Ac.add(fe);fe()});P(".gsc_lwpds_frm","submit",function(a){L(a);O("gsc-lwpds-submit",a.target)});
var le=window.location.href.split("#")[0];Xd=le.replace(/([?&])(cstart|pagesize)=[^&]*/g,"$1");Zd=Math.max(+le.replace(/.*[?&]cstart=([^&]*).*/,"$1")||0,0);ae=+le.replace(/.*[?&]pagesize=([^&]*).*/,"$1")||0;ae=Math.max(Math.min(ae,100),20);
P("#gsc_bpf_more","click",function(a){var b=a.currentTarget,c=ae,d=100>c?100-c:100;a=(Xd+"&cstart="+(Zd+c)+"&pagesize="+d).replace(/([?&])&+/g,"$1");Sd(0);b.disabled=!0;Qb(a,"json=1",function(e,f){b.disabled=!1;try{var h=200==e&&JSON.parse(f)}catch(m){}if(h&&"object"==typeof h){ae=c+=d;Sd(1);e=t("gsc_a_b");f=document.createElement(va.Y);f.innerHTML=""+h.B;f=Array.prototype.slice.call(f.rows);for(var k=0;k<f.length;k++)e.appendChild(f[k]);Vd();if(e=t("gsc_a_nn"))f=e.innerHTML.replace(/[0-9]+$/,""+
t("gsc_a_b").rows.length),e.innerHTML=f;b.disabled=!h.N}else Sd(2)})});P(["#gsc_fol_a","#gsc_fol_c","#gsc_fol_r"],"gs-change",de);P("#gsc_fol_m","input",de);P("#gsc_fol_f","submit",function(a){a.g&&a.g.preventDefault();a=t("gsc_fol_f");var b=t("gsc_fol_inp");b.innerHTML="";for(var c=be(tc),d=be(uc),e=0;e<c.length;e++)if(c[e]!=d[e]){var f=ee[e],h=document.createElement("input");h.type="hidden";h.name=c[e]?f:"un"+f;b.appendChild(h)}O("gsc-fol-submit",a)});P("#gsc_fol_f","gsc-fol-submit",function(a){a.currentTarget.submit()});
P("#gsc_md_hist","gs-md-lded",function(){var a=t("gsc_md_hist_c");if(!a.innerHTML){var b=document.getElementsByClassName("gsc_g_hist_wrp");1==b.length&&(a.appendChild(b[0].cloneNode(!0)),ge(a.lastChild))}});P(["#gsc_hist_opn",".gsc_md_hist_b"],"click",function(){var a=document.documentElement;!t("gsc_hist_opn")||p(a,"gs_el_ph")||p(a,"gs_el_ta")||R("gsc_md_hist")});
P("#gsc_lwp_mndt_lnk","click",function(a){var b=a.currentTarget.getAttribute("href")+"&tzom="+(new Date).getTimezoneOffset();window.location.assign(b);a.g.preventDefault()});P("#gsc_prf_btne","click",function(){var a=t("gsc_md_pro-d");a.setAttribute("data-ifc","");R(a.id,fb({t:"gsc_md_pro_ed"}))});P("#gsc_prf_btnf","click",function(){R("gsc_md_fol")});P("#gsc_md_fol_pub","click",function(){t("gsc_fol_mpf").submit()});P("#gsc_prf_iv_tg","click",function(){q(t("gsc_prf_w"),"gsc_prf_why")});
P(".gsc_prf_pel",["click","keydown"],function(a){("keydown"!=a.type||13==a.g.keyCode&&a.g&&!Oa(a.g))&&he()});P("#gsc_prf_pufii","change",function(){t("gsc_prf_puf").submit()});P(".gsc_prf_tab","click",function(a){var b=t("gsc_bdy");b.setAttribute("data-tab",a.currentTarget.id);b=b.querySelectorAll(".gsc_prf_tab");for(var c=0;c<b.length;c++){var d=b[c];d.setAttribute("aria-selected",""+(d==a.currentTarget))}});D(function(){Ac.add(ie);ie()});
P("#gsc_md_cbyd","gs-md-ldin",function(){var a=t("gsc_md_cbyd_merge");a&&(a.disabled=!0);Aa("")});P("#gsc_md_cbyd","gs-md-lded",function(){var a=t("gsc_md_cbyd_f"),b=t("gsc_md_cbyd_merge"),c=Fc,d=lb(c).s||"";c=kb(c).c||"";a.elements.s.value=d;Aa(c);b&&a.elements.choose&&(b.disabled=!1,b.getBoundingClientRect().bottom<window.innerHeight&&b.focus())});
P("#gsc_md_cbym",["gs-md-ldin","gs-md-lded"],function(){var a=lb(Fc).s||"",b=t("gsc_md_cbym_e");b&&a&&0>a.indexOf("&")&&b.setAttribute("data-href",(b.getAttribute("data-href")||"").replace(/(&citation_for_view=)[^&]*/,"$1"+a))});P("#gsc_md_cbym_e","click",function(a){a=a.currentTarget.getAttribute("data-href")||"";R("gs_md_cita-d",a)});Ub(Fd,Gd);D(function(){return setTimeout(Vd,0)});P(".gsc_a_x","change",Vd);
P("#gsc_x_all","gs-change",function(a){a=tc(a.currentTarget);for(var b=2==a?Wd:Td(),c=b.length;c--;)b[c].checked=0!=a;Ud()});P(".gsc_a_acm","click",function(a){L(a);var b=a.currentTarget;a=b.href;var c=b.getAttribute("data-eid")||"";b=b.getAttribute("data-eud")||"";a=t("gsc_md_cbyd_f").action+"&update_op=merge_options&s="+(b+","+c)+fb({c:a});R("gsc_md_cbyd",a)});
P(".gsc_a_am","click",function(a){a=a.currentTarget.getAttribute("data-eid")||"";a=(t("gsc_md_cbym_l").getAttribute("data-act")||"")+"&update_op=merge_options&s="+a;R("gsc_md_cbym",a)});P("#gs_sth","gs-sth-change",function(a){var b=t("gsc_a_tr0"),c=t("gsc_a_trh"),d=b.querySelector(".gsc_a_t"),e=c.querySelector(".gsc_a_t");p(a.currentTarget,"gs_sth_vis")?(e.style.width=d.offsetWidth+"px",b.style.height=c.offsetHeight+"px"):e.style.width=b.style.height="auto"});
P("#gs_md_cita-b-save","click",function(){var a=t("gsc_ecd_form");za(a,"continue").value=window.location.pathname+window.location.search;O("submit",a)});P(".gsc_ecd_form_tsel","click",function(a){var b=t("gsc_ecd_table"),c=za(t("gsc_ecd_form"),"articletype");a=a.currentTarget;c.value=a.getAttribute("data-type")||"";b.className=a.getAttribute("data-class")||"";b=document.querySelectorAll("#gsc_ecd_citation_type button");for(c=b.length;c--;)q(b[c],"gs_sel",b[c]==a)});
}({"customAC":2,"eventId":"3K45YaiQLMLMsQLZ-InYBQ"});</script></head><body><div id="gs_top" onclick=""><style>#gs_md_s,.gs_md_wnw{z-index:1200;position:fixed;top:0;left:0;width:100%;height:100%;visibility:hidden;}#gs_md_s{background-color:#fff;opacity:.5;}.gs_el_ta #gs_md_s,.gs_el_ph #gs_md_s{background-color:#666;}.gs_md_wnw{transition:all 0s .218s;}#gs_md_s.gs_vis,.gs_md_wnw.gs_vis{visibility:visible;transition:all 0s;}.gs_md_wnw>.gs_md_d{position:relative;margin:0 auto;width:464px;box-shadow:2px 2px 8px rgba(0,0,0,.2);white-space:normal;}.gs_el_ta .gs_md_wnw>.gs_md_d,.gs_el_ph .gs_md_wnw>.gs_md_d{box-shadow:2px 2px 8px rgba(0,0,0,.65);}.gs_el_ph .gs_md_wnw>.gs_md_d{width:80%;max-width:440px;}.gs_el_ph .gs_md_wmw>.gs_md_d{width:100%;height:100%;max-width:none;border:none;box-shadow:none;transform:translate(0,100%);transform:translate(0,100vh);transition:transform .27s cubic-bezier(.4,0,.6,1),opacity 0s .27s,visibility 0s .27s,max-height 0s .27s;}.gs_el_ph .gs_md_wmw>.gs_md_d.gs_vis{transform:translate(0,0);transition:transform .3s cubic-bezier(0,0,.2,1);}.gs_md_wmw>.gs_md_d.gs_abt,.gs_el_ph .gs_md_wmw>.gs_md_d.gs_abt{transition:none;}.gs_md_hdr{display:flex;align-items:center;height:47px;border-bottom:1px solid #e0e0e0;border-bottom-color:rgba(0,0,0,.12);background-color:#f5f5f5;}.gs_md_hdr>a,.gs_md_hdr>a.gs_btn_lrge{flex:0 0 auto;width:41px;height:47px;}.gs_el_ph .gs_md_hdr>a{margin:0 2px 0 0;}.gs_el_ph a.gs_md_hdr_c{margin:0 0 0 2px;}.gs_md_hdr_b{margin:0 41px 0 16px;}.gs_el_ph .gs_md_hdr_b{margin:0 16px;}.gs_md_hdr_t:empty~.gs_md_hdr_b{margin-left:0;}.gs_md_hdr_b:empty{width:41px;margin:0;}.gs_el_ph .gs_md_hdr_b:empty{margin-right:2px;}.gs_md_hdr_b:empty:not(:last-child){display:none;}.gs_md_hdr_b>button{min-width:51px;height:33px;}.gs_md_hdr_t{flex:1 1 auto;font-size:18px;font-weight:normal;color:#666;overflow:hidden;text-overflow:ellipsis;white-space:nowrap;text-align:center;}.gs_md_bdy{overflow-y:auto;box-sizing:border-box;padding:24px 41px 0 41px;}.gs_md_bdy:after{display:block;content:"";clear:both;padding-bottom:24px;}.gs_el_ph .gs_md_bdy{padding:16px 16px 0 16px;}.gs_el_ph .gs_md_bdy:after{padding-bottom:16px;}.gs_el_ph .gs_md_wmw .gs_md_bdy{position:absolute;width:100%;top:48px;bottom:0;}.gs_md_lbl{display:block;font-size:16px;margin:0 0 16px 0;word-wrap:break-word;}.gs_md_btns{margin:24px 0 0 0;white-space:nowrap;}.gs_el_ph .gs_md_btns{margin:16px 0 0 0;}.gs_md_btns button{margin-right:16px;}.gs_md_btns button:last-child{margin-right:0;}.gs_md_prg{margin:24px 0;text-align:center;}.gs_md_prg .gs_alrt{padding:4px 16px;}.gs_md_ldg:before{content:"";position:absolute;top:0;left:0;bottom:0;right:0;background-color:#fff;opacity:.5;z-index:100;}</style><div id="gs_md_ldg" style="display:none">Loading...</div><div id="gs_md_err" style="display:none">The system can't perform the operation now. Try again later.</div><div id="gs_md_s"></div><div data-h="0" class="gs_md_wnw"><div id="gsc_md_hist" class="gs_md_d gs_ttzi" role="dialog" tabindex="-1" aria-labelledby="gsc_md_hist-t" data-wfc="gsc_md_hist-x"><div class="gs_md_hdr"><a href="javascript:void(0)" id="gsc_md_hist-x" role="button" aria-label="Cancel" data-mdx="gsc_md_hist" class="gs_btnCLS gs_md_x gs_md_hdr_c gs_in_ib gs_btn_lrge"><span class="gs_ico"></span><span class="gs_lbl"></span></a><h2 id="gsc_md_hist-t" class="gs_md_hdr_t">Citations per year</h2><div class="gs_md_hdr_b"></div></div><div id="gsc_md_hist-bdy" class="gs_md_bdy"><style>#gsc_md_hist{width:80%;max-width:386px;}#gsc_md_hist_c{position:relative;width:100%;}</style><div id="gsc_md_hist_c"></div></div></div></div><div data-h="600" class="gs_md_wnw gs_md_wmw"><div id="gsc_md_cbyd" class="gs_md_d gs_ttzi" role="dialog" tabindex="-1" aria-labelledby="gsc_md_cbyd-t" data-cid="gsc_md_cbyd_l" data-wfc="gsc_md_cbyd-x"><div class="gs_md_hdr"><a href="javascript:void(0)" id="gsc_md_cbyd-x" role="button" aria-label="Cancel" data-mdx="gsc_md_cbyd" class="gs_btnCLS gs_md_x gs_md_hdr_c gs_in_ib gs_btn_lrge"><span class="gs_ico"></span><span class="gs_lbl"></span></a><h2 id="gsc_md_cbyd-t" class="gs_md_hdr_t">Duplicate citations</h2><div class="gs_md_hdr_b"></div></div><div id="gsc_md_cbyd-bdy" class="gs_md_bdy"><form id="gsc_md_cbyd_f" action="/citations?hl=en&amp;user=FhFQsc8AAAAJ&amp;view_op=list_works" method="post"><input type="hidden" name="s" value=""><div class="gs_md_lbl">The following articles are merged in Scholar. Their <a id="gsc_md_cbyd_c" href="javascript:void(0)">combined citations</a> are counted only for the first article.</div><div id="gsc_md_cbyd_l"></div></form></div></div></div><div data-h="600" class="gs_md_wnw gs_md_wmw"><div id="gsc_md_cbym" class="gs_md_d gs_ttzi" role="dialog" tabindex="-1" aria-labelledby="gsc_md_cbym-t" data-cid="gsc_md_cbym_l" data-wfc="gsc_md_cbym-x"><div class="gs_md_hdr"><a href="javascript:void(0)" id="gsc_md_cbym-x" role="button" aria-label="Cancel" data-mdx="gsc_md_cbym" class="gs_btnCLS gs_md_x gs_md_hdr_c gs_in_ib gs_btn_lrge"><span class="gs_ico"></span><span class="gs_lbl"></span></a><h2 id="gsc_md_cbym-t" class="gs_md_hdr_t">Merged citations</h2><div class="gs_md_hdr_b"></div></div><div id="gsc_md_cbym-bdy" class="gs_md_bdy"><div class="gs_md_lbl">This "Cited by" count includes citations to the following articles in Scholar. The ones marked <span id="gsc_md_cbym_s">*</span> may be different from the article in the profile.</div><div id="gsc_md_cbym_l" data-act="/citations?hl=en&amp;user=FhFQsc8AAAAJ&amp;view_op=list_works"></div></div></div></div><div data-h="900" class="gs_md_wnw gs_md_wmw"><div id="gsc_md_cod" class="gs_md_d gs_ttzi gsc_cod_lc" role="dialog" tabindex="-1" aria-labelledby="gsc_md_cod-t" data-cid="gsc_cods_res" data-wfc="gsc_md_cod-x"><div class="gs_md_hdr"><a href="javascript:void(0)" id="gsc_md_cod-x" role="button" aria-label="Cancel" data-mdx="gsc_md_cod" class="gs_btnCLS gs_md_x gs_md_hdr_c gs_in_ib gs_btn_lrge"><span class="gs_ico"></span><span class="gs_lbl"></span></a><h2 id="gsc_md_cod-t" class="gs_md_hdr_t"><span id="gsc_cod_t"><span id="gsc_cod_tadd">Add co-authors</span><span id="gsc_cod_tedit">Co-authors</span><a id="gsc_cod_trev" href="javascript:void(0)" data-txt="Review" data-lim="Limit reached"></a></span></h2><div class="gs_md_hdr_b"><button type="button" id="gsc_cod_done" aria-label="Add co-authors" disabled="" class="gs_btnDNW gs_in_ib gs_btn_act gs_btn_half gs_btn_lsb"><span class="gs_wr"><span class="gs_ico"></span><span class="gs_lbl"></span></span></button></div></div><div id="gsc_md_cod-bdy" class="gs_md_bdy"><div id="gsc_cods_urls" class="gsc_cods_hide" data-ls="" data-lc="/citations?view_op=list_colleagues&amp;hl=en&amp;json=&amp;user=FhFQsc8AAAAJ" data-sa=""></div><form id="gsc_cods_save" action="" method="POST"><input type="hidden" name="colleague_add"><input type="hidden" name="colleague_del"></form><div id="gsc_cods_res"></div></div></div></div><div data-h="800" class="gs_md_wnw gs_md_wmw"><div id="gs_md_cita-d" class="gs_md_d gs_ttzi" role="dialog" tabindex="-1" aria-labelledby="gs_md_cita-d-t" data-cid="gs_md_cita-l" data-wfc="gs_md_cita-d-x"><div class="gs_md_hdr"><a href="javascript:void(0)" id="gs_md_cita-d-x" role="button" aria-label="Cancel" data-mdx="gs_md_cita-d" class="gs_btnCLS gs_md_x gs_md_hdr_c gs_in_ib gs_btn_lrge"><span class="gs_ico"></span><span class="gs_lbl"></span></a><h2 id="gs_md_cita-d-t" class="gs_md_hdr_t"></h2><div class="gs_md_hdr_b"><button type="button" id="gs_md_cita-b-save" aria-label="Save" class="gs_btnDNW gs_in_ib gs_btn_act gs_btn_half gs_btn_lsb"><span class="gs_wr"><span class="gs_ico"></span><span class="gs_lbl"></span></span></button></div></div><div id="gs_md_cita-d-bdy" class="gs_md_bdy"><style>#gs_md_cita-d{width:90%;max-width:1000px;}.gs_el_ph #gs_md_cita-d{width:100%;max-width:none;}#gs_md_cita-d .gs_md_prg{min-height:600px;}</style><div id="gs_md_cita-l" aria-live="assertive"></div></div></div></div><div data-h="0" class="gs_md_wnw gs_md_wmw"><div id="gsc_md_fol" class="gs_md_d gs_ttzi" role="dialog" tabindex="-1" aria-labelledby="gsc_md_fol-t" data-wfc="gsc_md_fol-x"><div class="gs_md_hdr"><a href="javascript:void(0)" id="gsc_md_fol-x" role="button" aria-label="Cancel" data-mdx="gsc_md_fol" class="gs_btnCLS gs_md_x gs_md_hdr_c gs_in_ib gs_btn_lrge"><span class="gs_ico"></span><span class="gs_lbl"></span></a><h2 id="gsc_md_fol-t" class="gs_md_hdr_t">Follow this author</h2><div class="gs_md_hdr_b"></div></div><div id="gsc_md_fol-bdy" class="gs_md_bdy"><form method="post" id="gsc_fol_f" action="/citations?hl=en&amp;user=FhFQsc8AAAAJ&amp;view_op=list_works"><input type="hidden" name="xsrf" value="AMD79ooAAAAAYTsAXIZjCUSlF8b-IhjOQKNVAeXvQtXT"><input type="hidden" name="user" value="FhFQsc8AAAAJ"><div id="gsc_fol_inp"></div><div id="gsc_fol_cb"><div class="gsc_fol_cr"><a href="javascript:void(0)" id="gsc_fol_a" role="checkbox" aria-checked="false" data-s="0" class="gs_cb_gen gs_in_cb"><span class="gs_lbl">New articles by this author</span><span class="gs_chk"></span><span class="gs_cbx"></span></a></div><div class="gsc_fol_cr"><a href="javascript:void(0)" id="gsc_fol_c" role="checkbox" aria-checked="false" data-s="0" class="gs_cb_gen gs_in_cb"><span class="gs_lbl">New citations to this author</span><span class="gs_chk"></span><span class="gs_cbx"></span></a></div><div class="gsc_fol_cr"><a href="javascript:void(0)" id="gsc_fol_r" role="checkbox" aria-checked="false" data-s="0" class="gs_cb_gen gs_in_cb"><span class="gs_lbl">New articles related to this author's research</span><span class="gs_chk"></span><span class="gs_cbx"></span></a></div></div><div id="gsc_fol_email"><label id="gsc_fol_ml" for="gsc_fol_m">Email address for updates</label><div class="gs_in_txtw gs_in_txtb"><input type="text" class="gs_in_txt" name="email_for_op" value="" id="gsc_fol_m" maxlength="100" autocapitalize="off" autocorrect="off"></div></div><div class="gs_md_btns"><button type="submit" id="gsc_fol_b" disabled="" class=" gs_btn_act gs_btn_lrge gs_btn_lsu"><span class="gs_wr"><span class="gs_lbl">Done</span></span></button></div></form></div></div></div><!--[if lte IE 9]><div class="gs_alrt" style="padding:16px"><div>Sorry, some features may not work in this version of Internet Explorer.</div><div>Please use <a href="//www.google.com/chrome/">Google Chrome</a> or <a href="//www.mozilla.com/firefox/">Mozilla Firefox</a> for the best experience.</div></div><![endif]--><div id="gs_hdr_drs"></div><div id="gs_hdr_drw" class="gs_md_ulr" role="dialog" tabindex="-1" data-shd="gs_hdr_drs" data-wfc="gs_hdr_drw_mnu" data-cfc="gs_hdr_mnu"><div id="gs_hdr_drw_in"><div id="gs_hdr_drw_top"><a href="javascript:void(0)" id="gs_hdr_drw_mnu" role="button" aria-controls="gs_hdr_drw" aria-label="Options" class="gs_btnMNT gs_in_ib gs_btn_lrge"><span class="gs_ico"></span><span class="gs_lbl"></span></a><a id="gs_hdr_drw_lgo" href="/schhp?hl=en" aria-label="Homepage"></a></div><div><div class="gs_hdr_drw_sec"><a href="/citations?hl=en" role="menuitem" class="gs_btnPRO gs_in_ib gs_md_li gs_md_lix gs_in_gray"><span class="gs_ico"></span><span class="gs_lbl">My profile</span></a><a href="/scholar?scilib=1&amp;hl=en" role="menuitem" class="gs_btnL gs_in_ib gs_md_li gs_md_lix gs_in_gray"><span class="gs_ico"></span><span class="gs_lbl">My library</span></a><a href="/citations?view_op=metrics_intro&amp;hl=en" role="menuitem" class="gs_btnJ gs_in_ib gs_md_li gs_md_lix gs_in_gray"><span class="gs_ico"></span><span class="gs_lbl">Metrics</span></a><a href="/scholar_alerts?view_op=list_alerts&amp;hl=en" role="menuitem" class="gs_btnM gs_in_ib gs_md_li gs_md_lix gs_in_gray"><span class="gs_ico"></span><span class="gs_lbl">Alerts</span></a></div><div class="gs_hdr_drw_sec"><a href="/scholar_settings?hl=en" role="menuitem" class="gs_btnP gs_in_ib gs_md_li gs_md_lix gs_in_gray"><span class="gs_ico"></span><span class="gs_lbl">Settings</span></a></div></div><div id="gs_hdr_drw_bot" class="gs_hdr_drw_sec"><a href="https://accounts.google.com/Login?hl=en&amp;continue=https://scholar.google.com/schhp%3Fhl%3Den" class=" gs_in_ib gs_md_li gs_md_lix gs_in_gray"><span class="gs_ico"></span><span class="gs_lbl">Sign in</span></a></div></div></div><div id="gs_hdr" role="banner" class="gs_hdr_src"><a href="javascript:void(0)" id="gs_hdr_mnu" role="button" aria-controls="gs_hdr_drw" class="gs_btnMNT gs_in_ib gs_btn_lrge"><span class="gs_ico"></span><span class="gs_lbl"></span></a><a id="gs_hdr_lgo" class="" href="/schhp?hl=en" aria-label="Homepage"></a><div id="gs_hdr_md"><div id="gs_hdr_srch"><form id="gs_hdr_frm" action="/citations"><input type="hidden" name="view_op" value="search_authors"><input type="hidden" name="hl" value="en"><div class="gs_in_txtw gs_in_txtb"><input type="text" class="gs_in_txt" name="mauthors" value="" id="gs_hdr_tsi" placeholder="Search profiles" size="50" maxlength="2048" autocapitalize="off" aria-label="Search"></div><span id="gs_hdr_tsc"><span class="gs_ico gs_ico_X"></span></span><button type="submit" id="gs_hdr_tsb" name="btnG" aria-label="Search" class="gs_btnG gs_in_ib gs_btn_act gs_btn_half gs_btn_lsb"><span class="gs_wr"><span class="gs_ico"></span><span class="gs_lbl"></span></span></button></form></div></div><a href="javascript:void(0)" id="gs_hdr_sre" role="button" aria-controls="gs_hdr_frm" aria-label="Search" class="gs_btnTSB gs_in_ib gs_btn_lrge"><span class="gs_ico"></span><span class="gs_lbl"></span></a><div id="gs_hdr_act"><a id="gs_hdr_act_s" href="https://accounts.google.com/Login?hl=en&amp;continue=https://scholar.google.com/schhp%3Fhl%3Den">Sign in</a></div></div><style>#gs_alrt{position:fixed;bottom:48px;left:16px;max-width:384px;z-index:1250;display:flex;justify-content:space-between;align-items:center;font-size:13px;line-height:16px;color:#e2e2e2;background:#333;text-align:left;border-radius:3px;box-shadow:0 3px 5px -1px rgba(0,0,0,.2),0 6px 10px 0 rgba(0,0,0,.14),0 1px 18px 0 rgba(0,0,0,.12);visibility:hidden;transform-origin:center;transform:scale(0.8,0.8) translate(0,100%);}.gs_el_ph #gs_alrt{bottom:0;left:0;width:100%;max-width:none;border-radius:0;box-shadow:none;transform:scale(1,1) translate(0,100%);}#gs_alrt.gs_vis{visibility:visible;transform:scale(1,1) translate(0,0);}#gs_alrt.gs_anm{transition:transform .067s cubic-bezier(.4,0,1,1),visibility 0s .067s;}#gs_alrt.gs_vis.gs_anm{transition:transform .067s cubic-bezier(0,0,.2,1);}.gs_el_ph #gs_alrt.gs_anm{transition:transform .084s cubic-bezier(.4,0,1,1),visibility 0s .084s;}.gs_el_ph #gs_alrt.gs_vis.gs_anm{transition:transform .1s cubic-bezier(0,0,.2,1);}#gs_alrt_m{display:block;padding:16px;}#gs_alrt_l{display:block;padding:8px;margin:0 8px 0 -8px;border-radius:3px;color:#fcc934;text-transform:uppercase;text-decoration:none;}#gs_alrt_l:hover{background-color:rgba(255,255,255,.05)}#gs_alrt_l:active{background-color:rgba(255,255,255,.1)}#gs_alrt_l:empty{display:none}#gs_alrt_m a{padding:8px 0;color:#e2e2e2;text-decoration:underline;}#gs_alrt_m a:active{color:#f6aea9}</style><form action="" method="post" id="gs_alrt"><span id="gs_alrt_m"></span><span id="gs_alrt_h"></span><a id="gs_alrt_l" href="javascript:void(0)" class="gs_fm_s" data-fm="gs_alrt"></a></form><div id="gs_bdy"><div id="gs_bdy_sb" role="navigation"><div id="gs_bdy_sb_in"></div></div><div id="gs_bdy_ccl" role="main"><div id="gsc_bdy" class="gs_scl" data-tab="gsc_prf_t-art"><div class="gsc_rsb" role="navigation"><a id="gsc_rsb_gpl" class="gsc_rsb_s" href="/citations?hl=en">Get my own profile</a><div class="gsc_rsb_s gsc_prf_pnl" id="gsc_rsb_cit" role="region" aria-labelledby="gsc_prf_t-cit"><h3 class="gsc_rsb_header"><span class="gsc_rsb_title">Cited by</span><button type="button" id="gsc_hist_opn" class=" gs_btn_flat gs_btn_flact gs_btn_lrge gs_btn_half gs_btn_lsu gsc_rsb_action"><span class="gs_wr"><span class="gs_lbl">View all</span></span></button></h3><table id="gsc_rsb_st"><thead><tr><th class="gsc_rsb_sth"></th><th class="gsc_rsb_sth">All</th><th class="gsc_rsb_sth">Since 2016</th></tr></thead><tbody><tr><td class="gsc_rsb_sc1"><a href="javascript:void(0)" class="gsc_rsb_f gs_ibl" title="This is the number of citations to all publications. The second column has the &quot;recent&quot; version of this metric which is the number of new citations in the last 5 years to all publications.">Citations</a></td><td class="gsc_rsb_std">21125</td><td class="gsc_rsb_std">9320</td></tr><tr><td class="gsc_rsb_sc1"><a href="javascript:void(0)" class="gsc_rsb_f gs_ibl" title="h-index is the largest number h such that h publications have at least h citations. The second column has the &quot;recent&quot; version of this metric which is the largest number h such that h publications have at least h new citations in the last 5 years.">h-index</a></td><td class="gsc_rsb_std">69</td><td class="gsc_rsb_std">43</td></tr><tr><td class="gsc_rsb_sc1"><a href="javascript:void(0)" class="gsc_rsb_f gs_ibl" title="i10-index is the number of publications with at least 10 citations. The second column has the &quot;recent&quot; version of this metric which is the number of publications that have received at least 10 new citations in the last 5 years.">i10-index</a></td><td class="gsc_rsb_std">167</td><td class="gsc_rsb_std">123</td></tr></tbody></table><style>.gsc_g_t{position:absolute;bottom:0;color:#777;font-size:11px;}.gsc_g_a{position:absolute;bottom:13px;width:15px;background:#777;}.gsc_g_a:hover,.gsc_g_a:focus,.gsc_g_a:active{text-decoration:none;cursor:default;}.gsc_g_al{position:absolute;bottom:15px;left:7px;color:#222;background:white;font-size:11px;padding:1px;border:1px solid #777;border-radius:1px;visibility:hidden;opacity:0;transition:opacity .218s,visibility 0s .218s;}.gsc_g_a:hover .gsc_g_al,.gsc_g_a:focus .gsc_g_al,.gsc_g_a:active .gsc_g_al{visibility:visible;opacity:1;transition:all 0s;}#gsc_md_hist{max-width:806px;}.gsc_md_hist_w{position:relative;overflow:hidden;margin-right:43px;}.gs_md_bdy .gsc_md_hist_w,.gs_el_ph .gsc_md_hist_w,.gs_el_ta .gsc_md_hist_w{overflow-x:auto;padding-bottom:16px;}.gsc_md_hist_b{position:relative;height:174px;width:100%;}.gsc_md_hist_b .gsc_g_a{bottom:auto;}.gsc_md_hist_b .gsc_g_t{bottom:auto;top:161px;}.gsc_md_hist_b:after{position:absolute;right:760px;content:"\00A0";}.gsc_g_hist_x{position:relative;margin-right:45px;}.gsc_g_hist_xl{position:absolute;right:8px;width:35px;}.gs_el_ta .gsc_g_hist_xl,.gs_el_ph .gsc_g_hist_xl{right:16px;}.gsc_g_hist_wrp{padding-top:32px;position:relative;}.gs_el_ta .gsc_g_hist_wrp,.gs_el_ph .gsc_g_hist_wrp{padding-right:8px;}.gs_md_bdy .gsc_g_hist_wrp{border-top:0;}.gs_el_tc .gs_md_bdy .gsc_g_hist_wrp:after,.gs_el_tc.gs_el_ph .gsc_g_hist_wrp:after,.gs_el_tc.gs_el_ta .gsc_g_hist_wrp:after{display:block;content:"";position:absolute;z-index:100;top:0;left:0;width:20px;height:100%;background-image:linear-gradient(to left,rgba(255,255,255,0),rgba(255,255,255,1) 80%);}.gsc_g_x,.gsc_g_xt{position:absolute;left:0;border-bottom:1px solid #eee;width:100%;text-align:right;}.gsc_g_x{border-bottom:1px solid #eee;}.gsc_g_xtl{position:absolute;color:#777;}.gsc_g_gtr{position:absolute;}.gsc_g_a:last-child .gsc_g_al{right:0;left:auto;}</style><div class="gsc_g_hist_wrp" dir="rtl"><div class="gsc_g_hist_x"><div class="gsc_g_x" style="top:160px;"></div><div class="gsc_g_xt" style="top:0px;"></div><div class="gsc_g_xt" style="top:80px;"></div><div class="gsc_g_xt" style="top:120px;"></div><div class="gsc_g_xt" style="top:40px;"></div></div><div class="gsc_g_hist_xl"><div class="gsc_g_xtl" style="top:153px;">0</div><div class="gsc_g_xtl" style="top:-7px;">1900</div><div class="gsc_g_xtl" style="top:73px;">950</div><div class="gsc_g_xtl" style="top:113px;">475</div><div class="gsc_g_xtl" style="top:33px;">1425</div></div><div class="gsc_md_hist_w"><div class="gsc_md_hist_b"><span class="gsc_g_t" style="right:707px">1999</span><span class="gsc_g_t" style="right:675px">2000</span><span class="gsc_g_t" style="right:643px">2001</span><span class="gsc_g_t" style="right:611px">2002</span><span class="gsc_g_t" style="right:579px">2003</span><span class="gsc_g_t" style="right:547px">2004</span><span class="gsc_g_t" style="right:515px">2005</span><span class="gsc_g_t" style="right:483px">2006</span><span class="gsc_g_t" style="right:451px">2007</span><span class="gsc_g_t" style="right:419px">2008</span><span class="gsc_g_t" style="right:387px">2009</span><span class="gsc_g_t" style="right:355px">2010</span><span class="gsc_g_t" style="right:323px">2011</span><span class="gsc_g_t" style="right:291px">2012</span><span class="gsc_g_t" style="right:259px">2013</span><span class="gsc_g_t" style="right:227px">2014</span><span class="gsc_g_t" style="right:195px">2015</span><span class="gsc_g_t" style="right:163px">2016</span><span class="gsc_g_t" style="right:131px">2017</span><span class="gsc_g_t" style="right:99px">2018</span><span class="gsc_g_t" style="right:67px">2019</span><span class="gsc_g_t" style="right:35px">2020</span><span class="gsc_g_t" style="right:3px">2021</span><a href="javascript:void(0)" class="gsc_g_a" style="right:712px;top:156px;height:4px;z-index:23"><span class="gsc_g_al">54</span></a><a href="javascript:void(0)" class="gsc_g_a" style="right:680px;top:155px;height:5px;z-index:22"><span class="gsc_g_al">64</span></a><a href="javascript:void(0)" class="gsc_g_a" style="right:648px;top:153px;height:7px;z-index:21"><span class="gsc_g_al">91</span></a><a href="javascript:void(0)" class="gsc_g_a" style="right:616px;top:148px;height:12px;z-index:20"><span class="gsc_g_al">148</span></a><a href="javascript:void(0)" class="gsc_g_a" style="right:584px;top:143px;height:17px;z-index:19"><span class="gsc_g_al">211</span></a><a href="javascript:void(0)" class="gsc_g_a" style="right:552px;top:138px;height:22px;z-index:18"><span class="gsc_g_al">263</span></a><a href="javascript:void(0)" class="gsc_g_a" style="right:520px;top:132px;height:28px;z-index:17"><span class="gsc_g_al">338</span></a><a href="javascript:void(0)" class="gsc_g_a" style="right:488px;top:121px;height:39px;z-index:16"><span class="gsc_g_al">465</span></a><a href="javascript:void(0)" class="gsc_g_a" style="right:456px;top:113px;height:47px;z-index:15"><span class="gsc_g_al">568</span></a><a href="javascript:void(0)" class="gsc_g_a" style="right:424px;top:97px;height:63px;z-index:14"><span class="gsc_g_al">756</span></a><a href="javascript:void(0)" class="gsc_g_a" style="right:392px;top:97px;height:63px;z-index:13"><span class="gsc_g_al">759</span></a><a href="javascript:void(0)" class="gsc_g_a" style="right:360px;top:82px;height:78px;z-index:12"><span class="gsc_g_al">931</span></a><a href="javascript:void(0)" class="gsc_g_a" style="right:328px;top:69px;height:91px;z-index:11"><span class="gsc_g_al">1088</span></a><a href="javascript:void(0)" class="gsc_g_a" style="right:296px;top:59px;height:101px;z-index:10"><span class="gsc_g_al">1203</span></a><a href="javascript:void(0)" class="gsc_g_a" style="right:264px;top:50px;height:110px;z-index:9"><span class="gsc_g_al">1310</span></a><a href="javascript:void(0)" class="gsc_g_a" style="right:232px;top:37px;height:123px;z-index:8"><span class="gsc_g_al">1472</span></a><a href="javascript:void(0)" class="gsc_g_a" style="right:200px;top:21px;height:139px;z-index:7"><span class="gsc_g_al">1654</span></a><a href="javascript:void(0)" class="gsc_g_a" style="right:168px;top:33px;height:127px;z-index:6"><span class="gsc_g_al">1516</span></a><a href="javascript:void(0)" class="gsc_g_a" style="right:136px;top:18px;height:142px;z-index:5"><span class="gsc_g_al">1688</span></a><a href="javascript:void(0)" class="gsc_g_a" style="right:104px;top:31px;height:129px;z-index:4"><span class="gsc_g_al">1540</span></a><a href="javascript:void(0)" class="gsc_g_a" style="right:72px;top:37px;height:123px;z-index:3"><span class="gsc_g_al">1466</span></a><a href="javascript:void(0)" class="gsc_g_a" style="right:40px;top:8px;height:152px;z-index:2"><span class="gsc_g_al">1815</span></a><a href="javascript:void(0)" class="gsc_g_a" style="right:8px;top:52px;height:108px;z-index:1"><span class="gsc_g_al">1288</span></a></div></div></div></div><div class="gsc_rsb_s gsc_prf_pnl" id="gsc_rsb_mnd" role="region" aria-labelledby="gsc_prf_t-mnd"><div class="gsc_rsb_header gsc_rsb_m_header"><div class="gsc_rsb_m_title">Public access</div><a href="/citations?view_op=list_mandates&amp;hl=en&amp;user=FhFQsc8AAAAJ" id="gsc_lwp_mndt_lnk">View all</a></div><div class="gsc_rsb_hm gs_ota gs_oph"><button type="button" onclick="window.location='/citations?view_op\x3dlist_mandates\x26hl\x3den\x26user\x3dFhFQsc8AAAAJ'" class=" gs_btn_flat gs_btn_flact gs_btn_lrge gs_btn_half gs_btn_lsu"><span class="gs_wr"><span class="gs_lbl">View all</span></span></button></div><div class="gsc_rsb_m"><div class="gsc_rsb_m_a"><span>58 articles</span></div><div class="gsc_rsb_m_na"><div>13 articles</div></div><div class="gsc_rsb_m_bar"><div class="gsc_rsb_m_bar_na" style="width:18%"></div></div><div class="gsc_rsb_m_a"><span>available</span></div><div class="gsc_rsb_m_na"><span>not available</span></div><div class="gsc_rsb_m_desc">Based on funding mandates</div></div></div><div class="gsc_rsb_s gsc_prf_pnl" id="gsc_rsb_co" role="region" aria-labelledby="gsc_prf_t-ath"><h3 class="gsc_rsb_header"><span class="gsc_rsb_title">Co-authors</span><button type="button" id="gsc_coauth_opn" class=" gs_btn_flat gs_btn_flact gs_btn_lrge gs_btn_half gs_btn_lsu gsc_rsb_action"><span class="gs_wr"><span class="gs_lbl">View all</span></span></button></h3><ul class="gsc_rsb_a"><li><div class="gsc_rsb_aa" tabindex="0"><style>#gsc_rsb-mAQuYT0AAAAJ-img{width:32px;height:21px;}.gs_el_ta #gsc_rsb-mAQuYT0AAAAJ-img,.gs_el_ph #gsc_rsb-mAQuYT0AAAAJ-img{width:56px;height:37px;}</style><span id="gsc_rsb-mAQuYT0AAAAJ" class="gs_rimg gs_pp_tn gs_pp_mo_sm gsc_rsb_a_pht"><img alt="Huw Thomas" sizes="(max-width:981px) 56px,32px" src="https://scholar.googleusercontent.com/citations?view_op=small_photo&amp;user=mAQuYT0AAAAJ&amp;citpid=1" id="gsc_rsb-mAQuYT0AAAAJ-img" class="gs_pp_df" srcset="https://scholar.googleusercontent.com/citations?view_op=tiny_photo&amp;user=mAQuYT0AAAAJ&amp;citpid=1 32w,https://scholar.googleusercontent.com/citations?view_op=small_photo&amp;user=mAQuYT0AAAAJ&amp;citpid=1 56w,https://scholar.googleusercontent.com/citations?view_op=view_photo&amp;user=mAQuYT0AAAAJ&amp;citpid=1 128w"></span><span class="gsc_rsb_a_desc"><a tabindex="-1" href="/citations?user=mAQuYT0AAAAJ&amp;hl=en">Huw Thomas</a><span class="gsc_rsb_a_ext">Senior Research Associate</span><span class="gsc_rsb_a_ext gsc_rsb_a_ext2">Verified email at ncl.ac.uk</span><span class="gsc_rsb_tap"><span class="gs_btnPR"><span class="gs_ico"></span></span></span></span></div></li><li><div class="gsc_rsb_aa" tabindex="0"><style>#gsc_rsb-Y2VMJ3oAAAAJ-img{width:32px;height:32px;}.gs_el_ta #gsc_rsb-Y2VMJ3oAAAAJ-img,.gs_el_ph #gsc_rsb-Y2VMJ3oAAAAJ-img{width:56px;height:56px;}</style><span id="gsc_rsb-Y2VMJ3oAAAAJ" class="gs_rimg gs_pp_tn gs_pp_mo_sm gsc_rsb_a_pht"><img alt="Ian Robert Hardcastle" sizes="(max-width:981px) 56px,32px" src="/citations/images/avatar_scholar_56.png" id="gsc_rsb-Y2VMJ3oAAAAJ-img" class="gs_pp_df" srcset="/citations/images/avatar_scholar_32.png 32w,/citations/images/avatar_scholar_56.png 56w,/citations/images/avatar_scholar_128.png 128w"></span><span class="gsc_rsb_a_desc"><a tabindex="-1" href="/citations?user=Y2VMJ3oAAAAJ&amp;hl=en">Ian Robert Hardcastle</a><span class="gsc_rsb_a_ext">Newcastle University</span><span class="gsc_rsb_a_ext gsc_rsb_a_ext2">Verified email at ncl.ac.uk</span><span class="gsc_rsb_tap"><span class="gs_btnPR"><span class="gs_ico"></span></span></span></span></div></li><li><div class="gsc_rsb_aa" tabindex="0"><style>#gsc_rsb-tOpLB2cAAAAJ-img{width:26px;height:32px;}.gs_el_ta #gsc_rsb-tOpLB2cAAAAJ-img,.gs_el_ph #gsc_rsb-tOpLB2cAAAAJ-img{width:44px;height:56px;}</style><span id="gsc_rsb-tOpLB2cAAAAJ" class="gs_rimg gs_pp_tn gs_pp_mo_sm gsc_rsb_a_pht"><img alt="Martin Noble" sizes="(max-width:981px) 44px,26px" src="https://scholar.googleusercontent.com/citations?view_op=small_photo&amp;user=tOpLB2cAAAAJ&amp;citpid=3" id="gsc_rsb-tOpLB2cAAAAJ-img" class="gs_pp_df" srcset="https://scholar.googleusercontent.com/citations?view_op=tiny_photo&amp;user=tOpLB2cAAAAJ&amp;citpid=3 26w,https://scholar.googleusercontent.com/citations?view_op=small_photo&amp;user=tOpLB2cAAAAJ&amp;citpid=3 44w,https://scholar.googleusercontent.com/citations?view_op=view_photo&amp;user=tOpLB2cAAAAJ&amp;citpid=3 102w"></span><span class="gsc_rsb_a_desc"><a tabindex="-1" href="/citations?user=tOpLB2cAAAAJ&amp;hl=en">Martin Noble</a><span class="gsc_rsb_a_ext">Professor of Structural Biology and Anticancer Drug Design</span><span class="gsc_rsb_a_ext gsc_rsb_a_ext2">Verified email at ncl.ac.uk</span><span class="gsc_rsb_tap"><span class="gs_btnPR"><span class="gs_ico"></span></span></span></span></div></li><li><div class="gsc_rsb_aa" tabindex="0"><style>#gsc_rsb-gLbBS_sAAAAJ-img{width:32px;height:32px;}.gs_el_ta #gsc_rsb-gLbBS_sAAAAJ-img,.gs_el_ph #gsc_rsb-gLbBS_sAAAAJ-img{width:56px;height:56px;}</style><span id="gsc_rsb-gLbBS_sAAAAJ" class="gs_rimg gs_pp_tn gs_pp_mo_sm gsc_rsb_a_pht"><img alt="Jane Endicott" sizes="(max-width:981px) 56px,32px" src="/citations/images/avatar_scholar_56.png" id="gsc_rsb-gLbBS_sAAAAJ-img" class="gs_pp_df" srcset="/citations/images/avatar_scholar_32.png 32w,/citations/images/avatar_scholar_56.png 56w,/citations/images/avatar_scholar_128.png 128w"></span><span class="gsc_rsb_a_desc"><a tabindex="-1" href="/citations?user=gLbBS_sAAAAJ&amp;hl=en">Jane Endicott</a><span class="gsc_rsb_a_ext">Professor of Cancer Structural Biology, Newcastle University</span><span class="gsc_rsb_a_ext gsc_rsb_a_ext2">Verified email at ncl.ac.uk</span><span class="gsc_rsb_tap"><span class="gs_btnPR"><span class="gs_ico"></span></span></span></span></div></li><li><div class="gsc_rsb_aa" tabindex="0"><style>#gsc_rsb-nxePl5cAAAAJ-img{width:32px;height:32px;}.gs_el_ta #gsc_rsb-nxePl5cAAAAJ-img,.gs_el_ph #gsc_rsb-nxePl5cAAAAJ-img{width:56px;height:56px;}</style><span id="gsc_rsb-nxePl5cAAAAJ" class="gs_rimg gs_pp_tn gs_pp_mo_sm gsc_rsb_a_pht"><img alt="Thomas Helleday" sizes="(max-width:981px) 56px,32px" src="/citations/images/avatar_scholar_56.png" id="gsc_rsb-nxePl5cAAAAJ-img" class="gs_pp_df" srcset="/citations/images/avatar_scholar_32.png 32w,/citations/images/avatar_scholar_56.png 56w,/citations/images/avatar_scholar_128.png 128w"></span><span class="gsc_rsb_a_desc"><a tabindex="-1" href="/citations?user=nxePl5cAAAAJ&amp;hl=en">Thomas Helleday</a><span class="gsc_rsb_a_ext">University of Sheffield</span><span class="gsc_rsb_a_ext gsc_rsb_a_ext2">Verified email at sheffield.ac.uk</span><span class="gsc_rsb_tap"><span class="gs_btnPR"><span class="gs_ico"></span></span></span></span></div></li><li><div class="gsc_rsb_aa" tabindex="0"><style>#gsc_rsb-uCGp_8gAAAAJ-img{width:21px;height:32px;}.gs_el_ta #gsc_rsb-uCGp_8gAAAAJ-img,.gs_el_ph #gsc_rsb-uCGp_8gAAAAJ-img{width:37px;height:56px;}</style><span id="gsc_rsb-uCGp_8gAAAAJ" class="gs_rimg gs_pp_tn gs_pp_mo_sm gsc_rsb_a_pht"><img alt="Philip Jewsbury" sizes="(max-width:981px) 37px,21px" src="https://scholar.googleusercontent.com/citations?view_op=small_photo&amp;user=uCGp_8gAAAAJ&amp;citpid=2" id="gsc_rsb-uCGp_8gAAAAJ-img" class="gs_pp_df" srcset="https://scholar.googleusercontent.com/citations?view_op=tiny_photo&amp;user=uCGp_8gAAAAJ&amp;citpid=2 21w,https://scholar.googleusercontent.com/citations?view_op=small_photo&amp;user=uCGp_8gAAAAJ&amp;citpid=2 37w,https://scholar.googleusercontent.com/citations?view_op=view_photo&amp;user=uCGp_8gAAAAJ&amp;citpid=2 85w"></span><span class="gsc_rsb_a_desc"><a tabindex="-1" href="/citations?user=uCGp_8gAAAAJ&amp;hl=en">Philip Jewsbury</a><span class="gsc_rsb_a_ext">AstraZeneca Pharmaceuticals</span><span class="gsc_rsb_a_ext gsc_rsb_a_ext2">Verified email at wasabi1.plus.com</span><span class="gsc_rsb_tap"><span class="gs_btnPR"><span class="gs_ico"></span></span></span></span></div></li><li><div class="gsc_rsb_aa" tabindex="0"><style>#gsc_rsb-3yT6IX4AAAAJ-img{width:26px;height:32px;}.gs_el_ta #gsc_rsb-3yT6IX4AAAAJ-img,.gs_el_ph #gsc_rsb-3yT6IX4AAAAJ-img{width:45px;height:56px;}</style><span id="gsc_rsb-3yT6IX4AAAAJ" class="gs_rimg gs_pp_tn gs_pp_mo_sm gsc_rsb_a_pht"><img alt="Adrian L Harris" sizes="(max-width:981px) 45px,26px" src="https://scholar.googleusercontent.com/citations?view_op=small_photo&amp;user=3yT6IX4AAAAJ&amp;citpid=3" id="gsc_rsb-3yT6IX4AAAAJ-img" class="gs_pp_df" srcset="https://scholar.googleusercontent.com/citations?view_op=tiny_photo&amp;user=3yT6IX4AAAAJ&amp;citpid=3 26w,https://scholar.googleusercontent.com/citations?view_op=small_photo&amp;user=3yT6IX4AAAAJ&amp;citpid=3 45w,https://scholar.googleusercontent.com/citations?view_op=view_photo&amp;user=3yT6IX4AAAAJ&amp;citpid=3 102w"></span><span class="gsc_rsb_a_desc"><a tabindex="-1" href="/citations?user=3yT6IX4AAAAJ&amp;hl=en">Adrian L Harris</a><span class="gsc_rsb_a_ext">Professor of Medical Oncology, Oxford University</span><span class="gsc_rsb_a_ext gsc_rsb_a_ext2">Verified email at oncology.ox.ac.uk</span><span class="gsc_rsb_tap"><span class="gs_btnPR"><span class="gs_ico"></span></span></span></span></div></li><li><div class="gsc_rsb_aa" tabindex="0"><style>#gsc_rsb-wizjs54AAAAJ-img{width:32px;height:32px;}.gs_el_ta #gsc_rsb-wizjs54AAAAJ-img,.gs_el_ph #gsc_rsb-wizjs54AAAAJ-img{width:56px;height:56px;}</style><span id="gsc_rsb-wizjs54AAAAJ" class="gs_rimg gs_pp_tn gs_pp_mo_sm gsc_rsb_a_pht"><img alt="Celine Cano" sizes="(max-width:981px) 56px,32px" src="/citations/images/avatar_scholar_56.png" id="gsc_rsb-wizjs54AAAAJ-img" class="gs_pp_df" srcset="/citations/images/avatar_scholar_32.png 32w,/citations/images/avatar_scholar_56.png 56w,/citations/images/avatar_scholar_128.png 128w"></span><span class="gsc_rsb_a_desc"><a tabindex="-1" href="/citations?user=wizjs54AAAAJ&amp;hl=en">Celine Cano</a><span class="gsc_rsb_a_ext">Newcastle university</span><span class="gsc_rsb_a_ext gsc_rsb_a_ext2">Verified email at ncl.ac.uk</span><span class="gsc_rsb_tap"><span class="gs_btnPR"><span class="gs_ico"></span></span></span></span></div></li><li><div class="gsc_rsb_aa" tabindex="0"><style>#gsc_rsb-3Err48sAAAAJ-img{width:32px;height:32px;}.gs_el_ta #gsc_rsb-3Err48sAAAAJ-img,.gs_el_ph #gsc_rsb-3Err48sAAAAJ-img{width:56px;height:56px;}</style><span id="gsc_rsb-3Err48sAAAAJ" class="gs_rimg gs_pp_tn gs_pp_mo_sm gsc_rsb_a_pht"><img alt="Helen E Bryant" sizes="(max-width:981px) 56px,32px" src="/citations/images/avatar_scholar_56.png" id="gsc_rsb-3Err48sAAAAJ-img" class="gs_pp_df" srcset="/citations/images/avatar_scholar_32.png 32w,/citations/images/avatar_scholar_56.png 56w,/citations/images/avatar_scholar_128.png 128w"></span><span class="gsc_rsb_a_desc"><a tabindex="-1" href="/citations?user=3Err48sAAAAJ&amp;hl=en">Helen E Bryant</a><span class="gsc_rsb_a_ext">University of Sheffield</span><span class="gsc_rsb_a_ext gsc_rsb_a_ext2">Verified email at sheffield.ac.uk</span><span class="gsc_rsb_tap"><span class="gs_btnPR"><span class="gs_ico"></span></span></span></span></div></li><li><div class="gsc_rsb_aa" tabindex="0"><style>#gsc_rsb-u3-iWPQAAAAJ-img{width:32px;height:32px;}.gs_el_ta #gsc_rsb-u3-iWPQAAAAJ-img,.gs_el_ph #gsc_rsb-u3-iWPQAAAAJ-img{width:56px;height:56px;}</style><span id="gsc_rsb-u3-iWPQAAAAJ" class="gs_rimg gs_pp_tn gs_pp_mo_sm gsc_rsb_a_pht"><img alt="John Lunec" sizes="(max-width:981px) 56px,32px" src="https://scholar.googleusercontent.com/citations?view_op=small_photo&amp;user=u3-iWPQAAAAJ&amp;citpid=1" id="gsc_rsb-u3-iWPQAAAAJ-img" class="gs_pp_df" srcset="https://scholar.googleusercontent.com/citations?view_op=tiny_photo&amp;user=u3-iWPQAAAAJ&amp;citpid=1 32w,https://scholar.googleusercontent.com/citations?view_op=small_photo&amp;user=u3-iWPQAAAAJ&amp;citpid=1 56w,https://scholar.googleusercontent.com/citations?view_op=view_photo&amp;user=u3-iWPQAAAAJ&amp;citpid=1 128w"></span><span class="gsc_rsb_a_desc"><a tabindex="-1" href="/citations?user=u3-iWPQAAAAJ&amp;hl=en">John Lunec</a><span class="gsc_rsb_a_ext">Newcastle University</span><span class="gsc_rsb_a_ext gsc_rsb_a_ext2">Verified email at ncl.ac.uk</span><span class="gsc_rsb_tap"><span class="gs_btnPR"><span class="gs_ico"></span></span></span></span></div></li><li><div class="gsc_rsb_aa" tabindex="0"><style>#gsc_rsb-YvcTnK0AAAAJ-img{width:32px;height:32px;}.gs_el_ta #gsc_rsb-YvcTnK0AAAAJ-img,.gs_el_ph #gsc_rsb-YvcTnK0AAAAJ-img{width:56px;height:56px;}</style><span id="gsc_rsb-YvcTnK0AAAAJ" class="gs_rimg gs_pp_tn gs_pp_mo_sm gsc_rsb_a_pht"><img alt="Deborah A. Tweddle" sizes="(max-width:981px) 56px,32px" src="/citations/images/avatar_scholar_56.png" id="gsc_rsb-YvcTnK0AAAAJ-img" class="gs_pp_df" srcset="/citations/images/avatar_scholar_32.png 32w,/citations/images/avatar_scholar_56.png 56w,/citations/images/avatar_scholar_128.png 128w"></span><span class="gsc_rsb_a_desc"><a tabindex="-1" href="/citations?user=YvcTnK0AAAAJ&amp;hl=en">Deborah A. Tweddle</a><span class="gsc_rsb_a_ext">Professor of Paediatric Oncology, Newcastle University</span><span class="gsc_rsb_a_ext gsc_rsb_a_ext2">Verified email at newcastle.ac.uk</span><span class="gsc_rsb_tap"><span class="gs_btnPR"><span class="gs_ico"></span></span></span></span></div></li><li><div class="gsc_rsb_aa" tabindex="0"><style>#gsc_rsb-t6Tf6N0AAAAJ-img{width:24px;height:32px;}.gs_el_ta #gsc_rsb-t6Tf6N0AAAAJ-img,.gs_el_ph #gsc_rsb-t6Tf6N0AAAAJ-img{width:42px;height:56px;}</style><span id="gsc_rsb-t6Tf6N0AAAAJ" class="gs_rimg gs_pp_tn gs_pp_mo_sm gsc_rsb_a_pht"><img alt="Ian Hickson" sizes="(max-width:981px) 42px,24px" src="https://scholar.googleusercontent.com/citations?view_op=small_photo&amp;user=t6Tf6N0AAAAJ&amp;citpid=5" id="gsc_rsb-t6Tf6N0AAAAJ-img" class="gs_pp_df" srcset="https://scholar.googleusercontent.com/citations?view_op=tiny_photo&amp;user=t6Tf6N0AAAAJ&amp;citpid=5 24w,https://scholar.googleusercontent.com/citations?view_op=small_photo&amp;user=t6Tf6N0AAAAJ&amp;citpid=5 42w,https://scholar.googleusercontent.com/citations?view_op=view_photo&amp;user=t6Tf6N0AAAAJ&amp;citpid=5 96w"></span><span class="gsc_rsb_a_desc"><a tabindex="-1" href="/citations?user=t6Tf6N0AAAAJ&amp;hl=en">Ian Hickson</a><span class="gsc_rsb_a_ext">CRUK Newcastle Drug Discovery Unit, Newcastle University</span><span class="gsc_rsb_a_ext gsc_rsb_a_ext2">Verified email at newcastle.ac.uk</span><span class="gsc_rsb_tap"><span class="gs_btnPR"><span class="gs_ico"></span></span></span></span></div></li><li><div class="gsc_rsb_aa" tabindex="0"><style>#gsc_rsb-wdlFWPYAAAAJ-img{width:32px;height:32px;}.gs_el_ta #gsc_rsb-wdlFWPYAAAAJ-img,.gs_el_ph #gsc_rsb-wdlFWPYAAAAJ-img{width:56px;height:56px;}</style><span id="gsc_rsb-wdlFWPYAAAAJ" class="gs_rimg gs_pp_tn gs_pp_mo_sm gsc_rsb_a_pht"><img alt="Mark Meuth" sizes="(max-width:981px) 56px,32px" src="/citations/images/avatar_scholar_56.png" id="gsc_rsb-wdlFWPYAAAAJ-img" class="gs_pp_df" srcset="/citations/images/avatar_scholar_32.png 32w,/citations/images/avatar_scholar_56.png 56w,/citations/images/avatar_scholar_128.png 128w"></span><span class="gsc_rsb_a_desc"><a tabindex="-1" href="/citations?user=wdlFWPYAAAAJ&amp;hl=en">Mark Meuth</a><span class="gsc_rsb_a_ext"></span><span class="gsc_rsb_a_ext gsc_rsb_a_ext2">Verified email at sheffield.ac.uk</span><span class="gsc_rsb_tap"><span class="gs_btnPR"><span class="gs_ico"></span></span></span></span></div></li><li><div class="gsc_rsb_aa" tabindex="0"><style>#gsc_rsb-I70uprkAAAAJ-img{width:30px;height:32px;}.gs_el_ta #gsc_rsb-I70uprkAAAAJ-img,.gs_el_ph #gsc_rsb-I70uprkAAAAJ-img{width:52px;height:56px;}</style><span id="gsc_rsb-I70uprkAAAAJ" class="gs_rimg gs_pp_tn gs_pp_mo_sm gsc_rsb_a_pht"><img alt="Helen Reeves" sizes="(max-width:981px) 52px,30px" src="https://scholar.googleusercontent.com/citations?view_op=small_photo&amp;user=I70uprkAAAAJ&amp;citpid=3" id="gsc_rsb-I70uprkAAAAJ-img" class="gs_pp_df" srcset="https://scholar.googleusercontent.com/citations?view_op=tiny_photo&amp;user=I70uprkAAAAJ&amp;citpid=3 30w,https://scholar.googleusercontent.com/citations?view_op=small_photo&amp;user=I70uprkAAAAJ&amp;citpid=3 52w,https://scholar.googleusercontent.com/citations?view_op=view_photo&amp;user=I70uprkAAAAJ&amp;citpid=3 120w"></span><span class="gsc_rsb_a_desc"><a tabindex="-1" href="/citations?user=I70uprkAAAAJ&amp;hl=en">Helen Reeves</a><span class="gsc_rsb_a_ext">Newcastle University</span><span class="gsc_rsb_a_ext gsc_rsb_a_ext2">Verified email at newcastle.ac.uk</span><span class="gsc_rsb_tap"><span class="gs_btnPR"><span class="gs_ico"></span></span></span></span></div></li><li><div class="gsc_rsb_aa" tabindex="0"><style>#gsc_rsb-YdgYGsMAAAAJ-img{width:26px;height:32px;}.gs_el_ta #gsc_rsb-YdgYGsMAAAAJ-img,.gs_el_ph #gsc_rsb-YdgYGsMAAAAJ-img{width:45px;height:56px;}</style><span id="gsc_rsb-YdgYGsMAAAAJ" class="gs_rimg gs_pp_tn gs_pp_mo_sm gsc_rsb_a_pht"><img alt="David Jamieson" sizes="(max-width:981px) 45px,26px" src="https://scholar.googleusercontent.com/citations?view_op=small_photo&amp;user=YdgYGsMAAAAJ&amp;citpid=2" id="gsc_rsb-YdgYGsMAAAAJ-img" class="gs_pp_df" srcset="https://scholar.googleusercontent.com/citations?view_op=tiny_photo&amp;user=YdgYGsMAAAAJ&amp;citpid=2 26w,https://scholar.googleusercontent.com/citations?view_op=small_photo&amp;user=YdgYGsMAAAAJ&amp;citpid=2 45w,https://scholar.googleusercontent.com/citations?view_op=view_photo&amp;user=YdgYGsMAAAAJ&amp;citpid=2 103w"></span><span class="gsc_rsb_a_desc"><a tabindex="-1" href="/citations?user=YdgYGsMAAAAJ&amp;hl=en">David Jamieson</a><span class="gsc_rsb_a_ext">Newcastle University</span><span class="gsc_rsb_a_ext gsc_rsb_a_ext2">Verified email at ncl.ac.uk</span><span class="gsc_rsb_tap"><span class="gs_btnPR"><span class="gs_ico"></span></span></span></span></div></li><li><div class="gsc_rsb_aa" tabindex="0"><style>#gsc_rsb-CyPrfnYAAAAJ-img{width:32px;height:32px;}.gs_el_ta #gsc_rsb-CyPrfnYAAAAJ-img,.gs_el_ph #gsc_rsb-CyPrfnYAAAAJ-img{width:56px;height:56px;}</style><span id="gsc_rsb-CyPrfnYAAAAJ" class="gs_rimg gs_pp_tn gs_pp_mo_sm gsc_rsb_a_pht"><img alt="Margaret Bassendine" sizes="(max-width:981px) 56px,32px" src="/citations/images/avatar_scholar_56.png" id="gsc_rsb-CyPrfnYAAAAJ-img" class="gs_pp_df" srcset="/citations/images/avatar_scholar_32.png 32w,/citations/images/avatar_scholar_56.png 56w,/citations/images/avatar_scholar_128.png 128w"></span><span class="gsc_rsb_a_desc"><a tabindex="-1" href="/citations?user=CyPrfnYAAAAJ&amp;hl=en">Margaret Bassendine</a><span class="gsc_rsb_a_ext"></span><span class="gsc_rsb_a_ext gsc_rsb_a_ext2">Verified email at ncl.ac.uk</span><span class="gsc_rsb_tap"><span class="gs_btnPR"><span class="gs_ico"></span></span></span></span></div></li><li><div class="gsc_rsb_aa" tabindex="0"><style>#gsc_rsb-P7WYDHQAAAAJ-img{width:32px;height:30px;}.gs_el_ta #gsc_rsb-P7WYDHQAAAAJ-img,.gs_el_ph #gsc_rsb-P7WYDHQAAAAJ-img{width:56px;height:52px;}</style><span id="gsc_rsb-P7WYDHQAAAAJ" class="gs_rimg gs_pp_tn gs_pp_mo_sm gsc_rsb_a_pht"><img alt="Stephen Jackson" sizes="(max-width:981px) 56px,32px" src="https://scholar.googleusercontent.com/citations?view_op=small_photo&amp;user=P7WYDHQAAAAJ&amp;citpid=3" id="gsc_rsb-P7WYDHQAAAAJ-img" class="gs_pp_df" srcset="https://scholar.googleusercontent.com/citations?view_op=tiny_photo&amp;user=P7WYDHQAAAAJ&amp;citpid=3 32w,https://scholar.googleusercontent.com/citations?view_op=small_photo&amp;user=P7WYDHQAAAAJ&amp;citpid=3 56w,https://scholar.googleusercontent.com/citations?view_op=view_photo&amp;user=P7WYDHQAAAAJ&amp;citpid=3 128w"></span><span class="gsc_rsb_a_desc"><a tabindex="-1" href="/citations?user=P7WYDHQAAAAJ&amp;hl=en">Stephen Jackson</a><span class="gsc_rsb_a_ext">University of Cambridge</span><span class="gsc_rsb_a_ext gsc_rsb_a_ext2">Verified email at gurdon.cam.ac.uk</span><span class="gsc_rsb_tap"><span class="gs_btnPR"><span class="gs_ico"></span></span></span></span></div></li><li><div class="gsc_rsb_aa" tabindex="0"><style>#gsc_rsb-r92KDNkAAAAJ-img{width:32px;height:32px;}.gs_el_ta #gsc_rsb-r92KDNkAAAAJ-img,.gs_el_ph #gsc_rsb-r92KDNkAAAAJ-img{width:56px;height:56px;}</style><span id="gsc_rsb-r92KDNkAAAAJ" class="gs_rimg gs_pp_tn gs_pp_mo_sm gsc_rsb_a_pht"><img alt="Julie Tucker" sizes="(max-width:981px) 56px,32px" src="/citations/images/avatar_scholar_56.png" id="gsc_rsb-r92KDNkAAAAJ-img" class="gs_pp_df" srcset="/citations/images/avatar_scholar_32.png 32w,/citations/images/avatar_scholar_56.png 56w,/citations/images/avatar_scholar_128.png 128w"></span><span class="gsc_rsb_a_desc"><a tabindex="-1" href="/citations?user=r92KDNkAAAAJ&amp;hl=en">Julie Tucker</a><span class="gsc_rsb_a_ext">University of York</span><span class="gsc_rsb_a_ext gsc_rsb_a_ext2">Verified email at york.ac.uk</span><span class="gsc_rsb_tap"><span class="gs_btnPR"><span class="gs_ico"></span></span></span></span></div></li><li><div class="gsc_rsb_aa" tabindex="0"><style>#gsc_rsb-R_0E-K0AAAAJ-img{width:32px;height:32px;}.gs_el_ta #gsc_rsb-R_0E-K0AAAAJ-img,.gs_el_ph #gsc_rsb-R_0E-K0AAAAJ-img{width:56px;height:56px;}</style><span id="gsc_rsb-R_0E-K0AAAAJ" class="gs_rimg gs_pp_tn gs_pp_mo_sm gsc_rsb_a_pht"><img alt="Johann de Bono" sizes="(max-width:981px) 56px,32px" src="/citations/images/avatar_scholar_56.png" id="gsc_rsb-R_0E-K0AAAAJ-img" class="gs_pp_df" srcset="/citations/images/avatar_scholar_32.png 32w,/citations/images/avatar_scholar_56.png 56w,/citations/images/avatar_scholar_128.png 128w"></span><span class="gsc_rsb_a_desc"><a tabindex="-1" href="/citations?user=R_0E-K0AAAAJ&amp;hl=en">Johann de Bono</a><span class="gsc_rsb_a_ext">Institute of Cancer Research</span><span class="gsc_rsb_a_ext gsc_rsb_a_ext2">Verified email at icr.ac.uk</span><span class="gsc_rsb_tap"><span class="gs_btnPR"><span class="gs_ico"></span></span></span></span></div></li><li><div class="gsc_rsb_aa" tabindex="0"><style>#gsc_rsb-kefqjcIAAAAJ-img{width:32px;height:24px;}.gs_el_ta #gsc_rsb-kefqjcIAAAAJ-img,.gs_el_ph #gsc_rsb-kefqjcIAAAAJ-img{width:56px;height:42px;}</style><span id="gsc_rsb-kefqjcIAAAAJ" class="gs_rimg gs_pp_tn gs_pp_mo_sm gsc_rsb_a_pht"><img alt="Michele Tavecchio" sizes="(max-width:981px) 56px,32px" src="https://scholar.googleusercontent.com/citations?view_op=small_photo&amp;user=kefqjcIAAAAJ&amp;citpid=4" id="gsc_rsb-kefqjcIAAAAJ-img" class="gs_pp_df" srcset="https://scholar.googleusercontent.com/citations?view_op=tiny_photo&amp;user=kefqjcIAAAAJ&amp;citpid=4 32w,https://scholar.googleusercontent.com/citations?view_op=small_photo&amp;user=kefqjcIAAAAJ&amp;citpid=4 56w,https://scholar.googleusercontent.com/citations?view_op=view_photo&amp;user=kefqjcIAAAAJ&amp;citpid=4 128w"></span><span class="gsc_rsb_a_desc"><a tabindex="-1" href="/citations?user=kefqjcIAAAAJ&amp;hl=en">Michele Tavecchio</a><span class="gsc_rsb_a_ext">Senior Scientist, NeuroVive Pharmaceutical SA</span><span class="gsc_rsb_a_ext gsc_rsb_a_ext2">Verified email at neurovive.com</span><span class="gsc_rsb_tap"><span class="gs_btnPR"><span class="gs_ico"></span></span></span></span></div></li></ul><div class="gsc_rsb_hmv gs_ota gs_oph"><button type="button" class=" gs_btn_flat gs_btn_flact gs_btn_lrge gs_btn_lsu gsc_rsb_btnv"><span class="gs_wr"><span class="gs_lbl">View all</span></span></button></div></div></div><div class="gsc_lcl" role="main" id="gsc_prf_w"><div id="gsc_prf"><button type="button" id="gsc_prf_btnf" class="gs_btnMW gs_in_ib gs_btn_act gs_btn_lsu gs_btn_mph"><span class="gs_wr"><span class="gs_ico"></span><span class="gs_lbl">Follow</span></span></button><div id="gsc_prf_pu"><div id="gsc_prf_pua" class="gs_rimg"><style>#gsc_prf_pup-img{width:85px;height:128px;}@media print{#gs_top #gsc_prf_pup-img{width:53pt;height:80pt;}}</style><img alt="Nicola Curtin" sizes="print 53px,85px" src="https://scholar.googleusercontent.com/citations?view_op=view_photo&amp;user=FhFQsc8AAAAJ&amp;citpid=1" id="gsc_prf_pup-img" srcset="https://scholar.googleusercontent.com/citations?view_op=view_photo&amp;user=FhFQsc8AAAAJ&amp;citpid=1 85w,https://scholar.googleusercontent.com/citations?view_op=medium_photo&amp;user=FhFQsc8AAAAJ&amp;citpid=1 170w"></div></div><div id="gsc_prf_i"><div id="gsc_prf_in">Nicola Curtin</div><div class="gsc_prf_il"><a href="/citations?view_op=view_org&amp;hl=en&amp;org=7687019144636890226" class="gsc_prf_ila">Newcastle University</a></div><div class="gsc_prf_il" id="gsc_prf_ivh">Verified email at ncl.ac.uk - <a href="https://www.ncl.ac.uk/medical-sciences/people/profile/nicolacurtin.html" rel="nofollow" class="gsc_prf_ila">Homepage</a></div><div class="gsc_prf_il" id="gsc_prf_int"><a href="/citations?view_op=search_authors&amp;hl=en&amp;mauthors=label:oncology" class="gsc_prf_inta gs_ibl">Oncology</a><a href="/citations?view_op=search_authors&amp;hl=en&amp;mauthors=label:dna_damage_response" class="gsc_prf_inta gs_ibl">DNA damage response</a></div></div></div></div><div id="gsc_prf_t_wrp" role="navigation"><div id="gsc_prf_t" role="tablist"><a id="gsc_prf_t-art" class="gsc_prf_tab" href="javascript:void(0)" role="tab" aria-controls="gsc_art" aria-selected="true">Articles</a><a id="gsc_prf_t-cit" class="gsc_prf_tab" href="javascript:void(0)" role="tab" aria-controls="gsc_rsb_cit">Cited by</a><a id="gsc_prf_t-mnd" class="gsc_prf_tab" href="javascript:void(0)" role="tab" aria-controls="gsc_rsb_mnd">Public access</a><a id="gsc_prf_t-ath" class="gsc_prf_tab" href="javascript:void(0)" role="tab" aria-controls="gsc_rsb_co">Co-authors</a></div></div><div class="gsc_lcl gsc_prf_pnl" id="gsc_art" role="region" aria-labelledby="gsc_prf_t-art"><form method="post" action="/citations?hl=en&amp;user=FhFQsc8AAAAJ&amp;view_op=list_works"><input type="hidden" name="xsrf" value="AMD79ooAAAAAYTsAXIZjCUSlF8b-IhjOQKNVAeXvQtXT"><div id="gsc_a_tw"><table id="gsc_a_t"><thead><tr id="gsc_a_tr0" aria-hidden="true"><th class="gsc_a_t"></th><th class="gsc_a_c"></th><th class="gsc_a_y"></th></tr><tr id="gsc_a_trh"><th class="gsc_a_t" scope="col"><span id="gsc_a_ta"><a href="/citations?hl=en&amp;user=FhFQsc8AAAAJ&amp;view_op=list_works&amp;sortby=title" class="gsc_a_a">Title</a></span><div id="gsc_dd_sort-r" class="gs_md_r gs_md_rmb gs_md_rmbl"><button type="button" id="gsc_dd_sort-b" aria-controls="gsc_dd_sort-d" aria-haspopup="true" ontouchstart="gs_evt_dsp(event)" class=" gs_in_se gs_btn_mnu gs_btn_flat gs_btn_lrge gs_btn_half gs_btn_lsu gs_press gs_md_tb"><span class="gs_wr"><span class="gs_lbl">Sort</span><span class="gs_icm"></span></span></button><div id="gsc_dd_sort-d" class="gs_md_d gs_md_ulr" role="menu" tabindex="-1"><div id="gsc_dd_sort-s" class="gs_oph gsc_dd_sec gsc_dd_sep"><a role="menuitem" href="/citations?hl=en&amp;user=FhFQsc8AAAAJ&amp;view_op=list_works" tabindex="-1" class="gs_md_li gsc_dd_sort-sel">Sort by citations</a><a role="menuitem" href="/citations?hl=en&amp;user=FhFQsc8AAAAJ&amp;view_op=list_works&amp;sortby=pubdate" tabindex="-1" class="gs_md_li">Sort by year</a><a role="menuitem" href="/citations?hl=en&amp;user=FhFQsc8AAAAJ&amp;view_op=list_works&amp;sortby=title" tabindex="-1" class="gs_md_li">Sort by title</a></div></div></div></th><th class="gsc_a_c" scope="col" dir="rtl"><span id="gsc_a_ca"><div class="gs_nph">Cited by</div><div class="gs_oph">Cited by</div></span></th><th class="gsc_a_y" scope="col"><span class="gsc_a_h" id="gsc_a_ha"><a href="/citations?hl=en&amp;user=FhFQsc8AAAAJ&amp;view_op=list_works&amp;sortby=pubdate" class="gsc_a_a">Year</a></span></th></tr></thead><tbody id="gsc_a_b"><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;citation_for_view=FhFQsc8AAAAJ:mVmsd5A6BfQC" class="gsc_a_at">Specific killing of BRCA2-deficient tumours with inhibitors of poly (ADP-ribose) polymerase</a><div class="gs_gray">HE Bryant, N Schultz, HD Thomas, KM Parker, D Flower, E Lopez, S Kyle, ...</div><div class="gs_gray">Nature 434 (7035), 913-917<span class="gs_oph">, 2005</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=2927738719646973444" class="gsc_a_ac gs_ibl">4383</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2005</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;citation_for_view=FhFQsc8AAAAJ:BUYA1_V_uYcC" class="gsc_a_at">Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM</a><div class="gs_gray">I Hickson, Y Zhao, CJ Richardson, SJ Green, NMB Martin, AI Orr, ...</div><div class="gs_gray">Cancer research 64 (24), 9152-9159<span class="gs_oph">, 2004</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=12784208795845967474" class="gsc_a_ac gs_ibl">1261</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2004</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;citation_for_view=FhFQsc8AAAAJ:GnPB-g6toBAC" class="gsc_a_at">DNA repair dysregulation from cancer driver to therapeutic target</a><div class="gs_gray">NJ Curtin</div><div class="gs_gray">Nature Reviews Cancer 12 (12), 801-817<span class="gs_oph">, 2012</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=4810820412753225045" class="gsc_a_ac gs_ibl">860</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2012</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;citation_for_view=FhFQsc8AAAAJ:9ZlFYXVOiuMC" class="gsc_a_at">Anticancer chemosensitization and radiosensitization by the novel poly (ADP-ribose) polymerase-1 inhibitor AG14361</a><div class="gs_gray">CR Calabrese, R Almassy, S Barton, MA Batey, AH Calvert, ...</div><div class="gs_gray">Journal of the National Cancer Institute 96 (1), 56-67<span class="gs_oph">, 2004</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=2999800829200452746" class="gsc_a_ac gs_ibl">518</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2004</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;citation_for_view=FhFQsc8AAAAJ:nVrZBo8bIpAC" class="gsc_a_at">Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441</a><div class="gs_gray">Y Zhao, HD Thomas, MA Batey, IG Cowell, CJ Richardson, RJ Griffin, ...</div><div class="gs_gray">Cancer research 66 (10), 5354-5362<span class="gs_oph">, 2006</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=18246042054616604405" class="gsc_a_ac gs_ibl">433</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2006</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;citation_for_view=FhFQsc8AAAAJ:J_g5lzvAfSwC" class="gsc_a_at">Phase I study of the poly (ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors</a><div class="gs_gray">R Plummer, C Jones, M Middleton, R Wilson, J Evans, A Olsen, N Curtin, ...</div><div class="gs_gray">Clinical cancer research 14 (23), 7917-7923<span class="gs_oph">, 2008</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=4960820016765418724" class="gsc_a_ac gs_ibl">420</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2008</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;citation_for_view=FhFQsc8AAAAJ:4vMrXwiscB8C" class="gsc_a_at">Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer</a><div class="gs_gray">SA Eccles, EO Aboagye, S Ali, AS Anderson, J Armes, F Berditchevski, ...</div><div class="gs_gray">Breast Cancer Research 15 (5), 1-37<span class="gs_oph">, 2013</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=16848345574059897435" class="gsc_a_ac gs_ibl">413</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2013</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;citation_for_view=FhFQsc8AAAAJ:fQNAKQ3IYiAC" class="gsc_a_at">Radiosensitization and DNA repair inhibition by the combined use of novel inhibitors of DNA-dependent protein kinase and poly (ADP-ribose) polymerase-1</a><div class="gs_gray">SJ Veuger, NJ Curtin, CJ Richardson, GCM Smith, BW Durkacz</div><div class="gs_gray">Cancer research 63 (18), 6008-6015<span class="gs_oph">, 2003</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=8279553986666709224" class="gsc_a_ac gs_ibl">387</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2003</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;citation_for_view=FhFQsc8AAAAJ:HbR8gkJAVGIC" class="gsc_a_at">Resistance-Modifying Agents. 9.<sup></sup> Synthesis and Biological Properties of Benzimidazole Inhibitors of the DNA Repair Enzyme Poly(ADP-ribose) Polymerase</a><div class="gs_gray">AW White, R Almassy, AH Calvert, NJ Curtin, RJ Griffin, Z Hostomsky, ...</div><div class="gs_gray">Journal of medicinal chemistry 43 (22), 4084-4097<span class="gs_oph">, 2000</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=14849233099948567823" class="gsc_a_ac gs_ibl">351</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2000</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;citation_for_view=FhFQsc8AAAAJ:xtoqd-5pKcoC" class="gsc_a_at">Therapeutic applications of PARP inhibitors: anticancer therapy and beyond</a><div class="gs_gray">NJ Curtin, C Szabo</div><div class="gs_gray">Molecular aspects of medicine 34 (6), 1217-1256<span class="gs_oph">, 2013</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=14838396470446067894" class="gsc_a_ac gs_ibl">336</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2013</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;citation_for_view=FhFQsc8AAAAJ:B3FOqHPlNUQC" class="gsc_a_at">Preclinical selection of a novel poly (ADP-ribose) polymerase inhibitor for clinical trial</a><div class="gs_gray">HD Thomas, CR Calabrese, MA Batey, S Canan, Z Hostomsky, S Kyle, ...</div><div class="gs_gray">Molecular cancer therapeutics 6 (3), 945-956<span class="gs_oph">, 2007</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=7831237773460672995" class="gsc_a_ac gs_ibl">284</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2007</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;citation_for_view=FhFQsc8AAAAJ:J-pR_7NvFogC" class="gsc_a_at">The role of PARP in DNA repair and its therapeutic exploitation</a><div class="gs_gray">M Javle, NJ Curtin</div><div class="gs_gray">British journal of cancer 105 (8), 1114-1122<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=8716109414379299402" class="gsc_a_ac gs_ibl">268</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;citation_for_view=FhFQsc8AAAAJ:ZuybSZzF8UAC" class="gsc_a_at">Development of a functional assay for homologous recombination status in primary cultures of epithelial ovarian tumor and correlation with sensitivity to poly (ADP-ribose&nbsp;…</a><div class="gs_gray">A Mukhopadhyay, A Elattar, A Cerbinskaite, SJ Wilkinson, Y Drew, S Kyle, ...</div><div class="gs_gray">Clinical cancer research 16 (8), 2344-2351<span class="gs_oph">, 2010</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=10473439796896724041" class="gsc_a_ac gs_ibl">266</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2010</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;citation_for_view=FhFQsc8AAAAJ:wKETBy42zhYC" class="gsc_a_at">PARP inhibitors for cancer therapy</a><div class="gs_gray">NJ Curtin</div><div class="gs_gray">Expert Reviews Molecular Medicine 7 (4), 1-20<span class="gs_oph">, 2005</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=17312844411951426879" class="gsc_a_ac gs_ibl">262</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2005</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;citation_for_view=FhFQsc8AAAAJ:NJ774b8OgUMC" class="gsc_a_at">Therapeutic Potential of Poly(ADP-ribose) Polymerase Inhibitor AG014699 in Human Cancers With Mutated or Methylated <i>BRCA1</i> or <i>BRCA2</i></a><div class="gs_gray">Y Drew, EA Mulligan, WT Vong, HD Thomas, S Kahn, S Kyle, ...</div><div class="gs_gray">Journal of the national cancer institute 103 (4), 334-346<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=11061841354404629856" class="gsc_a_ac gs_ibl">258</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;citation_for_view=FhFQsc8AAAAJ:ML0RJ9NH7IQC" class="gsc_a_at">Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly (adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines</a><div class="gs_gray">CA Delaney, LZ Wang, S Kyle, AW White, AH Calvert, NJ Curtin, ...</div><div class="gs_gray">Clinical Cancer Research 6 (7), 2860-2867<span class="gs_oph">, 2000</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=12855575340252053875" class="gsc_a_ac gs_ibl">258</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2000</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;citation_for_view=FhFQsc8AAAAJ:ZHo1McVdvXMC" class="gsc_a_at">Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles</a><div class="gs_gray">CE Arris, FT Boyle, AH Calvert, NJ Curtin, JA Endicott, EF Garman, ...</div><div class="gs_gray">Journal of medicinal chemistry 43 (15), 2797-2804<span class="gs_oph">, 2000</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=5669031951271181686" class="gsc_a_ac gs_ibl">251</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2000</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;citation_for_view=FhFQsc8AAAAJ:IUKN3-7HHlwC" class="gsc_a_at">Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition</a><div class="gs_gray">N Johnson, YC Li, ZE Walton, KA Cheng, D Li, SJ Rodig, LA Moreau, ...</div><div class="gs_gray">Nature medicine 17 (7), 875-882<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=16590889553496514703" class="gsc_a_ac gs_ibl">249</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;citation_for_view=FhFQsc8AAAAJ:JoZmwDi-zQgC" class="gsc_a_at">Phase I, dose-escalation, two-part trial of the PARP inhibitor talazoparib in patients with advanced germline BRCA1/2 mutations and selected sporadic cancers</a><div class="gs_gray">J de Bono, RK Ramanathan, L Mina, R Chugh, J Glaspy, S Rafii, S Kaye, ...</div><div class="gs_gray">Cancer discovery 7 (6), 620-629<span class="gs_oph">, 2017</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=9653157378385652110" class="gsc_a_ac gs_ibl">243</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2017</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;citation_for_view=FhFQsc8AAAAJ:hC7cP41nSMkC" class="gsc_a_at">Structure-based design of a potent purine-based cyclin-dependent kinase inhibitor</a><div class="gs_gray">TG Davies, J Bentley, CE Arris, FT Boyle, NJ Curtin, JA Endicott, ...</div><div class="gs_gray">Nature structural biology 9 (10), 745-749<span class="gs_oph">, 2002</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=3417516643228300750" class="gsc_a_ac gs_ibl">243</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2002</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=FhFQsc8AAAAJ:kRWSkSYxWN8C" class="gsc_a_at">Mechanism of cell death following thymidylate synthase inhibition: 2′-deoxyuridine-5′-triphosphate accumulation, DNA damage, and growth inhibition following exposure to&nbsp;…</a><div class="gs_gray">NJ Curtin, AL Harris, GW Aherne</div><div class="gs_gray">Cancer Research 51 (9), 2346-2352<span class="gs_oph">, 1991</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=8648675683329196088" class="gsc_a_ac gs_ibl">214</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1991</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=FhFQsc8AAAAJ:bFI3QPDXJZMC" class="gsc_a_at">Tricyclic benzimidazoles as potent poly (ADP-ribose) polymerase-1 inhibitors</a><div class="gs_gray">DJ Skalitzky, JT Marakovits, KA Maegley, A Ekker, XH Yu, Z Hostomsky, ...</div><div class="gs_gray">Journal of medicinal chemistry 46 (2), 210-213<span class="gs_oph">, 2003</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=6271242504909524149" class="gsc_a_ac gs_ibl">188</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2003</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=FhFQsc8AAAAJ:RHpTSmoSYBkC" class="gsc_a_at">Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines</a><div class="gs_gray">A Peasland, LZ Wang, E Rowling, S Kyle, T Chen, A Hopkins, WA Cliby, ...</div><div class="gs_gray">British journal of cancer 105 (3), 372-381<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=3795974750794035607" class="gsc_a_ac gs_ibl">187</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=FhFQsc8AAAAJ:BqipwSGYUEgC" class="gsc_a_at">Resistance-Modifying Agents. 5.<sup></sup> Synthesis and Biological Properties of Quinazolinone Inhibitors of the DNA Repair Enzyme Poly(ADP-ribose) Polymerase (PARP)</a><div class="gs_gray">RJ Griffin, S Srinivasan, K Bowman, AH Calvert, NJ Curtin, DR Newell, ...</div><div class="gs_gray">Journal of medicinal chemistry 41 (26), 5247-5256<span class="gs_oph">, 1998</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=4785105486865450619" class="gsc_a_ac gs_ibl">181</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1998</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=FhFQsc8AAAAJ:4MWp96NkSFoC" class="gsc_a_at">Targeting the S and G2 checkpoint to treat cancer</a><div class="gs_gray">T Chen, PA Stephens, FK Middleton, NJ Curtin</div><div class="gs_gray">Drug discovery today 17 (5-6), 194-202<span class="gs_oph">, 2012</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=12905739204738898658" class="gsc_a_ac gs_ibl">177</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2012</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=FhFQsc8AAAAJ:blknAaTinKkC" class="gsc_a_at">Novel poly (ADP-ribose) polymerase-1 inhibitor, AG14361, restores sensitivity to temozolomide in mismatch repair-deficient cells</a><div class="gs_gray">NJ Curtin, LZ Wang, A Yiakouvaki, S Kyle, CA Arris, S Canan-Koch, ...</div><div class="gs_gray">Clinical Cancer Research 10 (3), 881-889<span class="gs_oph">, 2004</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=4557722662081124315" class="gsc_a_ac gs_ibl">173</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2004</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=FhFQsc8AAAAJ:u_35RYKgDlwC" class="gsc_a_at">A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation</a><div class="gs_gray">R Plummer, P Lorigan, N Steven, L Scott, MR Middleton, RH Wilson, ...</div><div class="gs_gray">Cancer chemotherapy and pharmacology 71 (5), 1191-1199<span class="gs_oph">, 2013</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=5882563328233591030" class="gsc_a_ac gs_ibl">171</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2013</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=FhFQsc8AAAAJ:9pM33mqn1YgC" class="gsc_a_at">Discovery of potent chromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK) using a small-molecule library approach</a><div class="gs_gray">IR Hardcastle, X Cockcroft, NJ Curtin, MD El-Murr, JJJ Leahy, M Stockley, ...</div><div class="gs_gray">Journal of medicinal chemistry 48 (24), 7829-7846<span class="gs_oph">, 2005</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=15722155837977050502" class="gsc_a_ac gs_ibl">168</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2005</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=FhFQsc8AAAAJ:eMMeJKvmdy0C" class="gsc_a_at">Differential effects of the poly (ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro</a><div class="gs_gray">KJ Bowman, DR Newell, AH Calvert, NJ Curtin</div><div class="gs_gray">British journal of cancer 84 (1), 106-112<span class="gs_oph">, 2001</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=9199540390610918450" class="gsc_a_ac gs_ibl">165</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2001</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=FhFQsc8AAAAJ:hMod-77fHWUC" class="gsc_a_at">PARP inhibitor development for systemic cancer targeting</a><div class="gs_gray">T Zaremba, NJ Curtin</div><div class="gs_gray">Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal&nbsp;…<span class="gs_oph">, 2007</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=4587478219803286619" class="gsc_a_ac gs_ibl">160</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2007</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=FhFQsc8AAAAJ:KbBQZpvPDL4C" class="gsc_a_at">Potentiation of temozolomide-induced cytotoxicity: a comparative study of the biological effects of poly (ADP-ribose) polymerase inhibitors</a><div class="gs_gray">S Boulton, LC Pemberton, JK Porteous, NJ Curtin, RJ Griffin, BT Golding, ...</div><div class="gs_gray">British journal of cancer 72 (4), 849-856<span class="gs_oph">, 1995</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=17510926530193273805" class="gsc_a_ac gs_ibl">158</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1995</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=FhFQsc8AAAAJ:XiSMed-E-HIC" class="gsc_a_at">Potentiation of anti-cancer agent cytotoxicity by the potent poly (ADP-ribose) polymerase inhibitors NU1025 and NU1064</a><div class="gs_gray">KJ Bowman, A White, BT Golding, RJ Griffin, NJ Curtin</div><div class="gs_gray">British journal of cancer 78 (10), 1269-1277<span class="gs_oph">, 1998</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=7294841017895439903" class="gsc_a_ac gs_ibl">149</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1998</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=FhFQsc8AAAAJ:_axFR9aDTf0C" class="gsc_a_at">Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly (ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers&nbsp;…</a><div class="gs_gray">Y Drew, J Ledermann, G Hall, D Rea, R Glasspool, M Highley, G Jayson, ...</div><div class="gs_gray">British journal of cancer 114 (7), 723-730<span class="gs_oph">, 2016</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=15291243621258146572" class="gsc_a_ac gs_ibl">145</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2016</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=FhFQsc8AAAAJ:AXPGKjj_ei8C" class="gsc_a_at">Novel tricyclic poly (ADP-ribose) polymerase-1 inhibitors with potent anticancer chemopotentiating activity: design, synthesis, and X-ray cocrystal structure</a><div class="gs_gray">SS Canan Koch, LH Thoresen, JG Tikhe, KA Maegley, RJ Almassy, J Li, ...</div><div class="gs_gray">Journal of medicinal chemistry 45 (23), 4961-4974<span class="gs_oph">, 2002</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=9145121467926267300" class="gsc_a_ac gs_ibl">143</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2002</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=FhFQsc8AAAAJ:qjMakFHDy7sC" class="gsc_a_at">Targeting the ATR-CHK1 axis in cancer therapy</a><div class="gs_gray">S Rundle, A Bradbury, Y Drew, NJ Curtin</div><div class="gs_gray">Cancers 9 (5), 41<span class="gs_oph">, 2017</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=450762422017239687" class="gsc_a_ac gs_ibl">142</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2017</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=FhFQsc8AAAAJ:uLbwQdceFCQC" class="gsc_a_at">The role of inhibitors of poly (ADP-ribose) polymerase as resistance-modifying agents in cancer therapy</a><div class="gs_gray">RJ Griffin, NJ Curtin, DR Newell, BT Golding, BW Durkacz, AH Calvert</div><div class="gs_gray">Biochimie 77 (6), 408-422<span class="gs_oph">, 1995</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=10919806580077176679" class="gsc_a_ac gs_ibl">139</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1995</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=FhFQsc8AAAAJ:M3ejUd6NZC8C" class="gsc_a_at">N<sup>2</sup>-Substituted <i>O</i><sup>6</sup>-Cyclohexylmethylguanine Derivatives:  Potent Inhibitors of Cyclin-Dependent Kinases 1 and 2</a><div class="gs_gray">IR Hardcastle, CE Arris, J Bentley, FT Boyle, Y Chen, NJ Curtin, ...</div><div class="gs_gray">Journal of medicinal chemistry 47 (15), 3710-3722<span class="gs_oph">, 2004</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=2743223326658959608" class="gsc_a_ac gs_ibl">135</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2004</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=FhFQsc8AAAAJ:mB3voiENLucC" class="gsc_a_at">Preclinical evaluation of a novel ATM inhibitor, KU59403, in vitro and in vivo in p53 functional and dysfunctional models of human cancer</a><div class="gs_gray">MA Batey, Y Zhao, S Kyle, C Richardson, A Slade, NMB Martin, A Lau, ...</div><div class="gs_gray">Molecular cancer therapeutics 12 (6), 959-967<span class="gs_oph">, 2013</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=3498976361417700153" class="gsc_a_ac gs_ibl">133</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2013</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=FhFQsc8AAAAJ:R3hNpaxXUhUC" class="gsc_a_at">Effects of novel inhibitors of poly (ADP-ribose) polymerase-1 and the DNA-dependent protein kinase on enzyme activities and DNA repair</a><div class="gs_gray">SJ Veuger, NJ Curtin, GCM Smith, BW Durkacz</div><div class="gs_gray">Oncogene 23 (44), 7322-7329<span class="gs_oph">, 2004</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=3670111438240605921" class="gsc_a_ac gs_ibl">133</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2004</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=FhFQsc8AAAAJ:Wp0gIr-vW9MC" class="gsc_a_at">Opportunities for the repurposing of PARP inhibitors for the therapy of non‐oncological diseases</a><div class="gs_gray">NA Berger, VC Besson, AH Boulares, A Bürkle, A Chiarugi, RS Clark, ...</div><div class="gs_gray">British journal of pharmacology 175 (2), 192-222<span class="gs_oph">, 2018</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=2828308462931297249" class="gsc_a_ac gs_ibl">121</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2018</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=FhFQsc8AAAAJ:bEWYMUwI8FkC" class="gsc_a_at">Identification of potent nontoxic poly (ADP-Ribose) polymerase-1 inhibitors: chemopotentiation and pharmacological studies</a><div class="gs_gray">CR Calabrese, MA Batey, HD Thomas, BW Durkacz, LZ Wang, S Kyle, ...</div><div class="gs_gray">Clinical cancer research 9 (7), 2711-2718<span class="gs_oph">, 2003</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=4129756251880911598" class="gsc_a_ac gs_ibl">120</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2003</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=FhFQsc8AAAAJ:86PQX7AUzd4C" class="gsc_a_at">Pemetrexed disodium, a novel antifolate with multiple targets</a><div class="gs_gray">NJ Curtin, AN Hughes</div><div class="gs_gray">The lancet oncology 2 (5), 298-306<span class="gs_oph">, 2001</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=15270977702944283030" class="gsc_a_ac gs_ibl">118</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2001</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=FhFQsc8AAAAJ:vV6vV6tmYwMC" class="gsc_a_at">Chemosensitization of cancer cells by KU-0060648, a dual inhibitor of DNA-PK and PI-3K</a><div class="gs_gray">JM Munck, MA Batey, Y Zhao, H Jenkins, CJ Richardson, C Cano, ...</div><div class="gs_gray">Molecular cancer therapeutics 11 (8), 1789-1798<span class="gs_oph">, 2012</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=3297653337324766565" class="gsc_a_ac gs_ibl">115</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2012</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=FhFQsc8AAAAJ:1yQoGdGgb4wC" class="gsc_a_at">The novel poly (ADP-Ribose) polymerase inhibitor, AG14361, sensitizes cells to topoisomerase I poisons by increasing the persistence of DNA strand breaks</a><div class="gs_gray">LM Smith, E Willmore, CA Austin, NJ Curtin</div><div class="gs_gray">Clinical Cancer Research 11 (23), 8449-8457<span class="gs_oph">, 2005</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=10515943778722997973" class="gsc_a_ac gs_ibl">112</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2005</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=FhFQsc8AAAAJ:SeFeTyx0c_EC" class="gsc_a_at">Isoindolinone-based inhibitors of the MDM2–p53 protein–protein interaction</a><div class="gs_gray">IR Hardcastle, SU Ahmed, H Atkins, AH Calvert, NJ Curtin, G Farnie, ...</div><div class="gs_gray">Bioorganic &amp; medicinal chemistry letters 15 (5), 1515-1520<span class="gs_oph">, 2005</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=5569678660606134620" class="gsc_a_ac gs_ibl">111</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2005</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=FhFQsc8AAAAJ:Ug5p-4gJ2f0C" class="gsc_a_at">DNA-PK inhibition by NU7441 sensitizes breast cancer cells to ionizing radiation and doxorubicin</a><div class="gs_gray">WM Ciszewski, M Tavecchio, J Dastych, NJ Curtin</div><div class="gs_gray">Breast cancer research and treatment 143 (1), 47-55<span class="gs_oph">, 2014</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=14960722722504256258" class="gsc_a_ac gs_ibl">110</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2014</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=FhFQsc8AAAAJ:Mojj43d5GZwC" class="gsc_a_at">Temozolomide pharmacodynamics in patients with metastatic melanoma: dna damage and activity of repair enzymes O6-alkylguanine alkyltransferase and poly (ADP-ribose) polymerase-1</a><div class="gs_gray">ER Plummer, MR Middleton, C Jones, A Olsen, I Hickson, P McHugh, ...</div><div class="gs_gray">Clinical Cancer Research 11 (9), 3402-3409<span class="gs_oph">, 2005</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=9143223602821957844" class="gsc_a_ac gs_ibl">109</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2005</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=FhFQsc8AAAAJ:MLfJN-KU85MC" class="gsc_a_at">Clinicopathological features of homologous recombination–deficient epithelial ovarian cancers: sensitivity to PARP inhibitors, platinum, and survival</a><div class="gs_gray">A Mukhopadhyay, ER Plummer, A Elattar, S Soohoo, B Uzir, JE Quinn, ...</div><div class="gs_gray">Cancer research 72 (22), 5675-5682<span class="gs_oph">, 2012</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=14083912527072493519" class="gsc_a_ac gs_ibl">105</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2012</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=FhFQsc8AAAAJ:6ZxmRoH8BuwC" class="gsc_a_at">Probing the ATP Ribose-Binding Domain of Cyclin-Dependent Kinases 1 and 2 with <i>O</i><sup>6</sup>-Substituted Guanine Derivatives</a><div class="gs_gray">AE Gibson, CE Arris, J Bentley, FT Boyle, NJ Curtin, TG Davies, ...</div><div class="gs_gray">Journal of medicinal chemistry 45 (16), 3381-3393<span class="gs_oph">, 2002</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=16391067502111659566" class="gsc_a_ac gs_ibl">105</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2002</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=FhFQsc8AAAAJ:gsN89kCJA0AC" class="gsc_a_at">Novel potent inhibitors of the DNA repair enzyme poly (ADP-ribose) polymerase (PARP)</a><div class="gs_gray">RJ Griffin, LC Pemberton, BT GOLDING, D RHODES, C BLEASDALE</div><div class="gs_gray">Anti-cancer drug design 10 (6), 507-514<span class="gs_oph">, 1995</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=13763771755364634174" class="gsc_a_ac gs_ibl">104</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1995</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=FhFQsc8AAAAJ:Z5m8FVwuT1cC" class="gsc_a_at">6-thioguanine selectively kills BRCA2-defective tumors and overcomes PARP inhibitor resistance</a><div class="gs_gray">N Issaeva, HD Thomas, T Djurenovic, JE Jaspers, I Stoimenov, S Kyle, ...</div><div class="gs_gray">Cancer research 70 (15), 6268-6276<span class="gs_oph">, 2010</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=12850814458428980681" class="gsc_a_ac gs_ibl">102</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2010</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=FhFQsc8AAAAJ:geHnlv5EZngC" class="gsc_a_at">First-in-human trial of novel oral PARP inhibitor BMN 673 in patients with solid tumors.</a><div class="gs_gray">JS De Bono, LA Mina, M Gonzalez, NJ Curtin, E Wang, JW Henshaw, ...</div><div class="gs_gray">Journal of Clinical Oncology 31 (15_suppl), 2580-2580<span class="gs_oph">, 2013</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=8022552362155655860" class="gsc_a_ac gs_ibl">101</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2013</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=FhFQsc8AAAAJ:bKqednn6t2AC" class="gsc_a_at">Potentiation of cytotoxic drug activity in human tumour cell lines, by amine-substituted 2-arylbenzimidazole-4-carboxamide PARP-1 inhibitors</a><div class="gs_gray">AW White, NJ Curtin, BW Eastman, BT Golding, Z Hostomsky, S Kyle, J Li, ...</div><div class="gs_gray">Bioorganic &amp; medicinal chemistry letters 14 (10), 2433-2437<span class="gs_oph">, 2004</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=17221558441727397487" class="gsc_a_ac gs_ibl">98</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2004</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=FhFQsc8AAAAJ:L7CI7m0gUJcC" class="gsc_a_at">Visualization of a DNA-PK/PARP1 complex</a><div class="gs_gray">L Spagnolo, J Barbeau, NJ Curtin, EP Morris, LH Pearl</div><div class="gs_gray">Nucleic acids research 40 (9), 4168-4177<span class="gs_oph">, 2012</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=13053665694467899687" class="gsc_a_ac gs_ibl">95</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2012</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=FhFQsc8AAAAJ:u-coK7KVo8oC" class="gsc_a_at">The impact of p53 status on cellular sensitivity to antifolate drugs</a><div class="gs_gray">X Lu, J Errington, NJ Curtin, J Lunec, DR Newell</div><div class="gs_gray">Clinical Cancer Research 7 (7), 2114-2123<span class="gs_oph">, 2001</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=18054534916882658896" class="gsc_a_ac gs_ibl">95</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2001</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=FhFQsc8AAAAJ:VL0QpB8kHFEC" class="gsc_a_at">Potentiation of paclitaxel-induced apoptosis by the novel cyclin-dependent kinase inhibitor NU6140: a possible role for survivin down-regulation</a><div class="gs_gray">M Pennati, AJ Campbell, M Curto, M Binda, YZ Cheng, LZ Wang, N Curtin, ...</div><div class="gs_gray">Molecular cancer therapeutics 4 (9), 1328-1337<span class="gs_oph">, 2005</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=10387989162834977999" class="gsc_a_ac gs_ibl">93</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2005</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=FhFQsc8AAAAJ:ufrVoPGSRksC" class="gsc_a_at">Poly (ADP-ribose) polymerase-1 polymorphisms, expression and activity in selected human tumour cell lines</a><div class="gs_gray">T Zaremba, P Ketzer, M Cole, S Coulthard, ER Plummer, NJ Curtin</div><div class="gs_gray">British journal of cancer 101 (2), 256-262<span class="gs_oph">, 2009</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=1528169074858903854" class="gsc_a_ac gs_ibl">91</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2009</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=FhFQsc8AAAAJ:Ri6SYOTghG4C" class="gsc_a_at">Inhibiting the DNA damage response as a therapeutic manoeuvre in cancer</a><div class="gs_gray">NJ Curtin</div><div class="gs_gray">British journal of pharmacology 169 (8), 1745-1765<span class="gs_oph">, 2013</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=15431556094323280747" class="gsc_a_ac gs_ibl">90</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2013</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=FhFQsc8AAAAJ:9c2xU6iGI7YC" class="gsc_a_at">PARP inhibitors for anticancer therapy</a><div class="gs_gray">N Curtin</div><div class="gs_gray">Biochemical Society Transactions 42 (1), 82-88<span class="gs_oph">, 2014</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=16637655373977371239" class="gsc_a_ac gs_ibl">84</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2014</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=FhFQsc8AAAAJ:sNmaIFBj_lkC" class="gsc_a_at">Structure-based design of 2-arylamino-4-cyclohexylmethyl-5-nitroso-6-aminopyrimidine inhibitors of cyclin-dependent kinases 1 and 2</a><div class="gs_gray">KL Sayle, J Bentley, FT Boyle, AH Calvert, Y Cheng, NJ Curtin, ...</div><div class="gs_gray">Bioorganic &amp; medicinal chemistry letters 13 (18), 3079-3082<span class="gs_oph">, 2003</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=16381335366586449328" class="gsc_a_ac gs_ibl">84</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2003</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=FhFQsc8AAAAJ:YOwf2qJgpHMC" class="gsc_a_at">Inhibition of poly (ADP-ribose) polymerase-1 enhances temozolomide and topotecan activity against childhood neuroblastoma</a><div class="gs_gray">RA Daniel, AL Rozanska, HD Thomas, EA Mulligan, Y Drew, ...</div><div class="gs_gray">Clinical Cancer Research 15 (4), 1241-1249<span class="gs_oph">, 2009</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=2683630062430747483" class="gsc_a_ac gs_ibl">83</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2009</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=FhFQsc8AAAAJ:8xutWZnSdmoC" class="gsc_a_at">Effective sensitization of temozolomide by ABT-888 is lost with development of temozolomide resistance in glioblastoma xenograft lines</a><div class="gs_gray">MJ Clarke, EA Mulligan, PT Grogan, AC Mladek, BL Carlson, ...</div><div class="gs_gray">Molecular cancer therapeutics 8 (2), 407-414<span class="gs_oph">, 2009</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=17882659493493784034" class="gsc_a_ac gs_ibl">83</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2009</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=FhFQsc8AAAAJ:r_AWSJRzSzQC" class="gsc_a_at">Pyranone, thiopyranone, and pyridone inhibitors of phosphatidylinositol 3-kinase related kinases. Structure− activity relationships for DNA-dependent protein kinase inhibition&nbsp;…</a><div class="gs_gray">JJ Hollick, LJM Rigoreau, C Cano-Soumillac, X Cockcroft, NJ Curtin, ...</div><div class="gs_gray">Journal of medicinal chemistry 50 (8), 1958-1972<span class="gs_oph">, 2007</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=17635684454098145447" class="gsc_a_ac gs_ibl">83</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2007</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=FhFQsc8AAAAJ:5icHVeHT4IsC" class="gsc_a_at">Benzamide analogs useful as PARP (ADP-ribosyltransferase, ADPRT) DNA repair enzyme inhibitors</a><div class="gs_gray">RJ Griffin, AH Calvert, NJ Curtin, DR Newell, BT Golding</div><div class="gs_gray">US Patent 5,756,510<span class="gs_oph">, 1998</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=18316480718151313205" class="gsc_a_ac gs_ibl">79</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1998</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=FhFQsc8AAAAJ:PVjk1bu6vJQC" class="gsc_a_at">Poly (ADP-ribose) polymerase-1 (PARP-1) pharmacogenetics, activity and expression analysis in cancer patients and healthy volunteers</a><div class="gs_gray">T Zaremba, HD Thomas, M Cole, SA Coulthard, ER Plummer, NJ Curtin</div><div class="gs_gray">Biochemical Journal 436 (3), 671-679<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=15237710520024988332" class="gsc_a_ac gs_ibl">78</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=FhFQsc8AAAAJ:M05iB0D1s5AC" class="gsc_a_at">Imagestream detection and characterisation of circulating tumour cells–A liquid biopsy for hepatocellular carcinoma?</a><div class="gs_gray">LF Ogle, JG Orr, CE Willoughby, C Hutton, S McPherson, R Plummer, ...</div><div class="gs_gray">Journal of hepatology 65 (2), 305-313<span class="gs_oph">, 2016</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=5511763250399519748" class="gsc_a_ac gs_ibl">76</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2016</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=FhFQsc8AAAAJ:umqufdRvDiIC" class="gsc_a_at">The potential for poly (ADP-ribose) polymerase inhibitors in cancer therapy</a><div class="gs_gray">M Javle, NJ Curtin</div><div class="gs_gray">Therapeutic advances in medical oncology 3 (6), 257-267<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=16284251663457249508" class="gsc_a_ac gs_ibl">76</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=FhFQsc8AAAAJ:FAceZFleit8C" class="gsc_a_at">Defective homologous recombination in human cancers</a><div class="gs_gray">A Cerbinskaite, A Mukhopadhyay, ER Plummer, NJ Curtin, ...</div><div class="gs_gray">Cancer treatment reviews 38 (2), 89-100<span class="gs_oph">, 2012</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=15991698916497117454" class="gsc_a_ac gs_ibl">74</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2012</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=FhFQsc8AAAAJ:9Nmd_mFXekcC" class="gsc_a_at">Further characterisation of the cellular activity of the DNA-PK inhibitor, NU7441, reveals potential cross-talk with homologous recombination</a><div class="gs_gray">M Tavecchio, JM Munck, C Cano, DR Newell, NJ Curtin</div><div class="gs_gray">Cancer chemotherapy and pharmacology 69 (1), 155-164<span class="gs_oph">, 2012</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=12141080561510398428" class="gsc_a_ac gs_ibl">71</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2012</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=FhFQsc8AAAAJ:dTyEYWd-f8wC" class="gsc_a_at">DNA-PK—A Candidate Driver of Hepatocarcinogenesis and Tissue Biomarker That Predicts Response to Treatment and Survival</a><div class="gs_gray">L Cornell, JM Munck, C Alsinet, A Villanueva, L Ogle, CE Willoughby, ...</div><div class="gs_gray">Clinical Cancer Research 21 (4), 925-933<span class="gs_oph">, 2015</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=4074129389834622642" class="gsc_a_ac gs_ibl">67</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2015</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=FhFQsc8AAAAJ:3fE2CSJIrl8C" class="gsc_a_at">Microsatellite instability induced mutations in DNA repair genes CtIP and MRE11 confer hypersensitivity to poly (ADP-ribose) polymerase inhibitors in myeloid malignancies</a><div class="gs_gray">TJ Gaymes, AM Mohamedali, M Patterson, N Matto, A Smith, ...</div><div class="gs_gray">Haematologica 98 (9), 1397<span class="gs_oph">, 2013</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=2379915599743812059" class="gsc_a_ac gs_ibl">66</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2013</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=FhFQsc8AAAAJ:YohjEiUPhakC" class="gsc_a_at">4-Alkoxy-2, 6-diaminopyrimidine derivatives: inhibitors of cyclin dependent kinases 1 and 2</a><div class="gs_gray">V Mesguiche, RJ Parsons, CE Arris, J Bentley, FT Boyle, NJ Curtin, ...</div><div class="gs_gray">Bioorganic &amp; medicinal chemistry letters 13 (2), 217-222<span class="gs_oph">, 2003</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=15382946096765526858" class="gsc_a_ac gs_ibl">65</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2003</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=FhFQsc8AAAAJ:KUbvn5osdkgC" class="gsc_a_at">Targeting the DNA double strand break repair machinery in prostate cancer</a><div class="gs_gray">FS Shaheen, P Znojek, A Fisher, M Webster, R Plummer, L Gaughan, ...</div><div class="gs_gray">PloS one 6 (5), e20311<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=13543573837282580060" class="gsc_a_ac gs_ibl">64</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=FhFQsc8AAAAJ:UxriW0iASnsC" class="gsc_a_at">Searching for cyclin-dependent kinase inhibitors using a new variant of the cope elimination</a><div class="gs_gray">RJ Griffin, A Henderson, NJ Curtin, A Echalier, JA Endicott, IR Hardcastle, ...</div><div class="gs_gray">Journal of the American Chemical Society 128 (18), 6012-6013<span class="gs_oph">, 2006</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=6973549941742535361" class="gsc_a_ac gs_ibl">64</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2006</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=FhFQsc8AAAAJ:LPZeul_q3PIC" class="gsc_a_at">Poly (ADP-Ribose) polymerase-1 and DNA-dependent protein kinase have equivalent roles in double strand break repair following ionizing radiation</a><div class="gs_gray">J Mitchell, GCM Smith, NJ Curtin</div><div class="gs_gray">International Journal of Radiation Oncology* Biology* Physics 75 (5), 1520-1527<span class="gs_oph">, 2009</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=8186204454914979882" class="gsc_a_ac gs_ibl">63</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2009</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=FhFQsc8AAAAJ:mvPsJ3kp5DgC" class="gsc_a_at">Untangling the ATR-CHEK1 network for prognostication, prediction and therapeutic target validation in breast cancer</a><div class="gs_gray">TMA Abdel-Fatah, FK Middleton, A Arora, D Agarwal, T Chen, ...</div><div class="gs_gray">Molecular oncology 9 (3), 569-585<span class="gs_oph">, 2015</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=8636977006765275803" class="gsc_a_ac gs_ibl">58</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2015</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=FhFQsc8AAAAJ:yFnVuubrUp4C" class="gsc_a_at">Design, Synthesis, and Evaluation of 3,4-Dihydro-2<i>H</i>-[1,4]diazepino[6,7,1-<i>hi</i>]indol-1-ones as Inhibitors of Poly(ADP-Ribose) Polymerase</a><div class="gs_gray">JG Tikhe, SE Webber, Z Hostomsky, KA Maegley, A Ekkers, J Li, XH Yu, ...</div><div class="gs_gray">Journal of medicinal chemistry 47 (22), 5467-5481<span class="gs_oph">, 2004</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=17242124507324512999" class="gsc_a_ac gs_ibl">58</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2004</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=FhFQsc8AAAAJ:_Re3VWB3Y0AC" class="gsc_a_at">Resistance-Modifying Agents. 8.<sup></sup> Inhibition of <i>O</i><sup>6</sup>-Alkylguanine-DNA Alkyltransferase by <i>O</i><sup>6</sup>-Alkenyl-, <i>O</i><sup>6</sup>-Cycloalkenyl-, and <i>O</i><sup>6</sup>-(2-Oxoalkyl)guanines and Potentiation of&nbsp;…</a><div class="gs_gray">RJ Griffin, CE Arris, C Bleasdale, FT Boyle, AH Calvert, NJ Curtin, C Dalby, ...</div><div class="gs_gray">Journal of medicinal chemistry 43 (22), 4071-4083<span class="gs_oph">, 2000</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=11241413490455656460" class="gsc_a_ac gs_ibl">58</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2000</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=FhFQsc8AAAAJ:WF5omc3nYNoC" class="gsc_a_at">Efficacy of PARP inhibitor rucaparib in orthotopic glioblastoma xenografts is limited by ineffective drug penetration into the central nervous system</a><div class="gs_gray">KE Parrish, L Cen, J Murray, D Calligaris, S Kizilbash, RK Mittapalli, ...</div><div class="gs_gray">Molecular cancer therapeutics 14 (12), 2735-2743<span class="gs_oph">, 2015</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=1262702746259477066" class="gsc_a_ac gs_ibl">57</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2015</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=FhFQsc8AAAAJ:4JMBOYKVnBMC" class="gsc_a_at">Vasoactivity of AG014699, a clinically active small molecule inhibitor of poly (ADP-ribose) polymerase: a contributory factor to chemopotentiation in vivo?</a><div class="gs_gray">M Ali, BA Telfer, C McCrudden, M O'Rourke, HD Thomas, M Kamjoo, ...</div><div class="gs_gray">Clinical cancer research 15 (19), 6106-6112<span class="gs_oph">, 2009</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=16662900312378386694" class="gsc_a_ac gs_ibl">56</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2009</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=FhFQsc8AAAAJ:roLk4NBRz8UC" class="gsc_a_at">Central nervous system penetration and enhancement of temozolomide activity in childhood medulloblastoma models by poly (ADP-ribose) polymerase inhibitor AG-014699</a><div class="gs_gray">RA Daniel, AL Rozanska, EA Mulligan, Y Drew, HD Thomas, ...</div><div class="gs_gray">British journal of cancer 103 (10), 1588-1596<span class="gs_oph">, 2010</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=1794414985213402576" class="gsc_a_ac gs_ibl">55</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2010</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=FhFQsc8AAAAJ:ZeXyd9-uunAC" class="gsc_a_at">The clinically active PARP inhibitor AG014699 ameliorates cardiotoxicity but does not enhance the efficacy of doxorubicin, despite improving tumor perfusion and radiation&nbsp;…</a><div class="gs_gray">M Ali, M Kamjoo, HD Thomas, S Kyle, I Pavlovska, M Babur, BA Telfer, ...</div><div class="gs_gray">Molecular cancer therapeutics 10 (12), 2320-2329<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=14502654682197682556" class="gsc_a_ac gs_ibl">54</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=FhFQsc8AAAAJ:xtRiw3GOFMkC" class="gsc_a_at">Pre-clinical evaluation of cyclin-dependent kinase 2 and 1 inhibition in anti-estrogen-sensitive and resistant breast cancer cells</a><div class="gs_gray">N Johnson, J Bentley, LZ Wang, DR Newell, CN Robson, GI Shapiro, ...</div><div class="gs_gray">British journal of cancer 102 (2), 342-350<span class="gs_oph">, 2010</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=6492524819319958614" class="gsc_a_ac gs_ibl">53</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2010</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=FhFQsc8AAAAJ:k_IJM867U9cC" class="gsc_a_at">Ovarian cancers harbor defects in nonhomologous end joining resulting in resistance to rucaparib</a><div class="gs_gray">A McCormick, P Donoghue, M Dixon, R O'Sullivan, RL O'Donnell, ...</div><div class="gs_gray">Clinical Cancer Research 23 (8), 2050-2060<span class="gs_oph">, 2017</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=3965056647455627870" class="gsc_a_ac gs_ibl">50</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2017</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=FhFQsc8AAAAJ:g5m5HwL7SMYC" class="gsc_a_at">Resistance-Modifying Agents. 11.<sup></sup> Pyrimido[5,4-<i>d</i>]pyrimidine Modulators of Antitumor Drug Activity. Synthesis and Structure−Activity Relationships for Nucleoside Transport&nbsp;…</a><div class="gs_gray">NJ Curtin, HC Barlow, KJ Bowman, AH Calvert, R Davison, BT Golding, ...</div><div class="gs_gray">Journal of medicinal chemistry 47 (20), 4905-4922<span class="gs_oph">, 2004</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=5515679993582154575" class="gsc_a_ac gs_ibl">49</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2004</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=FhFQsc8AAAAJ:ruyezt5ZtCIC" class="gsc_a_at">Common cancer-associated imbalances in the DNA damage response confer sensitivity to single agent ATR inhibition</a><div class="gs_gray">FK Middleton, MJ Patterson, CJ Elstob, S Fordham, A Herriott, MA Wade, ...</div><div class="gs_gray">Oncotarget 6 (32), 32396<span class="gs_oph">, 2015</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=14940248738249381070" class="gsc_a_ac gs_ibl">48</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2015</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=FhFQsc8AAAAJ:j3f4tGmQtD8C" class="gsc_a_at">Induction of remission in hepatocellular carcinoma with a new thymidylate synthase inhibitor, CB3717: a phase II study</a><div class="gs_gray">MF Bassendine, NJ Curtin, H Loose, AL Harris, OFW James</div><div class="gs_gray">Journal of hepatology 4 (3), 349-356<span class="gs_oph">, 1987</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=3942441929418799846" class="gsc_a_ac gs_ibl">47</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1987</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=FhFQsc8AAAAJ:Tiz5es2fbqcC" class="gsc_a_at">The use of ovarian cancer cells from patients undergoing surgery to generate primary cultures capable of undergoing functional analysis</a><div class="gs_gray">RL O′ Donnell, A McCormick, A Mukhopadhyay, LC Woodhouse, ...</div><div class="gs_gray">PloS one 9 (3), e90604<span class="gs_oph">, 2014</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=1905612121001181922,9297474239952407817" class="gsc_a_ac gs_ibl">46</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2014</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=FhFQsc8AAAAJ:_FxGoFyzp5QC" class="gsc_a_at">DNA-dependent protein kinase (DNA-PK) inhibitors. Synthesis and biological activity of quinolin-4-one and pyridopyrimidin-4-one surrogates for the chromen-4-one chemotype</a><div class="gs_gray">C Cano, OR Barbeau, C Bailey, XL Cockcroft, NJ Curtin, H Duggan, ...</div><div class="gs_gray">Journal of medicinal chemistry 53 (24), 8498-8507<span class="gs_oph">, 2010</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=1786393763017001563" class="gsc_a_ac gs_ibl">46</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2010</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=FhFQsc8AAAAJ:v1_lew4L6wgC" class="gsc_a_at">Targeting ATR as cancer therapy: a new era for synthetic lethality and synergistic combinations?</a><div class="gs_gray">A Bradbury, S Hall, N Curtin, Y Drew</div><div class="gs_gray">Pharmacology &amp; therapeutics 207, 107450<span class="gs_oph">, 2020</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=18380399295030367190" class="gsc_a_ac gs_ibl">44</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2020</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=FhFQsc8AAAAJ:olpn-zPbct0C" class="gsc_a_at">Enzymic retrodifferentiation during hepatocarcinogenesis and liver regeneration in rats in vivo</a><div class="gs_gray">NJ Curtin, K Snell</div><div class="gs_gray">British journal of cancer 48 (4), 495-505<span class="gs_oph">, 1983</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=8972968097611063239" class="gsc_a_ac gs_ibl">44</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1983</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=FhFQsc8AAAAJ:TFP_iSt0sucC" class="gsc_a_at">High‐resolution imaging for the detection and characterisation of circulating tumour cells from patients with oesophageal, hepatocellular, thyroid and ovarian cancers</a><div class="gs_gray">BM Dent, LF Ogle, RL O'Donnell, N Hayes, U Malik, NJ Curtin, AV Boddy, ...</div><div class="gs_gray">International journal of cancer 138 (1), 206-216<span class="gs_oph">, 2016</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=4168830449363029063" class="gsc_a_ac gs_ibl">42</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2016</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=FhFQsc8AAAAJ:HIFyuExEbWQC" class="gsc_a_at">Phase II trial of the poly(ADP-ribose) polymerase (PARP) inhibitor AG-014699 in <i>BRCA</i> 1 and 2–mutated, advanced ovarian and/or locally advanced or metastatic&nbsp;…</a><div class="gs_gray">Y Drew, JA Ledermann, A Jones, G Hall, GC Jayson, M Highley, D Rea, ...</div><div class="gs_gray">Journal of Clinical Oncology 29 (15_suppl), 3104-3104<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=16823634520809677153" class="gsc_a_ac gs_ibl">41</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=FhFQsc8AAAAJ:owLR8QvbtFgC" class="gsc_a_at">Poly (ADP-ribose) polymerase inhibition: past, present and future</a><div class="gs_gray">NJ Curtin, C Szabo</div><div class="gs_gray">Nature Reviews Drug Discovery 19 (10), 711-736<span class="gs_oph">, 2020</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=9908852776983511813" class="gsc_a_ac gs_ibl">40</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2020</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=FhFQsc8AAAAJ:P5F9QuxV20EC" class="gsc_a_at">Tumour cell retention of rucaparib, sustained PARP inhibition and efficacy of weekly as well as daily schedules</a><div class="gs_gray">J Murray, H Thomas, P Berry, S Kyle, M Patterson, C Jones, G Los, ...</div><div class="gs_gray">British journal of cancer 110 (8), 1977-1984<span class="gs_oph">, 2014</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=6778400680507910521" class="gsc_a_ac gs_ibl">39</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2014</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=FhFQsc8AAAAJ:IjCSPb-OGe4C" class="gsc_a_at">Triple negative breast cancer: proposals for a pragmatic definition and implications for patient management and trial design</a><div class="gs_gray">W Eiermann, J Bergh, F Cardoso, P Conte, J Crown, NJ Curtin, J Gligorov, ...</div><div class="gs_gray">The Breast 21 (1), 20-26<span class="gs_oph">, 2012</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=659437090704704888" class="gsc_a_ac gs_ibl">38</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2012</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=FhFQsc8AAAAJ:dshw04ExmUIC" class="gsc_a_at">Therapeutic combinations comprising poly (ADP-ribose) polymerases inhibitor</a><div class="gs_gray">HM Steinfeldt, TJ Boritzki, AH Calvert, NJ Curtin, MR Dewji, Z Hostomsky, ...</div><div class="gs_gray">US Patent App. 11/231,470<span class="gs_oph">, 2006</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=6869249616782450801" class="gsc_a_ac gs_ibl">38</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2006</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=FhFQsc8AAAAJ:HE397vMXCloC" class="gsc_a_at">1-Substituted (Dibenzo[<i>b,d</i>]thiophen-4-yl)-2-morpholino-4<i>H</i>-chromen-4-ones Endowed with Dual DNA-PK/PI3-K Inhibitory Activity</a><div class="gs_gray">C Cano, K Saravanan, C Bailey, J Bardos, NJ Curtin, M Frigerio, ...</div><div class="gs_gray">Journal of medicinal chemistry 56 (16), 6386-6401<span class="gs_oph">, 2013</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=9022696338517960678" class="gsc_a_ac gs_ibl">37</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2013</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=FhFQsc8AAAAJ:epqYDVWIO7EC" class="gsc_a_at">Dipyridamole potentiates the in vitro activity of MTA (LY231514) by inhibition of thymidine transport</a><div class="gs_gray">PG Smith, E Marshman, DR Newell, NJ Curtin</div><div class="gs_gray">British journal of cancer 82 (4), 924-930<span class="gs_oph">, 2000</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=12525734198962285343" class="gsc_a_ac gs_ibl">37</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2000</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=FhFQsc8AAAAJ:vDijr-p_gm4C" class="gsc_a_at">Preferential potentiation of topoisomerase I poison cytotoxicity by PARP inhibition in S phase</a><div class="gs_gray">P Znojek, E Willmore, NJ Curtin</div><div class="gs_gray">British journal of cancer 111 (7), 1319-1326<span class="gs_oph">, 2014</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=12663158297318875363" class="gsc_a_ac gs_ibl">36</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2014</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:4DMP91E08xMC" class="gsc_a_at">Therapeutic potential of CDK inhibitor NU2058 in androgen-independent prostate cancer</a><div class="gs_gray">AC Rigas, CN Robson, NJ Curtin</div><div class="gs_gray">Oncogene 26 (55), 7611-7619<span class="gs_oph">, 2007</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=2804241520710121692" class="gsc_a_ac gs_ibl">36</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2007</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:EYYDruWGBe4C" class="gsc_a_at">Poly (ADP-ribose) polymerase inhibitors in Ewing sarcoma</a><div class="gs_gray">B Vormoor, NJ Curtin</div><div class="gs_gray">Current opinion in oncology 26 (4), 428<span class="gs_oph">, 2014</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=12959774110777072214" class="gsc_a_ac gs_ibl">35</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2014</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:LhH-TYMQEocC" class="gsc_a_at">Cellular ATP depletion by LY309887 as a predictor of growth inhibition in human tumor cell lines</a><div class="gs_gray">X Lu, J Errington, VJ Chen, NJ Curtin, AV Boddy, DR Newell</div><div class="gs_gray">Clinical cancer research 6 (1), 271-277<span class="gs_oph">, 2000</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=17711771114969632860" class="gsc_a_ac gs_ibl">35</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2000</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:t6usbXjVLHcC" class="gsc_a_at">Probing the active site and mechanism of action of O6-methylguanine-DNA methyltransferase with substrate analogues (O6-substituted guanines)</a><div class="gs_gray">CE Arris, C Bleasdale, AH Calvert, NJ Curtin, C Dalby</div><div class="gs_gray">Anti-cancer drug design 9 (5), 401-408<span class="gs_oph">, 1994</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=13403969956329888745" class="gsc_a_ac gs_ibl">35</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1994</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:vbGhcppDl1QC" class="gsc_a_at">Effect of chronic N, N-diethylnitrosamine on the excision of O6-ethylguanine from rat liver DNA.</a><div class="gs_gray">GP Margison, NJ Curtin, K Snell, AW Craig</div><div class="gs_gray">British journal of cancer 40 (5), 809<span class="gs_oph">, 1979</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=12942836902004960395" class="gsc_a_ac gs_ibl">35</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1979</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:_FM0Bhl9EiAC" class="gsc_a_at">Therapeutic potential of drugs to modulate DNA repair in cancer</a><div class="gs_gray">N Curtin</div><div class="gs_gray">Expert opinion on therapeutic targets 11 (6), 783-799<span class="gs_oph">, 2007</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=15740038504674623984" class="gsc_a_ac gs_ibl">33</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2007</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:5awf1xo2G04C" class="gsc_a_at">Poly (ADP-ribose) polymerase (PARP) and PARP inhibitors</a><div class="gs_gray">NJ Curtin</div><div class="gs_gray">Drug Discovery Today: Disease Models 9 (2), e51-e58<span class="gs_oph">, 2012</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=10041576147636213542" class="gsc_a_ac gs_ibl">32</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2012</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:eflP2zaiRacC" class="gsc_a_at">Synthesis and biological evaluation of 5-substituted O 4-alkylpyrimidines as CDK2 inhibitors</a><div class="gs_gray">F Marchetti, C Cano, NJ Curtin, BT Golding, RJ Griffin, K Haggerty, ...</div><div class="gs_gray">Organic &amp; biomolecular chemistry 8 (10), 2397-2407<span class="gs_oph">, 2010</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=8481384902182482274" class="gsc_a_ac gs_ibl">32</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2010</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:uWiczbcajpAC" class="gsc_a_at">Exploiting the Achilles heel of cancer: the therapeutic potential of poly (ADP-ribose) polymerase inhibitors in BRCA2-defective cancer</a><div class="gs_gray">S Kyle, HD Thomas, J Mitchell, NJ Curtin</div><div class="gs_gray">The British journal of radiology 81 (special_issue_1), S6-S11<span class="gs_oph">, 2008</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=12747680304306702057" class="gsc_a_ac gs_ibl">32</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2008</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:PELIpwtuRlgC" class="gsc_a_at">Chk1 phosphorylated at serine345 is a predictor of early local recurrence and radio-resistance in breast cancer</a><div class="gs_gray">N Alsubhi, F Middleton, TMA Abdel-Fatah, P Stephens, R Doherty, ...</div><div class="gs_gray">Molecular oncology 10 (2), 213-223<span class="gs_oph">, 2016</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=9561712678508842280" class="gsc_a_ac gs_ibl">30</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2016</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:D_sINldO8mEC" class="gsc_a_at">PARP1 expression, activity and ex vivo sensitivity to the PARP inhibitor, talazoparib (BMN 673), in chronic lymphocytic leukaemia</a><div class="gs_gray">A Herriott, SJ Tudhope, G Junge, N Rodrigues, MJ Patterson, ...</div><div class="gs_gray">Oncotarget 6 (41), 43978<span class="gs_oph">, 2015</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=8420148022159099415" class="gsc_a_ac gs_ibl">30</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2015</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:8k81kl-MbHgC" class="gsc_a_at">Therapeutic compounds</a><div class="gs_gray">T Helleday, N Curtin</div><div class="gs_gray">US Patent 7,351,701<span class="gs_oph">, 2008</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=2287502888702895666" class="gsc_a_ac gs_ibl">30</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2008</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:yD5IFk8b50cC" class="gsc_a_at">8-Biarylchromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK)</a><div class="gs_gray">M Desage-El Murr, C Cano, BT Golding, IR Hardcastle, M Hummersome, ...</div><div class="gs_gray">Bioorganic &amp; medicinal chemistry letters 18 (17), 4885-4890<span class="gs_oph">, 2008</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=6071435623937609446" class="gsc_a_ac gs_ibl">29</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2008</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:OcBU2YAGkTUC" class="gsc_a_at">DNA interstrand cross-linking and TP53 status as determinants of tumour cell sensitivity in vitro to the antibody-directed enzyme prodrug therapy ZD2767</a><div class="gs_gray">NR Monks, DC Blakey, SJ East, RI Dowell, JA Calvete, NJ Curtin, CE Arris, ...</div><div class="gs_gray">European Journal of Cancer 38 (11), 1543-1552<span class="gs_oph">, 2002</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=17312876515481604879" class="gsc_a_ac gs_ibl">29</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2002</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:dfsIfKJdRG4C" class="gsc_a_at">A comparative study of genome-wide SNP, CGH microarray and protein expression analysis to explore genotypic and phenotypic mechanisms of acquired antiestrogen resistance in&nbsp;…</a><div class="gs_gray">N Johnson, V Speirs, NJ Curtin, AG Hall</div><div class="gs_gray">Breast cancer research and treatment 111 (1), 55-63<span class="gs_oph">, 2008</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=6024281809468335613" class="gsc_a_ac gs_ibl">28</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2008</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:Tyk-4Ss8FVUC" class="gsc_a_at">Dipyridamole-mediated reversal of multidrug resistance in MRP over-expressing human lung carcinoma cells in vitro</a><div class="gs_gray">NJ Curtin, DP Turner</div><div class="gs_gray">European Journal of Cancer 35 (6), 1020-1026<span class="gs_oph">, 1999</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=685588620186823312" class="gsc_a_ac gs_ibl">28</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1999</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:0EnyYjriUFMC" class="gsc_a_at">Effect of cell cycle inhibition on cisplatin-induced cytotoxicity</a><div class="gs_gray">ML Fishel, DR Newell, RJ Griffin, R Davison, LZ Wang, NJ Curtin, ...</div><div class="gs_gray">Journal of Pharmacology and Experimental Therapeutics 312 (1), 206-213<span class="gs_oph">, 2005</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=2246352799140407021" class="gsc_a_ac gs_ibl">27</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2005</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:-FonjvnnhkoC" class="gsc_a_at">Novel benzimidazole and quinazolinone inhibitors of the DNA repair enzyme poly (ADP‐ribose) polymerase</a><div class="gs_gray">RJ GRIFFIN, S SRINIVASAN, AW WHITE, K BOWMAN, AH CALVERT, ...</div><div class="gs_gray">Pharmacy and Pharmacology Communications 2 (1), 43-47<span class="gs_oph">, 1996</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=14652452439393780256" class="gsc_a_ac gs_ibl">27</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1996</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:IaI1MmNe2tcC" class="gsc_a_at">Repositioning PARP inhibitors for SARS‐CoV‐2 infection (COVID‐19); a new multi‐pronged therapy for acute respiratory distress syndrome?</a><div class="gs_gray">N Curtin, K Bányai, J Thaventhiran, J Le Quesne, Z Helyes, P Bai</div><div class="gs_gray">British Journal of Pharmacology 177 (16), 3635-3645<span class="gs_oph">, 2020</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=3920560076774893386" class="gsc_a_ac gs_ibl">26</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2020</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:lmc2jWPfTJgC" class="gsc_a_at">Primary hepatocellular carcinoma localised by a radiolabelled monoclonal antibody</a><div class="gs_gray">N Markham, A Ritson, O James, N Curtin, M Bassendine, K Sikora</div><div class="gs_gray">Journal of hepatology 2 (1), 25-31<span class="gs_oph">, 1986</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=14142595707510128196" class="gsc_a_ac gs_ibl">26</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1986</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:FiytvqdAVhgC" class="gsc_a_at">DNA damage checkpoint kinases in cancer</a><div class="gs_gray">HL Smith, H Southgate, DA Tweddle, NJ Curtin</div><div class="gs_gray">Expert Reviews in Molecular Medicine 22<span class="gs_oph">, 2020</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=12138905392865160853" class="gsc_a_ac gs_ibl">24</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2020</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:Ehil0879vHcC" class="gsc_a_at">ATR as a Therapeutic Target</a><div class="gs_gray">FK Middleton, NJ Curtin</div><div class="gs_gray">Advances in DNA Repair in Cancer Therapy, 211-228<span class="gs_oph">, 2013</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=17857648911450038198" class="gsc_a_ac gs_ibl">24</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2013</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:fEOibwPWpKIC" class="gsc_a_at">Benzimidazole compounds</a><div class="gs_gray">RJ Griffin, AH Calvert, NJ Curtin, DR Newell, BT Golding</div><div class="gs_gray">US Patent 6,310,082<span class="gs_oph">, 2001</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=11745020523946869501" class="gsc_a_ac gs_ibl">24</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2001</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:j8SEvjWlNXcC" class="gsc_a_at">Inhibition of the growth of human hepatocellular carcinoma in vitro and in athymic mice by a quinazoline inhibitor of thymidylate synthase, CB3717</a><div class="gs_gray">NJ Curtin, AL Harris, OF James, MF Bassendine</div><div class="gs_gray">British journal of cancer 53 (3), 361-368<span class="gs_oph">, 1986</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=11767865087713514089" class="gsc_a_ac gs_ibl">23</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1986</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:f2IySw72cVMC" class="gsc_a_at">Validating and enabling phosphoglycerate dehydrogenase (PHGDH) as a target for fragment-based drug discovery in PHGDH-amplified breast cancer</a><div class="gs_gray">JE Unterlass, A Baslé, TJ Blackburn, J Tucker, C Cano, MEM Noble, ...</div><div class="gs_gray">Oncotarget 9 (17), 13139<span class="gs_oph">, 2018</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=6270006020749831452" class="gsc_a_ac gs_ibl">22</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2018</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:kzcrU_BdoSEC" class="gsc_a_at">Assessing the function of homologous recombination DNA repair in malignant pleural effusion (MPE) samples</a><div class="gs_gray">MJ Patterson, RE Sutton, I Forrest, R Sharrock, M Lane, A Kaufmann, ...</div><div class="gs_gray">British journal of cancer 111 (1), 94-100<span class="gs_oph">, 2014</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=11141938827751204514" class="gsc_a_ac gs_ibl">22</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2014</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:rO6llkc54NcC" class="gsc_a_at">Doxorubicin-induced suppression of poly (ADP-ribose) polymerase-1 (PARP-1) activity and expression and its implication for PARP inhibitors in clinical trials</a><div class="gs_gray">T Zaremba, H Thomas, M Cole, ER Plummer, NJ Curtin</div><div class="gs_gray">Cancer chemotherapy and pharmacology 66 (4), 807-812<span class="gs_oph">, 2010</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=5689963734761154443" class="gsc_a_ac gs_ibl">22</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2010</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:a0OBvERweLwC" class="gsc_a_at">DNA-PK inhibitors</a><div class="gs_gray">GCM Smith, NMB Martin, KA Menear, MG Hummersone, XL Cockcroft, ...</div><div class="gs_gray">US Patent 7,696,203<span class="gs_oph">, 2010</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=6077050235179980821" class="gsc_a_ac gs_ibl">22</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2010</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:l7t_Zn2s7bgC" class="gsc_a_at">Method for measuring ATR inhibition mediated increases in DNA damage</a><div class="gs_gray">S Falcon, P Reaper, J Pollard, N Curtin, F Middleton, T Chen</div><div class="gs_gray">US Patent 8,999,632<span class="gs_oph">, 2015</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=7607168041276388742" class="gsc_a_ac gs_ibl">21</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2015</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:VaXvl8Fpj5cC" class="gsc_a_at">Nucleoside Transport Inhibitors: Structure− Activity Relationships for Pyrimido [5, 4-d] pyrimidine Derivatives That Potentiate Pemetrexed Cytotoxicity in the Presence of α1&nbsp;…</a><div class="gs_gray">K Saravanan, HC Barlow, M Barton, AH Calvert, BT Golding, DR Newell, ...</div><div class="gs_gray">Journal of medicinal chemistry 54 (6), 1847-1859<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=14345286714781386071" class="gsc_a_ac gs_ibl">21</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:cWzG1nlazyYC" class="gsc_a_at">PARP inhibitors and epithelial ovarian cancer: an approach to targeted chemotherapy and personalised medicine</a><div class="gs_gray">A Mukhopadhyay, N Curtin, R Plummer, RJ Edmondson</div><div class="gs_gray">BJOG: An International Journal of Obstetrics &amp; Gynaecology 118 (4), 429-432<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=17081740616352109929" class="gsc_a_ac gs_ibl">21</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:ULOm3_A8WrAC" class="gsc_a_at">Benzoxazole-4-carboxamides and their use in inhibiting poly (ADP-ribose) polymerase activity and improving cytotoxic effectiveness of cytotoxic drugs or radiotherapy</a><div class="gs_gray">RJ Griffin, AH Calvert, NJ Curtin, DR Newell, BT Golding</div><div class="gs_gray">US Patent 6,015,827<span class="gs_oph">, 2000</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=2677012491456661620" class="gsc_a_ac gs_ibl">21</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2000</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:e5wmG9Sq2KIC" class="gsc_a_at">Potentiation of the cytotoxicity of thymidylate synthase (TS) inhibitors by dipyridamole analogues with reduced α 1-acid glycoprotein binding</a><div class="gs_gray">NJ Curtin, KJ Bowman, RN Turner, B Huang, PJ Loughlin, AH Calvert, ...</div><div class="gs_gray">British journal of cancer 80 (11), 1738-1746<span class="gs_oph">, 1999</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=3726389737457752988" class="gsc_a_ac gs_ibl">21</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1999</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:HtS1dXgVpQUC" class="gsc_a_at">mTORC1 and DNA-PKcs as novel molecular determinants of sensitivity to Chk1 inhibition</a><div class="gs_gray">AJ Massey, P Stephens, R Rawlinson, L McGurk, R Plummer, NJ Curtin</div><div class="gs_gray">Molecular oncology 10 (1), 101-112<span class="gs_oph">, 2016</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=17176165831998054384" class="gsc_a_ac gs_ibl">20</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2016</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:OR75R8vi5nAC" class="gsc_a_at">Structure-based design of 2-arylamino-4-cyclohexylmethoxy-5-nitroso-6-aminopyrimidine inhibitors of cyclin-dependent kinase 2</a><div class="gs_gray">F Marchetti, KL Sayle, J Bentley, W Clegg, NJ Curtin, JA Endicott, ...</div><div class="gs_gray">Organic &amp; biomolecular chemistry 5 (10), 1577-1585<span class="gs_oph">, 2007</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=17315069342331864089" class="gsc_a_ac gs_ibl">20</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2007</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:tH6gc1N1XXoC" class="gsc_a_at">The impact of p53 dysfunction in ATR inhibitor cytotoxicity and chemo-and radiosensitisation</a><div class="gs_gray">FK Middleton, JR Pollard, NJ Curtin</div><div class="gs_gray">Cancers 10 (8), 275<span class="gs_oph">, 2018</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=3051376466418120161" class="gsc_a_ac gs_ibl">19</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2018</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:ClCfbGk0d_YC" class="gsc_a_at">Method for measuring ATR inhibition mediated increases in DNA damage</a><div class="gs_gray">S Falcon, P Reaper, J Pollard, N Curtin, F Middleton, T Chen</div><div class="gs_gray">US Patent 9,791,456<span class="gs_oph">, 2017</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=14988329214366522349" class="gsc_a_ac gs_ibl">19</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2017</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:KlAtU1dfN6UC" class="gsc_a_at">DNA-PK inhibitors</a><div class="gs_gray">GCM Smith, NMB Martin, KA Menear, MG Hummersone, LJM Rigoreau, ...</div><div class="gs_gray">US Patent 7,402,607<span class="gs_oph">, 2008</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=2496591664189973055" class="gsc_a_ac gs_ibl">19</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2008</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:AvfA0Oy_GE0C" class="gsc_a_at">In vitro and in vivo properties of novel nucleoside transport inhibitors with improved pharmacological properties that potentiate antifolate activity</a><div class="gs_gray">PG Smith, HD Thomas, HC Barlow, RJ Griffin, BT Golding, AH Calvert, ...</div><div class="gs_gray">Clinical cancer research 7 (7), 2105-2113<span class="gs_oph">, 2001</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=12757510023060877346" class="gsc_a_ac gs_ibl">19</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2001</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:Aul-kAQHnToC" class="gsc_a_at">Prevention of thymidine and hypoxanthine rescue from MTA (LY231514) growth inhibition by dipyridamole in human lung cancer cell lines.</a><div class="gs_gray">PG Smith, E Marshman, AH Calvert, DR Newell, NJ Curtin</div><div class="gs_gray">Seminars in oncology 26 (2 Suppl 6), 63-67<span class="gs_oph">, 1999</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=18054033690721042300" class="gsc_a_ac gs_ibl">19</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1999</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:4fGpz3EwCPoC" class="gsc_a_at">Potentiation of quinazoline antifolate (CB3717) toxicity by dipyridamole in human lung carcinoma, A549, cells</a><div class="gs_gray">NJ Curtin, AL Harris</div><div class="gs_gray">Biochemical pharmacology 37 (11), 2113-2120<span class="gs_oph">, 1988</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=15699465610571532434" class="gsc_a_ac gs_ibl">19</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1988</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:YFjsv_pBGBYC" class="gsc_a_at">Structural insights into the enzymatic activity and potential substrate promiscuity of human 3-phosphoglycerate dehydrogenase (PHGDH)</a><div class="gs_gray">JE Unterlass, RJ Wood, A Baslé, J Tucker, C Cano, MME Noble, NJ Curtin</div><div class="gs_gray">Oncotarget 8 (61), 104478<span class="gs_oph">, 2017</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=4659706260269309124" class="gsc_a_ac gs_ibl">18</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2017</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:Fu2w8maKXqMC" class="gsc_a_at">Development of pharmacodynamic biomarkers for ATR inhibitors</a><div class="gs_gray">T Chen, FK Middleton, S Falcon, PM Reaper, JR Pollard, NJ Curtin</div><div class="gs_gray">Molecular oncology 9 (2), 463-472<span class="gs_oph">, 2015</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=11108151769230701572" class="gsc_a_ac gs_ibl">18</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2015</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:NXb4pA-qfm4C" class="gsc_a_at">Transient treatment with CDK inhibitors eliminates proliferative potential even when their abilities to evoke apoptosis and DNA damage are blocked</a><div class="gs_gray">SF Scrace, P Kierstan, J Borgognoni, LZ Wang, S Denny, J Wayne, ...</div><div class="gs_gray">Cell Cycle 7 (24), 3898-3907<span class="gs_oph">, 2008</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=16180888968543217130" class="gsc_a_ac gs_ibl">18</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2008</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:8AbLer7MMksC" class="gsc_a_at">The quantitation by radioimmunoassay of 2′-deoxyuridine 5′-triphosphate in extracts of thymidylate synthase-inhibited cells</a><div class="gs_gray">EM Piall, NJ Curtin, GW Aherne, AL Harris, V Marks</div><div class="gs_gray">Analytical biochemistry 177 (2), 347-352<span class="gs_oph">, 1989</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=8073407075714433764" class="gsc_a_ac gs_ibl">18</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1989</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:VLnqNzywnoUC" class="gsc_a_at">Combination treatment with rucaparib (Rubraca) and MDM2 inhibitors, Nutlin-3 and RG7388, has synergistic and dose reduction potential in ovarian cancer</a><div class="gs_gray">M Zanjirband, N Curtin, RJ Edmondson, J Lunec</div><div class="gs_gray">Oncotarget 8 (41), 69779<span class="gs_oph">, 2017</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=11835274867685995791" class="gsc_a_ac gs_ibl">17</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2017</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:WC9gN4BGCRcC" class="gsc_a_at">PARP inhibitors for cancer therapy</a><div class="gs_gray">NJ Curtin</div><div class="gs_gray">Expert reviews in molecular medicine 7 (4), 1-20<span class="gs_oph">, 2005</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=18230665394753501024" class="gsc_a_ac gs_ibl">17</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2005</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:a3BOlSfXSfwC" class="gsc_a_at">Induction of apoptosis by the ADEPT agent ZD2767: comparison with the classical nitrogen mustard chlorambucil and a monofunctional ZD2767 analogue</a><div class="gs_gray">NR Monks, DC Blakey, NJ Curtin, SJ East, A Heuze, DR Newell</div><div class="gs_gray">British journal of cancer 85 (5), 764-771<span class="gs_oph">, 2001</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=17729585889212754214" class="gsc_a_ac gs_ibl">17</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2001</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:UebtZRa9Y70C" class="gsc_a_at">Modulation of dipyridamole action by α1acid glycoprotein: reduced potentiation of quinazoline antifolate (CB3717) cytotoxicity by dipyridamole</a><div class="gs_gray">NJ Curtin, DR Newell, AL Harris</div><div class="gs_gray">Biochemical pharmacology 38 (19), 3281-3288<span class="gs_oph">, 1989</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=1986262977627852662" class="gsc_a_ac gs_ibl">17</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1989</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:S16KYo8Pm5AC" class="gsc_a_at">Preclinical in vitro and in vivo evaluation of the potent and specific cyclin-dependent kinase 2 inhibitor NU6102 and a water soluble prodrug NU6301</a><div class="gs_gray">HD Thomas, LZ Wang, C Roche, J Bentley, Y Cheng, IR Hardcastle, ...</div><div class="gs_gray">European Journal of Cancer 47 (13), 2052-2059<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=14688015525233358121" class="gsc_a_ac gs_ibl">16</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:HeT0ZceujKMC" class="gsc_a_at">Selective potentiation of lometrexol growth inhibition by dipyridamole through cell-specific inhibition of hypoxanthine salvage</a><div class="gs_gray">RN Turner, GW Aherne, NJ Curtin</div><div class="gs_gray">British journal of cancer 76 (10), 1300-1307<span class="gs_oph">, 1997</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=17624833182787316398" class="gsc_a_ac gs_ibl">16</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1997</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:nZcligLrVowC" class="gsc_a_at">Dipyridamole increases VP16 growth inhibition, accumulation and retention in parental and multidrug-resistant CHO cells</a><div class="gs_gray">RN Turner, NJ Curtin</div><div class="gs_gray">British journal of cancer 73 (7), 856-860<span class="gs_oph">, 1996</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=17845334415100728286" class="gsc_a_ac gs_ibl">16</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1996</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:maZDTaKrznsC" class="gsc_a_at">Controlled stepwise conversion of 2, 4, 6, 8-tetrachloropyrimido [5, 4-d] pyrimidine into 2, 4, 6, 8-tetrasubstituted pyrimido [5, 4-d] pyrimidines</a><div class="gs_gray">JS Northen, FT Boyle, W Clegg, NJ Curtin, AJ Edwards, RJ Griffin, ...</div><div class="gs_gray">Journal of the Chemical Society, Perkin Transactions 1, 108-115<span class="gs_oph">, 2002</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=4323790675876962318" class="gsc_a_ac gs_ibl">15</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2002</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:lgwcVrK6X84C" class="gsc_a_at">Warburg and Krebs and related effects in cancer</a><div class="gs_gray">JE Unterlass, NJ Curtin</div><div class="gs_gray">Expert reviews in molecular medicine 21<span class="gs_oph">, 2019</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=5523292603060381332" class="gsc_a_ac gs_ibl">14</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2019</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:b0M2c_1WBrUC" class="gsc_a_at">Inhibition of ATR acutely sensitizes acute myeloid leukemia cells to nucleoside analogs that target ribonucleotide reductase</a><div class="gs_gray">SE Fordham, HJ Blair, CJ Elstob, R Plummer, Y Drew, NJ Curtin, ...</div><div class="gs_gray">Blood advances 2 (10), 1157-1169<span class="gs_oph">, 2018</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=6417632384206483141" class="gsc_a_ac gs_ibl">14</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2018</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:ZzlSgRqYykMC" class="gsc_a_at">Vasoactivity of rucaparib, a PARP-1 inhibitor, is a complex process that involves myosin light chain kinase, P2 receptors, and PARP itself</a><div class="gs_gray">CM McCrudden, MG O’Rourke, KE Cherry, HF Yuen, D O’Rourke, ...</div><div class="gs_gray">PloS one 10 (2), e0118187<span class="gs_oph">, 2015</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=18045295053972045014" class="gsc_a_ac gs_ibl">14</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2015</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:fPk4N6BV_jEC" class="gsc_a_at">Dna-pk inhibitors</a><div class="gs_gray">NMB Martin, GCM Smith, RJ Griffin, BT Golding, IR Hardcastle, DR Newell, ...</div><div class="gs_gray">US Patent 7,226,918<span class="gs_oph">, 2007</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=5883844722949367969" class="gsc_a_ac gs_ibl">14</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2007</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:jL-93Qbq4QoC" class="gsc_a_at">Exploring the frequency of homologous recombination DNA repair dysfunction in multiple cancer types</a><div class="gs_gray">L Gentles, B Goranov, E Matheson, A Herriott, A Kaufmann, S Hall, ...</div><div class="gs_gray">Cancers 11 (3), 354<span class="gs_oph">, 2019</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=16061385984602516975" class="gsc_a_ac gs_ibl">13</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2019</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:5MTHONV0fEkC" class="gsc_a_at">Resistance-modifying agents. Part 7: 2, 6-disubstituted-4, 8-dibenzylaminopyrimido [5, 4-d] pyrimidines that inhibit nucleoside transport in the presence of α1-acid&nbsp;…</a><div class="gs_gray">HC Barlow, KJ Bowman, NJ Curtin, AH Calvert, BT Golding, B Huang, ...</div><div class="gs_gray">Bioorganic &amp; medicinal chemistry letters 10 (6), 585-589<span class="gs_oph">, 2000</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=18161405719774710052" class="gsc_a_ac gs_ibl">13</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2000</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:ALROH1vI_8AC" class="gsc_a_at">Why BRCA mutations are not tumour-agnostic biomarkers for PARP inhibitor therapy</a><div class="gs_gray">NJ Curtin, Y Drew, S Sharma-Saha</div><div class="gs_gray">Nature Reviews Clinical Oncology 16 (12), 725-726<span class="gs_oph">, 2019</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=17088093494940144381" class="gsc_a_ac gs_ibl">12</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2019</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:2osOgNQ5qMEC" class="gsc_a_at">PARP inhibitor rucaparib induces changes in NAD levels in cells and liver tissues as assessed by MRS</a><div class="gs_gray">GS Almeida, CM Bawn, M Galler, I Wilson, HD Thomas, S Kyle, NJ Curtin, ...</div><div class="gs_gray">NMR in Biomedicine 30 (9), e3736<span class="gs_oph">, 2017</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=378294024734113408" class="gsc_a_ac gs_ibl">12</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2017</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:BwyfMAYsbu0C" class="gsc_a_at">Hypoxanthine transport in human tumour cell lines. Relationship to the inhibition of hypoxanthine rescue by dipyridamole</a><div class="gs_gray">E Marshman, GA Taylor, HD Thomas, DR Newell, NJ Curtin</div><div class="gs_gray">Biochemical pharmacology 61 (4), 477-484<span class="gs_oph">, 2001</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=15254242384285139732" class="gsc_a_ac gs_ibl">12</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2001</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:MhiOAD_qIWkC" class="gsc_a_at">New PARP inhibitors for chemo-and radio-therapy of cancer</a><div class="gs_gray">NJ Curtin, BT Golding, RJ Griffin, DR Newell, MJ Roberts, S Srinivasan, ...</div><div class="gs_gray">From DNA Damage and Stress Signalling to Cell Death: Poly ADP-Ribosylation&nbsp;…<span class="gs_oph">, 2000</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=17967178241597209742" class="gsc_a_ac gs_ibl">12</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2000</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:9vf0nzSNQJEC" class="gsc_a_at">Therapeutic compounds</a><div class="gs_gray">T Helleday, N Curtin</div><div class="gs_gray">US Patent 7,531,530<span class="gs_oph">, 2009</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=9781451970972258945" class="gsc_a_ac gs_ibl">11</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2009</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:Y0pCki6q_DkC" class="gsc_a_at">Cyclin dependent kinase inhibiting purine derivatives</a><div class="gs_gray">RJ Griffin, AH Calvert, NJ Curtin, DR Newell, BT Golding, JA Endicott, ...</div><div class="gs_gray">US Patent 6,303,618<span class="gs_oph">, 2001</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=942838235450648402" class="gsc_a_ac gs_ibl">11</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2001</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:3htObqc8RwsC" class="gsc_a_at">Method of improving the effectiveness of a cytotoxic drug or radiotherapy using a quinazolinone compound</a><div class="gs_gray">RJ Griffin, AH Calvert, NJ Curtin, DR Newell, BT Golding</div><div class="gs_gray">US Patent 6,316,455<span class="gs_oph">, 2001</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=17442586794318202891" class="gsc_a_ac gs_ibl">10</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2001</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:nb7KW1ujOQ8C" class="gsc_a_at">Dipyridamole potentiates antipurine antifolate activity in the presence of hypoxanthine in tumor cells but not in normal tissues in vitro.</a><div class="gs_gray">E Marshman, DR Newell, AH Calvert, AM Dickinson, HR Patel, ...</div><div class="gs_gray">Clinical cancer research 4 (11), 2895-2902<span class="gs_oph">, 1998</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=6793621807347451007" class="gsc_a_ac gs_ibl">10</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1998</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:7BrZ7Jt4UNcC" class="gsc_a_at">ATR inhibition potentiates PARP inhibitor cytotoxicity in high risk neuroblastoma cell lines by multiple mechanisms</a><div class="gs_gray">HED Southgate, L Chen, DA Tweddle, NJ Curtin</div><div class="gs_gray">Cancers 12 (5), 1095<span class="gs_oph">, 2020</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=16665975006685975348" class="gsc_a_ac gs_ibl">9</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2020</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:WbkHhVStYXYC" class="gsc_a_at">Phase I, dose-escalation, 2-part trial of Poly (ADP-Ribose) polymerase inhibitor talazoparib in patients with advanced germline BRCA1/2 mutations and selected sporadic cancers</a><div class="gs_gray">J de Bono, RK Ramanathan, L Mina, R Chugh, J Glaspy, S Rafii, S Kaye, ...</div><div class="gs_gray">Cancer discovery<span class="gs_oph">, 2017</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=7474662595410130671" class="gsc_a_ac gs_ibl">9</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2017</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:yB1At4FlUx8C" class="gsc_a_at">Advanced ovarian cancer displays functional intratumor heterogeneity that correlates to ex vivo drug sensitivity</a><div class="gs_gray">RL O’Donnell, A Kaufmann, L Woodhouse, A McCormick, PA Cross, ...</div><div class="gs_gray">International Journal of Gynecologic Cancer 26 (6)<span class="gs_oph">, 2016</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=12195913919674985757" class="gsc_a_ac gs_ibl">9</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2016</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:_OXeSy2IsFwC" class="gsc_a_at">Dna-pk inhibitors</a><div class="gs_gray">NMB Martin, GCM Smith, RJ Griffin, BT Golding, IR Hardcastle, DR Newell, ...</div><div class="gs_gray">US Patent 7,674,823<span class="gs_oph">, 2010</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=18025320370935170289" class="gsc_a_ac gs_ibl">9</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2010</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:tuHXwOkdijsC" class="gsc_a_at">Preclinical evaluation of a novel pyrimidopyrimidine for the prevention of nucleoside and nucleobase reversal of antifolate cytotoxicity</a><div class="gs_gray">HD Thomas, K Saravanan, LZ Wang, MJ Lin, JS Northen, H Barlow, ...</div><div class="gs_gray">Molecular cancer therapeutics 8 (7), 1828-1837<span class="gs_oph">, 2009</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=14060003057419437196" class="gsc_a_ac gs_ibl">9</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2009</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:M3NEmzRMIkIC" class="gsc_a_at">Thiopyrane-4-ones as DNA protein kinase inhibitors</a><div class="gs_gray">NMB Martin, GCM Smith, RJ Griffin, BT Golding, IR Hardcastle, ...</div><div class="gs_gray">US Patent 7,105,518<span class="gs_oph">, 2006</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=4428440814645260300" class="gsc_a_ac gs_ibl">9</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2006</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:bnK-pcrLprsC" class="gsc_a_at">Final clinical, pharmacokinetic and pharmacodynamic results of the phase I study of the novel poly (ADP-ribose) polymerase (PARP) inhibitor, AG014699, in combination with&nbsp;…</a><div class="gs_gray">ER Plummer, M Middleton, R Wilson, J Evans, C Jones, A Olson, ...</div><div class="gs_gray">AACR/NCI/EORTC International Conference on Molecular Targets and Cancer&nbsp;…<span class="gs_oph">, 2005</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=8808205069624539534" class="gsc_a_ac gs_ibl">9</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2005</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:artPoR2Yc-kC" class="gsc_a_at">Evaluating the potential of kinase inhibitors to suppress DNA repair and sensitise ovarian cancer cells to PARP inhibitors</a><div class="gs_gray">A Mukhopadhyay, Y Drew, E Matheson, M Salehan, L Gentles, JA Pachter, ...</div><div class="gs_gray">Biochemical pharmacology 167, 125-132<span class="gs_oph">, 2019</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=6774072638699952508" class="gsc_a_ac gs_ibl">8</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2019</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:tzM49s52ZIMC" class="gsc_a_at">Sensitizing Ewing sarcoma to chemo-and radiotherapy by inhibition of the DNA-repair enzymes DNA protein kinase (DNA-PK) and poly-ADP-ribose polymerase (PARP) 1/2</a><div class="gs_gray">B Vormoor, YT Schlosser, H Blair, A Sharma, S Wilkinson, DR Newell, ...</div><div class="gs_gray">Oncotarget 8 (69), 113418<span class="gs_oph">, 2017</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=11254195709527513031" class="gsc_a_ac gs_ibl">8</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2017</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:zA6iFVUQeVQC" class="gsc_a_at">Poly (ADP-Ribose) polymerase in cervical cancer pathogenesis: Mechanism and potential role for PARP inhibitors</a><div class="gs_gray">IC Kotsopoulos, A Kucukmetin, A Mukhopadhyay, J Lunec, NJ Curtin</div><div class="gs_gray">International Journal of Gynecologic Cancer 26 (4)<span class="gs_oph">, 2016</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=5880419043790962377" class="gsc_a_ac gs_ibl">8</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2016</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:e_rmSamDkqQC" class="gsc_a_at">DNA-PK inhibitors</a><div class="gs_gray">G Smith, N Martin, K Menear, M Hummersone, XL Cockcroft, M Frigerio, ...</div><div class="gs_gray">US Patent App. 11/403,763<span class="gs_oph">, 2006</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=14679118019761749633" class="gsc_a_ac gs_ibl">8</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2006</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:MpfHP-DdYjUC" class="gsc_a_at">Targeting the DNA damage response for the treatment of high risk neuroblastoma</a><div class="gs_gray">HED Southgate, L Chen, NJ Curtin, DA Tweddle</div><div class="gs_gray">Frontiers in oncology 10, 371<span class="gs_oph">, 2020</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=1240780443597098255" class="gsc_a_ac gs_ibl">7</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2020</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:nRpfm8aw39MC" class="gsc_a_at">Exploring the synergy between PARP and CHK1 inhibition in matched BRCA2 mutant and corrected cells</a><div class="gs_gray">HL Smith, L Prendergast, NJ Curtin</div><div class="gs_gray">Cancers 12 (4), 878<span class="gs_oph">, 2020</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=18273905753205060778" class="gsc_a_ac gs_ibl">7</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2020</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:NMxIlDl6LWMC" class="gsc_a_at">PARP inhibitors for cancer therapy</a><div class="gs_gray">NJ Curtin, RA Sharma</div><div class="gs_gray">Humana Press<span class="gs_oph">, 2015</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=4626183013932758438" class="gsc_a_ac gs_ibl">7</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2015</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:TIZ-Mc8IlK0C" class="gsc_a_at">Dna-Pk Inhibitors</a><div class="gs_gray">G Smith, N Martin, R Griffin, B Golding, I Hardcastle, K Saravanan, ...</div><div class="gs_gray">US Patent App. 11/575,606<span class="gs_oph">, 2007</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=13728757203271301372" class="gsc_a_ac gs_ibl">7</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2007</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:lSLTfruPkqcC" class="gsc_a_at">The use of PARP inhibitors in cancer therapy: use as adjuvant with chemotherapy or radiotherapy, use as a single agent in susceptible patients, and techniques used to identify&nbsp;…</a><div class="gs_gray">S Shall, T Gaymes, F Farzaneh, NJ Curtin, GJ Mufti</div><div class="gs_gray">Poly (ADP-Ribose) Polymerase, 343-370<span class="gs_oph">, 2017</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=5021073301222745842" class="gsc_a_ac gs_ibl">6</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2017</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:ye4kPcJQO24C" class="gsc_a_at">Atm inhibitor</a><div class="gs_gray">G Smith, N Martin, A Slade, K Menear, M Hummersone, XL Cockcroft, ...</div><div class="gs_gray">US Patent App. 11/468,315<span class="gs_oph">, 2007</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=10385581745232605396" class="gsc_a_ac gs_ibl">6</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2007</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:W7OEmFMy1HYC" class="gsc_a_at">Cyclin dependent kinase inhibiting purine derivatives</a><div class="gs_gray">R Griffin, A Calvert, N Curtin, B Golding, I Hardcastle, D Newell, ...</div><div class="gs_gray">US Patent App. 10/466,693<span class="gs_oph">, 2004</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=1033225982306964486" class="gsc_a_ac gs_ibl">6</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2004</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:JV2RwH3_ST0C" class="gsc_a_at">The Enhanced Repair of <u>O</u><sup>6</sup>-Alkylguanine in Mammalian Systems</a><div class="gs_gray">PJ O’Connor, GP Margison, R Montesano, JD Buckley, YH Chu, ...</div><div class="gs_gray">Chromosome Damage and Repair, 233-245<span class="gs_oph">, 1981</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=4434924973227415434" class="gsc_a_ac gs_ibl">6</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1981</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:35N4QoGY0k4C" class="gsc_a_at">PARP activity in peripheral blood lymphocytes as a predictive biomarker for PARP inhibition in tumor tissues–A population pharmacokinetic/pharmacodynamic analysis of rucaparib</a><div class="gs_gray">DD Wang, C Li, W Sun, S Zhang, DR Shalinsky, KA Kern, NJ Curtin, ...</div><div class="gs_gray">Clinical pharmacology in drug development 4 (2), 89-98<span class="gs_oph">, 2015</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=5137579202923001716" class="gsc_a_ac gs_ibl">5</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2015</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:PaBasH6fAo0C" class="gsc_a_at">PARP and PARP inhibitor therapeutics</a><div class="gs_gray">NJ Curtin</div><div class="gs_gray">DNA Repair and Cancer, 531-581<span class="gs_oph">, 2013</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=5175767887222216942" class="gsc_a_ac gs_ibl">5</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2013</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:EkHepimYqZsC" class="gsc_a_at">The use of PARP inhibitors in cancer therapy: use as adjuvant with chemotherapy or radiotherapy; use as a single agent in susceptible patients; techniques used to identify&nbsp;…</a><div class="gs_gray">S Shall, T Gaymes, F Farzaneh, N Curtin, GJ Mufti</div><div class="gs_gray">Poly (ADP-ribose) Polymerase, 239-266<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=12440736395303718744" class="gsc_a_ac gs_ibl">5</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:DUooU5lO8OsC" class="gsc_a_at">Identification of potent water-soluble DNA-dependent protein kinase (DNA-PK) inhibitors using a small-molecule library approach</a><div class="gs_gray">K Saravanan, M Albertella, C Cano, N Curtin, M Frigerio, B Golding, ...</div><div class="gs_gray">Cancer Research 68 (9 Supplement), 4156-4156<span class="gs_oph">, 2008</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=16384203919702315894" class="gsc_a_ac gs_ibl">5</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2008</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:tOudhMTPpwUC" class="gsc_a_at">Cellular glutathione as a determinant of the sensitivity of colorectal tumour cell-lines to ZD2767 antibody-directed enzyme prodrug therapy (ADEPT)</a><div class="gs_gray">NR Monks, JA Calvete, NJ Curtin, DC Blakey, SJ East, DR Newell</div><div class="gs_gray">British journal of cancer 83 (2), 267-269<span class="gs_oph">, 2000</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=7625902838983507977" class="gsc_a_ac gs_ibl">5</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2000</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:7Hz3ACDFbsoC" class="gsc_a_at">The development of Rucaparib/Rubraca®: A story of the synergy between science and serendipity</a><div class="gs_gray">NJ Curtin</div><div class="gs_gray">Cancers 12 (3), 564<span class="gs_oph">, 2020</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=14397886211208557086" class="gsc_a_ac gs_ibl">4</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2020</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:8d8msizDQcsC" class="gsc_a_at">PTU-042 DNA-PK or ATM inhibition inhibits non-homologous end joining and enhances chemo-and radio sensitivity in hepatocellular cancer cell lines</a><div class="gs_gray">L Cornell, J Munck, N Curtin, H Reeves</div><div class="gs_gray">Gut 61 (Suppl 2), A201-A201<span class="gs_oph">, 2012</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=16005108496082614095" class="gsc_a_ac gs_ibl">4</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2012</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:2P1L_qKh6hAC" class="gsc_a_at">The role of PARP in DNA repair and its therapeutic exploitation</a><div class="gs_gray">NJ Curtin, A Mukhopadhyay, Y Drew, R Plummer</div><div class="gs_gray">DNA Repair in Cancer Therapy, 55-73<span class="gs_oph">, 2012</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=5407215783711039447" class="gsc_a_ac gs_ibl">4</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2012</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:ns9cj8rnVeAC" class="gsc_a_at">Investigating DNA double strand break formation and repair in response to the PARP inhibitor AG014699 in cell lines defective in Homologous Recombination: a role for PARP&nbsp;…</a><div class="gs_gray">Y Drew, W Vong, S Khan, S Kyle, R Edmondson, R Plummer, N Curtin</div><div class="gs_gray">Cancer Research 68 (9 Supplement), 859-859<span class="gs_oph">, 2008</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=4837569081713021368" class="gsc_a_ac gs_ibl">4</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2008</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:5nxA0vEk-isC" class="gsc_a_at">Temozolomide Pharmacodynamics in Patients with Metastatic Melanoma: DNA Damage and Activity of Repair Enzymes O 6-Alkylguanine Alkyltransferase and Poly (ADP-Ribose) Polymerase-1</a><div class="gs_gray">GP Margison, G McGown, M Thorncroft, AJ Watson, AV Boddy, AH Calvert, ...</div><div class="gs_gray">Clin Cancer Res 2005 (11), 9<span class="gs_oph">, 2005</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=2261719521297020616" class="gsc_a_ac gs_ibl">4</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2005</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:5ugPr518TE4C" class="gsc_a_at">CHRONIC ADMINISTRATION OF N-NITROSAMINES ENHANCES THE REMOVAL OF O6-ALKYLGUANINES FROM RAT-LIVER DNA INVIVO</a><div class="gs_gray">GP Margison, AW Craig, H Brésil, N Curtin, K Snell, R Montesano</div><div class="gs_gray">BRITISH JOURNAL OF CANCER 40 (5), 815-816<span class="gs_oph">, 1979</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=8807983393168403084" class="gsc_a_ac gs_ibl">4</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1979</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:kuK5TVdYjLIC" class="gsc_a_at">Targeting the DNA damage response for anti-cancer therapy</a><div class="gs_gray">J Pollard, N Curtin</div><div class="gs_gray">Humana Press<span class="gs_oph">, 2018</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=13785386668040703521" class="gsc_a_ac gs_ibl">3</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2018</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:dQ2og3OwTAUC" class="gsc_a_at">Ovarian cancers harbor defects in nonhomologous end joining resulting in error prone repair and resistance to rucaparib</a><div class="gs_gray">A McCormick, M Dixon, R ODonnell, NJ Curtin, RJ Edmondson</div><div class="gs_gray">Clinical Cancer Research 19<span class="gs_oph">, 2013</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=10721698526060936030,13890794308102123800" class="gsc_a_ac gs_ibl">3</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2013</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:lvd772isFD0C" class="gsc_a_at">349 Ewing's Sarcoma Cells Can Be Sensitized to Temozolomide and to a Lesser Extent to Radiotherapy by Co-treatment with a PARP-inhibitor (AG014699)</a><div class="gs_gray">B Vormoor, S Wilkinson, F Harvey, R Plummer, N Curtin</div><div class="gs_gray">European Journal of Cancer, 106-107<span class="gs_oph">, 2012</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=18180226541574872729" class="gsc_a_ac gs_ibl">3</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2012</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:3s1wT3WcHBgC" class="gsc_a_at">Strategies employed for the development of PARP inhibitors</a><div class="gs_gray">S Canan, K Maegley, N Curtin</div><div class="gs_gray">Poly (ADP-ribose) Polymerase, 463-489<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=5681189594908683555" class="gsc_a_ac gs_ibl">3</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:MXK_kJrjxJIC" class="gsc_a_at">Poly (ADP-ribose) polymerase-1 (PARP-1) genomics in relation to activity in healthy volunteers and cancer patients</a><div class="gs_gray">T Zaremba, M Cole, S Coulthard, E Plummer, N Curtin</div><div class="gs_gray">Cancer Research 68 (9 Supplement), 540-540<span class="gs_oph">, 2008</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=2322078903492819328" class="gsc_a_ac gs_ibl">3</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2008</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:z_wVstp3MssC" class="gsc_a_at">A radioimmunoassay for deoxythymidine triphosphate</a><div class="gs_gray">GW AHERNE, E PIALL, S AITKENHEAD, N CURTIN</div><div class="gs_gray">Biochemical Society Transactions 17 (6), 1052-1052<span class="gs_oph">, 1989</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=11956671317417715746" class="gsc_a_ac gs_ibl">3</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1989</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:9yKSN-GCB0IC" class="gsc_a_at">Changes in developmental-specific enzyme activities during experimental hepatocarcinogenesis in the rat <i>in vivo</i></a><div class="gs_gray">NJ CURTIN, K SNELL</div><div class="gs_gray">Biochemical Society Transactions 8 (1), 94-94<span class="gs_oph">, 1980</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=306333303678246697" class="gsc_a_ac gs_ibl">3</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1980</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:WHdLCjDvYFkC" class="gsc_a_at">Characterisation of Ovarian Cancer Cell Line NIH-OVCAR3 and Implications of Genomic, Transcriptomic, Proteomic and Functional DNA Damage Response Biomarkers for Therapeutic&nbsp;…</a><div class="gs_gray">A Bradbury, R O’Donnell, Y Drew, NJ Curtin, S Sharma Saha</div><div class="gs_gray">Cancers 12 (7), 1939<span class="gs_oph">, 2020</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=16943029529536434530" class="gsc_a_ac gs_ibl">2</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2020</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:gKiMpY-AVTkC" class="gsc_a_at">Characterization and drug sensitivity of a novel human ovarian clear cell carcinoma cell line genomically and phenotypically similar to the original tumor</a><div class="gs_gray">M Franklin, L Gentles, E Matheson, N Bown, P Cross, A Ralte, ...</div><div class="gs_gray">Cancer medicine 7 (9), 4744-4754<span class="gs_oph">, 2018</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=8785608108575919528" class="gsc_a_ac gs_ibl">2</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2018</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:PR6Y55bgFSsC" class="gsc_a_at">Strategies Employed for the Development of PARP Inhibitors</a><div class="gs_gray">S Canan, K Maegley, NJ Curtin</div><div class="gs_gray">Poly (ADP-Ribose) Polymerase, 271-297<span class="gs_oph">, 2017</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=10623490466583945493" class="gsc_a_ac gs_ibl">2</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2017</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:qxL8FJ1GzNcC" class="gsc_a_at">Inhibition of DNA Repair as a Therapeutic Target</a><div class="gs_gray">S Veuger, NJ Curtin</div><div class="gs_gray">Cancer Drug Design and Discovery<span class="gs_oph">, 2014</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=2763465002152933525" class="gsc_a_ac gs_ibl">2</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2014</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:HtEfBTGE9r8C" class="gsc_a_at">Abstract A220: Inhibition of PBMC PARP activity with the novel PARP 1/2 inhibitor BMN 673 in patients with advanced solid tumors.</a><div class="gs_gray">JW Henshaw, H Zhou, A Herriott, M Patterson, EW Wang, D Musson, ...</div><div class="gs_gray">Molecular Cancer Therapeutics 12 (11 Supplement), A220-A220<span class="gs_oph">, 2013</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=16195319074625584038" class="gsc_a_ac gs_ibl">2</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2013</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:kNdYIx-mwKoC" class="gsc_a_at">High Activity of Poly (ADP-Ribose) Polymerase in Chronic Lymphocytic Leukemia</a><div class="gs_gray">E Willmore, N Rodrigues, L Allinson, GP Summerfield, J Wallis, C Lowe, ...</div><div class="gs_gray">Blood, The Journal of the American Society of Hematology 120 (21), 1788-1788<span class="gs_oph">, 2012</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=2392937408408224495" class="gsc_a_ac gs_ibl">2</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2012</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:SjuI4pbJlxcC" class="gsc_a_at">Ltd. Substituted Heterocycles And Their Use As CHK1, PDK1 AND PAK Inhibitors</a><div class="gs_gray">UK AstraZeneca</div><div class="gs_gray">WO2006106326<span class="gs_oph">, 2006</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=12363215505949911717,5200722006875113045" class="gsc_a_ac gs_ibl">2</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2006</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:2KloaMYe4IUC" class="gsc_a_at">Identification of the potent and selective DNA-dependent protein kinase (DNA-PK) inhibitor NU7441 by screening of chromenone libraries</a><div class="gs_gray">RJ Griffin, NJ Curtin, BT Golding, S Guiard, IR Hardcastle, JJ Leahy, ...</div><div class="gs_gray">Cancer Research 64 (7 Supplement), 1236-1237<span class="gs_oph">, 2004</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=11349783837370292060" class="gsc_a_ac gs_ibl">2</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2004</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:SP6oXDckpogC" class="gsc_a_at">Structural and thermodynamic validation of inactive CDK2 as a template for structure-based drug design</a><div class="gs_gray">TG Davies, JA Endicot, MEM Noble, LN Johnson, CE Arris, J Bentley, ...</div><div class="gs_gray">Cellular and Molecular Biology Letters 2 (06), 514-515<span class="gs_oph">, 2001</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=6992564789775021495" class="gsc_a_ac gs_ibl">2</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2001</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:prdVHNxh-e8C" class="gsc_a_at">Integration of computer-aided automated analysis algorithms in the development and validation of immunohistochemistry biomarkers in ovarian cancer</a><div class="gs_gray">L Gentles, R Howarth, WJ Lee, S Sharma-Saha, A Ralte, N Curtin, Y Drew, ...</div><div class="gs_gray">Journal of Clinical Pathology 74 (7), 469-474<span class="gs_oph">, 2021</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=5538696994609735845" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2021</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:XUvXOeBm_78C" class="gsc_a_at">The role of PARP and the therapeutic potential of PARP inhibitors in cancer</a><div class="gs_gray">NJ Curtin</div><div class="gs_gray">DNA Damage, DNA Repair and Disease 2, 319-360<span class="gs_oph">, 2020</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=8896934610491056238" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2020</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:CB2v5VPnA5kC" class="gsc_a_at">55P Evaluation of MDM2-p53 antagonists, nutlin-3 and RG7388, combined with the PARPi rucaparib in primary cultures of ovarian cancer</a><div class="gs_gray">M Zanjirband, L Gentles, NJ Curtin, RL O'Donnell, J Lunec</div><div class="gs_gray">Annals of Oncology 31, S1234<span class="gs_oph">, 2020</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=12669174689254313369" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2020</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:jgBuDB5drN8C" class="gsc_a_at">CTRad 10 years on: from 10-point plan to top 10 achievements</a><div class="gs_gray">AJ Chalmers, C Chan, D Sebag-Montefiore</div><div class="gs_gray">Clinical Oncology 32 (1), 9-12<span class="gs_oph">, 2020</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=15544756089178442312" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2020</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:0izLItjtcgwC" class="gsc_a_at">Targeting ATR for Cancer Therapy: Profile and Expectations for ATR Inhibitors</a><div class="gs_gray">N Curtin, J Pollard</div><div class="gs_gray">Targeting the DNA Damage Response for Anti-Cancer Therapy, 63-97<span class="gs_oph">, 2018</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=16051367298992712521" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2018</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:hkOj_22Ku90C" class="gsc_a_at">IN VITRO SINGLE AGENT RUCAPARIB CYTOTOXICITY AND CISPLATIN CHEMO-POTENTIATION IN CERVICAL CANCER CELL LINES</a><div class="gs_gray">IC Kotsopoulos, JA Begbie, A Mukhopadhyay, J Lunec, NJ Curtin, ...</div><div class="gs_gray">16th Biennial Meeting of the International Gynecologic Cancer Society<span class="gs_oph">, 2016</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=10649082103963746962" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2016</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:zLWjf1WUPmwC" class="gsc_a_at">Intra-and inter-tumour heterogeneity in epithelial ovarian cancer: consequences for biomarker dependent stratification of therapies</a><div class="gs_gray">RL O'Donnell, A Kaufman, L Woodhous, A McCormick, NJ Curtin, ...</div><div class="gs_gray">Annual Meeting of the Blair Bell Research Society<span class="gs_oph">, 2015</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=12489219534698887210" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2015</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:hFOr9nPyWt4C" class="gsc_a_at">The role of homologous recombination recovery in cisplatin and rucaparib resistance in ovarian cancer</a><div class="gs_gray">A McCormick, S Nakjang, P Donoghue, N Curtin, R Edmondson</div><div class="gs_gray">19th International Meeting of the European Society of Gynecological Oncology&nbsp;…<span class="gs_oph">, 2015</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=3432763936333680456" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2015</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:g3aElNc5_aQC" class="gsc_a_at">PARP inhibitors target ATM+ p53-defective gastric cancer</a><div class="gs_gray">NJ Curtin</div><div class="gs_gray">Cell Cycle 13 (20), 3161-3162<span class="gs_oph">, 2014</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=13257035180584402189" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2014</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:yMeIxYmEMEAC" class="gsc_a_at">Stability of PARP Inhibition by BMN 673 in Human PBMCs (and Leukaemic Cell Cultures)</a><div class="gs_gray">MJ Patterson, J Murray, NJ Curtin</div><div class="gs_gray">24th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics<span class="gs_oph">, 2012</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=2852772807412970605" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2012</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:edDO8Oi4QzsC" class="gsc_a_at">277 Single Agent Activity of the Novel Checkpoint 1 Kinase Inhibitor V158411</a><div class="gs_gray">P Stephens, A Massey, R Plummer, N Curtin</div><div class="gs_gray">European Journal of Cancer, 85<span class="gs_oph">, 2012</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=14962942965293330138" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2012</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:a9-T7VOCCH8C" class="gsc_a_at">Compromised cdk1 activity sensitizes BRCA-proficient cancer cells to inhibition of poly (ADP-ribose) polymerase</a><div class="gs_gray">N Johnson, YC Li, LA Moreau, HD Thomas, DR Newell, AD D'andrea, ...</div><div class="gs_gray">Cancer Research 70 (8 Supplement), 3882-3882<span class="gs_oph">, 2010</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=16250391272182160806" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2010</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:eJXPG6dFmWUC" class="gsc_a_at">DNA Damage Signalling and Repair in cancer: Therapeutic Potential</a><div class="gs_gray">J Ford, T Helleday, N Curtin</div><div class="gs_gray">Asco educational book, 467-473<span class="gs_oph">, 2010</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=8319519017089015660" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2010</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:Zph67rFs4hoC" class="gsc_a_at">PARP inhibitors in ovarian cancer</a><div class="gs_gray">H Calvert, N Curtin, R Plummer</div><div class="gs_gray">ANNALS OF ONCOLOGY 19, 23-23<span class="gs_oph">, 2008</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=2635770073225585076" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2008</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:ipzZ9siozwsC" class="gsc_a_at">Inhibition of DNA repair as therapeutic target</a><div class="gs_gray">NJ Curtin, T Helleday</div><div class="gs_gray">Cancer drug design and discovery, 284-304<span class="gs_oph">, 2008</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=1996936292553989998" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2008</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:N5tVd3kTz84C" class="gsc_a_at">245 INVITED PARP inhibitors in cancer treatment</a><div class="gs_gray">H Calvert, ER Plummer, NJ Curtin, R Edmondson, Y Drew</div><div class="gs_gray">Ejc Supplements 12 (6), 80<span class="gs_oph">, 2008</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=5971045775739104936" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2008</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:QIV2ME_5wuYC" class="gsc_a_at">Preclinical evaluation of the poly-ADP ribose polymerase 1 (PARP-1) inhibitor AG014699 in combination with topotecan and temozolomide for the treatment of medulloblastoma and&nbsp;…</a><div class="gs_gray">R Daniel, A Rozanska, H Thomas, D Castelbuono, A Boddy, D Tweddle, ...</div><div class="gs_gray">Cancer Research 67 (9 Supplement), LB-293-LB-293<span class="gs_oph">, 2007</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=3056437737843465450" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2007</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:uc_IGeMz5qoC" class="gsc_a_at">499 POSTER Identification of a PARP inhibitor for clinical trial: preclinical studies</a><div class="gs_gray">H Thomas, C Calabrese, S Canan, K Maegley, D Newell, D Skalitzki, ...</div><div class="gs_gray">EJC Supplements 12 (4), 152<span class="gs_oph">, 2006</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=12272601109827355226" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2006</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:7T2F9Uy0os0C" class="gsc_a_at">The effect of a novel CDK inhibitor NU2058 on antiestrogen sensitive and resistant breast cancer cell growth and downstream events</a><div class="gs_gray">N Johnson, NJ Curtin</div><div class="gs_gray">Cancer Research 65 (9 Supplement), 1046-1046<span class="gs_oph">, 2005</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=11229329031171766702" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2005</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:dhFuZR0502QC" class="gsc_a_at">Radio and chemosensitization by a novel DNA-PK inhibitor (NU7441) in colon cancer</a><div class="gs_gray">Y Zhao, M Batey, H Thomas, GC Smith, DR Newell, NJ Curtin</div><div class="gs_gray">Cancer Research 65 (9 Supplement), 1180-1181<span class="gs_oph">, 2005</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=3078947014273025761" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2005</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:uJ-U7cs_P_0C" class="gsc_a_at">The role of poly (ADP-ribose) polymerase-1 (PARP-1) in the cellular response to Topoisomerase I poisons</a><div class="gs_gray">L Smith, E Willmore, Z Hostomsky, SE Webber, CA Austin, NJ Curtin</div><div class="gs_gray">EUROPEAN JOURNAL OF CANCER 38, S69-S69<span class="gs_oph">, 2002</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=11804593053275307545" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2002</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:Dip1O2bNi0gC" class="gsc_a_at">Anti-cancer chemosensitization in vitro and in vivo by a novel potent poly (ADP-ribose) polymerase (PARP1) inhibitor, TBI-361.</a><div class="gs_gray">NJ Curtin, SB Barton, MA Batey, CR Calabrese, AH Calvert, BW Durkacz, ...</div><div class="gs_gray">Clinical Cancer Research<span class="gs_oph">, 2001</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=14815845444415278487" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2001</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:_B80troHkn4C" class="gsc_a_at">Radiosensitization by novel inhibitors of PARP, PI, and DNA-PK, NU7026, in vitro</a><div class="gs_gray">SJ Veuger, BW Durkacz, BT Golding, RJ Griffin, N Martin, DR Newell, ...</div><div class="gs_gray">British Journal of Cancer<span class="gs_oph">, 2001</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=9453371933471897871" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2001</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:DJbcl8HfkQkC" class="gsc_a_at">In vitro growth activity of novel purine-and pyrimidine-based CDK1 and CDK2 inhibitors</a><div class="gs_gray">CE Arris, FT Boyle, AH Calvert, NJ Curtin, PJ Dewsbury, JA Endicott, ...</div><div class="gs_gray">British Journal of Cancer 80, 110-<span class="gs_oph">, 1999</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=17137439557830974181" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1999</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:tYavs44e6CUC" class="gsc_a_at">Antiproliferative cyclin dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles.</a><div class="gs_gray">DR Newell, CE Arris, FT Boyle, AH Calvert, NJ Curtin, P Dewsbury, ...</div><div class="gs_gray">CLIN CANCER RES 5, 3755S-3755S<span class="gs_oph">, 1999</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=13702501063086299326" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1999</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:M7yex6snE4oC" class="gsc_a_at">A NEW THYMIDYLATE SYNTHASE (TS) INHIBITOR, CB3717, IN HUMAN PRIMARY LIVER-CANCER (PLC)-INVITRO, XENOGRAFT AND PHASE-II STUDIES</a><div class="gs_gray">MF Bassendine, AL Harris, N Curtin, O James</div><div class="gs_gray">British Journal of Cancer 54 (1), 200-200<span class="gs_oph">, 1986</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=14529680336576245888" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1986</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:-f6ydRqryjwC" class="gsc_a_at">LOCALIZATION OF PRIMARY HEPATOCELLULAR-CARCINOMA BY A RADIOLABELED MONOCLONAL-ANTIBODY</a><div class="gs_gray">NI MARKHAM, OFW JAMES, K SIKORA, MF BASSENDINE, N CURTIN, ...</div><div class="gs_gray">GASTROENTEROLOGY 88 (5), 1489-1489<span class="gs_oph">, 1985</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=3420768258303670152" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1985</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:hsZV8lGYWTMC" class="gsc_a_at">Differences in durability of PARP inhibition by PARP inhibitors in ovarian cancer cells</a><div class="gs_gray">H Smith, A Mukhopadhyay, Y Drew, E Willmore, N Curtin</div><div class="gs_gray">MDPI<span class="gs_oph">, 2021</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2021</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:LPtt_HFRSbwC" class="gsc_a_at">Increased replication stress sensitises high risk neuroblastoma cells to ATR and PARP inhibition</a><div class="gs_gray">H Southgate, L Chen, DA Tweddle, NJ Curtin</div><div class="gs_gray">Medical Sciences Forum 3 (1), 10<span class="gs_oph">, 2021</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2021</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:3NQIlFlcGxIC" class="gsc_a_at">Genomic, Transcriptomic, and Functional Alterations in DNA Damage Response Pathways as Putative Biomarkers of Chemotherapy Response in Ovarian Cancer</a><div class="gs_gray">S Sharma Saha, L Gentles, A Bradbury, D Brecht, R Robinson, ...</div><div class="gs_gray">Cancers 13 (6), 1420<span class="gs_oph">, 2021</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2021</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:-mN3Mh-tlDkC" class="gsc_a_at">PARPs, PAR and NAD Metabolism and Their Inhibitors in Cancer</a><div class="gs_gray">N Curtin, P Bai</div><div class="gs_gray">Cancers 12 (12), 3494<span class="gs_oph">, 2020</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2020</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:Br1UauaknNIC" class="gsc_a_at">SP-0517: Increasing the therapeutic index of radiation by combination with rucaparib in cervical cancer</a><div class="gs_gray">S Saha, R Howarth, A Dubrovska, K Marchbank, N Curtin</div><div class="gs_gray">Radiotherapy and Oncology 152, S283-S284<span class="gs_oph">, 2020</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2020</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:L1USKYWJimsC" class="gsc_a_at">Investigating synergy between WEE1 and PARP inhibitors in BRCA2 mutant and corrected cells</a><div class="gs_gray">H Smith, L Prendergast, N Curtin</div><div class="gs_gray">European Journal of Cancer 138, S36-S37<span class="gs_oph">, 2020</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2020</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:jU7OWUQzBzMC" class="gsc_a_at">Potential use of the PARP inhibitor rucaparib to enhance cervical cancer treatment</a><div class="gs_gray">S Saha, R Howarth, I Pappworth, K Marchbank, N Curtin</div><div class="gs_gray">European Journal of Cancer 138, S37<span class="gs_oph">, 2020</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2020</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:7H_MAutzIkAC" class="gsc_a_at">Preclinical investigation of ATR inhibition alone and in combination with PARP inhibition in high risk neuroblastoma</a><div class="gs_gray">HE Southgate, L Chen, NJ Curtin, DA Tweddle</div><div class="gs_gray">Cancer Research 80 (16 Supplement), 1374-1374<span class="gs_oph">, 2020</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2020</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:WC23djZS0W4C" class="gsc_a_at">Investigating synergy between CHK1 and PARP inhibitors in BRCA2 mutant and restored cells</a><div class="gs_gray">HL Smith, L Prendergast, NJ Curtin</div><div class="gs_gray">Cancer Research 80 (16 Supplement), 1375-1375<span class="gs_oph">, 2020</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2020</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:7wO8s98CvbsC" class="gsc_a_at">Investigating determinants of sensitivity to ATR inhibition, as predictive biomarkers to single agent ATR inhibitor, VE-821, in ovarian cancer</a><div class="gs_gray">AM Bradbury, FT Zenke, Y Drew, NJ Curtin</div><div class="gs_gray">Cancer Research 80 (16 Supplement), 4125-4125<span class="gs_oph">, 2020</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2020</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:BzfGm06jWhQC" class="gsc_a_at">EP295 Investigating the effect of hypercapnia, hypoxia and pH on cellular proliferation in cervical cancer</a><div class="gs_gray">L Gentles, SS Saha, M Case, P Korompelis, Y Drew, N Curtin, ...</div><div class="gs_gray">International Journal of Gynecologic Cancer 29 (Suppl 4)<span class="gs_oph">, 2019</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2019</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:cK4Rrx0J3m0C" class="gsc_a_at">PARP inhibition causes replication stress in preclinical models of high risk neuroblastoma and synergises with inhibition of ATR</a><div class="gs_gray">H Southgate, NJ Curtin, DA Tweddle</div><div class="gs_gray">BRITISH JOURNAL OF CANCER 121, 20-20<span class="gs_oph">, 2019</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2019</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:buQ7SEKw-1sC" class="gsc_a_at">Investigating the effect of replication stress and other phenotypic factors as determinants of sensitivity to single agent ATR inhibitor, VE-821 in ovarian cancer cell lines</a><div class="gs_gray">A Bradbury, D King, H Bryant, F Zenke, Y Drew, N Curtin</div><div class="gs_gray">EUROPEAN JOURNAL OF CANCER 103, E32-E32<span class="gs_oph">, 2018</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2018</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:wMgC3FpKEyYC" class="gsc_a_at">Biomarker development in ovarian cancer using multispectral immune profiling of the DNA damage response</a><div class="gs_gray">H Robinson, L Gentles, C Kirk, H Smith, L Wilson, N Curtin, R O'donnell</div><div class="gs_gray">EUROPEAN JOURNAL OF CANCER 103, E34-E34<span class="gs_oph">, 2018</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2018</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:QD3KBmkZPeQC" class="gsc_a_at">Preclinical evaluation of the ATR inhibitor VE-821 alone and in combination with the PARP inhibitor olaparib in neuroblastoma</a><div class="gs_gray">H Southgate, L Chen, NJ Curtin, DA Tweddle</div><div class="gs_gray">EUROPEAN JOURNAL OF CANCER 103, E31-E31<span class="gs_oph">, 2018</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2018</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:LgRImbQfgY4C" class="gsc_a_at">An investigation of the effect of tissue ischaemia upon DNA damage protein markers in ovarian cancer</a><div class="gs_gray">S Tomassini, L Gentles, C Kirk, P Cross, H Thomas, S Wedge, N Curtin, ...</div><div class="gs_gray">European Journal of Surgical Oncology 44, S37<span class="gs_oph">, 2018</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2018</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:4hFrxpcac9AC" class="gsc_a_at">An investigation of the effect of tissue ischaemia upon DNA damage protein markers in ovarian cancer</a><div class="gs_gray">S Tomassini, L Gentles, C Kirk, P Cross, H Thomas, S Wedge, N Curtin, ...</div><div class="gs_gray">European Journal of Surgical Oncology 43 (11), 2234<span class="gs_oph">, 2017</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2017</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:70eg2SAEIzsC" class="gsc_a_at">O'Donnell RL, Kaufmann A, Woodhouse L, McCormick A, Cross PA</a><div class="gs_gray">RJ Edmondson, NJ Curtin</div><div class="gs_gray"></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2017</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:BJbdYPG6LGMC" class="gsc_a_at">Improving outcome in homologous recombination competent epithelial ovarian cancer: Hyperthemia and surgeon's perspective</a><div class="gs_gray">A Mukhopadhyay, G Abdulrahman, E Davison, E Matheson, Y Drew, ...</div><div class="gs_gray">MOLECULAR CANCER RESEARCH 15<span class="gs_oph">, 2017</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2017</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:KxtntwgDAa4C" class="gsc_a_at">Abstract A05: Improving outcome in homologous recombination competent epithelial ovarian cancer: Hyperthemia and surgeon's perspective</a><div class="gs_gray">A Mukhopadhyay, G Abdulrahman, E Davison, E Matheson, Y Drew, ...</div><div class="gs_gray">Molecular Cancer Research 15 (4 Supplement), A05-A05<span class="gs_oph">, 2017</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2017</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:t7zJ5fGR-2UC" class="gsc_a_at">Targeting DNA Damage Response Pathways in Cancer</a><div class="gs_gray">GO Abdulrahman, NJ Curtin</div><div class="gs_gray">Comprehensive Medicinal Chemistry III<span class="gs_oph">, 2017</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2017</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:48xauSegjOkC" class="gsc_a_at">Evaluation of different methods to assess homologous recombination status and sensitivity to PARP inhibitors in ovarian cancer</a><div class="gs_gray">A Mukhopadhyay, N Curtin, R Edmondson</div><div class="gs_gray">Asian Journal of Oncology 2 (S 01), 038<span class="gs_oph">, 2016</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2016</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:CaZNVDsoPx4C" class="gsc_a_at">Clinico-pathological correlation of homologous recombination status in epithelial ovarian cancer: Surgeon’s perspective</a><div class="gs_gray">A Mukhopadhyay, N Curtin, R Edmondson</div><div class="gs_gray">Asian Journal of Oncology 2 (S 01), 041<span class="gs_oph">, 2016</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2016</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:vDZJ-YLwNdEC" class="gsc_a_at">Unterlass JE, Baslé A, Blackburn TJ, Tucker J, Turlais F, Cano C, Noble MME</a><div class="gs_gray">NJ Curtin</div><div class="gs_gray"></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2016</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:RYcK_YlVTxYC" class="gsc_a_at">Preclinical studies of the PARP inhibitor olaparib in combination with imatinib in BRCA stratified ovarian cancer</a><div class="gs_gray">E Matheson, M Salehan, A Mukhopadhyay, NJ Curtin, Y Drew</div><div class="gs_gray">16th Biennial Meeting of the International Gynecologic Cancer Society<span class="gs_oph">, 2016</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2016</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:L8Ckcad2t8MC" class="gsc_a_at">Investigating PARP inhibitor sensitisation by hyperthermia and HSP90 inhibition</a><div class="gs_gray">GO Abdulrahman, E Davison, E Matheson, Y Drew, N Curtin, ...</div><div class="gs_gray">16th Biennial Meeting of the International Gynecologic Cancer Society<span class="gs_oph">, 2016</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2016</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:aqlVkmm33-oC" class="gsc_a_at">Inhibition of ATR in Combination with Nucleoside Analogues Eradicates Acute Myeloid Leukaemia in an Orthotopic Murine Xenograft Model</a><div class="gs_gray">SE Fordham, HJ Blair, CJ Elstob, D Pal, N Curtin, P Milne, M Collin, ...</div><div class="gs_gray">Blood 128 (22), 4031<span class="gs_oph">, 2016</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2016</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:5qfkUJPXOUwC" class="gsc_a_at">Towards structure-based drug design of 3-phosphoglycerate dehydrogenase inhibitors</a><div class="gs_gray">JE Unterlass, N Aljufri, S Bex, C Cano, MEM Noble, NJ Curtin</div><div class="gs_gray">Cancer Research 75 (15 Supplement), 2448-2448<span class="gs_oph">, 2015</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2015</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:nrtMV_XWKgEC" class="gsc_a_at">Chemical inhibition or transient knockdown of wild-type p53 induced phosphatase 1 (WIP1/PPM1D) potentiates the response to MDM2 inhibitors in a p53-dependent manner</a><div class="gs_gray">A Esfandiari, NJ Curtin, J Lunec</div><div class="gs_gray">Cancer Research 75 (15 Supplement), 1785-1785<span class="gs_oph">, 2015</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2015</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:fFSKOagxvKUC" class="gsc_a_at">Defects in non-homologous end joining pathway in ovarian cancers results in resistance to rucaparib</a><div class="gs_gray">A McCormick, P Donoghue, M Dixon, R O'Donnell, A Kaufmann, N Curtin, ...</div><div class="gs_gray">Blair Bell Research Society<span class="gs_oph">, 2015</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2015</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:WZBGuue-350C" class="gsc_a_at">Biomarkers for PARP Inhibitors</a><div class="gs_gray">C Dearman, RA Sharma, NJ Curtin</div><div class="gs_gray">PARP Inhibitors for Cancer Therapy, 553-579<span class="gs_oph">, 2015</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2015</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:pqnbT2bcN3wC" class="gsc_a_at">Inhibition of DNA-Repair Enzymes (DNA-Pk and Parp) to Sensitize Ewing Sarcoma to Chemo-And Radiotherapy</a><div class="gs_gray">B Vormoor, Y Schlosser, H Blair, S Wilkinson, DR Newell, N Curtin</div><div class="gs_gray">47th Congress of the International Society of Paediatric Oncology (SIOP)<span class="gs_oph">, 2015</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2015</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:QYdC8u9Cj1oC" class="gsc_a_at">Molecular characterization of matched ovarian ascites and tumors suggests multiple mechanisms for a homologous recombination defective phenotype</a><div class="gs_gray">RJ Edmondson, A Mukhopadhyay, L Van Neste, W Van Criekinge, ...</div><div class="gs_gray">Cancer Research 74 (19 Supplement), 5608-5608<span class="gs_oph">, 2014</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2014</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:anf4URPfarAC" class="gsc_a_at">Investigating p53 and other potential determinants of cell sensitivity to ATR inhibition by VE-821</a><div class="gs_gray">FK Middleton, T Chen, JR Pollard, NJ Curtin</div><div class="gs_gray">Cancer Research 74 (19 Supplement), 2418-2418<span class="gs_oph">, 2014</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2014</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:gVv57TyPmFsC" class="gsc_a_at">Investigating PARP-1 expression and activity in male and female, benign and malignant renal tissue</a><div class="gs_gray">E Shekarchi-Khanghahi, NJ Curtin, R Heer</div><div class="gs_gray">Annual Meeting of the Society-of-Academic-and-Research-Surgery<span class="gs_oph">, 2014</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2014</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:WJVC3Jt7v1AC" class="gsc_a_at">558: p53 and other components of the DNA damage response as determinants of cell sensitivity to ATR inhibition</a><div class="gs_gray">FK Middleton, T Chen, JR Pollard, NJ Curtin</div><div class="gs_gray">European Journal of Cancer, S134<span class="gs_oph">, 2014</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2014</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:UHK10RUVsp4C" class="gsc_a_at">Evaluation of different methods to assess homologous recombination status and sensitivity to PARP inhibitors in ovarian cancer</a><div class="gs_gray">A Mukhopadhyay, M Dixon, E Mulligan, H Schuhwerk, J Murray, J Quinn, ...</div><div class="gs_gray">15th Biennial meeting of the International Gynecologic Cancer Society 24 (9&nbsp;…<span class="gs_oph">, 2014</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2014</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:tkaPQYYpVKoC" class="gsc_a_at">Patterson MJ, Sutton RJ, Forrest I, Sharrock R, Lane M, Kaufmann A</a><div class="gs_gray">R O'Donnell, R Edmondson, BT Wilson, N Curtin</div><div class="gs_gray">British Journal of Cancer 111 (1), 94-100<span class="gs_oph">, 2014</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2014</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:4fKUyHm3Qg0C" class="gsc_a_at">P87 DETECTION OF CIRCULATING TUMOUR CELLS (CTCS) IN HEPATOCELLULAR (HCC) CANCER PATIENTS USING THE IMAGESTREAM</a><div class="gs_gray">L Ogle, D Jamieson, R O'Donnell, B Dent, A Boddy, N Curtin, R Plummer, ...</div><div class="gs_gray">Journal of Hepatology 1 (60), S95<span class="gs_oph">, 2014</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2014</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:VOx2b1Wkg3QC" class="gsc_a_at">Abstract C75: Rucaparib (CO-338) accumulation and persistence of PARP inhibition in vitro and in vivo and efficacy of intermittent vs continuous schedules.</a><div class="gs_gray">JC Murray, HD Thomas, P Berry, S Kyle, C Jones, R Plummer, AV Boddy, ...</div><div class="gs_gray">Molecular Cancer Therapeutics 12 (11 Supplement), C75-C75<span class="gs_oph">, 2013</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2013</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:Ade32sEp0pkC" class="gsc_a_at">首页» 文章» 文章详细信息</a><div class="gs_gray">SA Eccles, EO Aboagye, S Ali, AS Anderson, J Armes, F Berditchevski, ...</div><div class="gs_gray">Breast Cancer Research 15 (5)<span class="gs_oph">, 2013</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2013</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:6bLC7aUMtPcC" class="gsc_a_at">A gap analysis for breast cancer research: identifying translational priorities</a><div class="gs_gray">S Eccles, E Aboagye, S Ali, A Anderson, J Armes, F Berditchevski, ...</div><div class="gs_gray">Breast Cancer Research Review 15 (5), R92<span class="gs_oph">, 2013</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2013</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:OP4eGU-M3BUC" class="gsc_a_at">Abstract PR10: Intra-and intertumor heterogeneity in epithelial ovarian cancer: Consequences for biomarker-dependent stratification of therapies</a><div class="gs_gray">RL O'Donnell, LC Woodhouse, A McCormick, A Kaufmann, M Dixon, ...</div><div class="gs_gray">Clinical Cancer Research 19 (19 Supplement), PR10-PR10<span class="gs_oph">, 2013</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2013</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:_Ybze24A_UAC" class="gsc_a_at">Abstract A33: Therapeutic potential of sapacitabine in ovarian cancers defective in homologous recombination</a><div class="gs_gray">RL O'Donnell, JCC Murray, AGB Buskin, S Frame, DG Blake, M Dixon, ...</div><div class="gs_gray">Clinical Cancer Research 19 (19 Supplement), A33-A33<span class="gs_oph">, 2013</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2013</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:IWHjjKOFINEC" class="gsc_a_at">PARP inhibitor sensitivity in high risk MDS and acute myeloid leukaemia is associated with microsatellite instability dependent frameshift mutations in DNA repair genes</a><div class="gs_gray">TJ Gaymes, AM Mohamedali, M Patterson, N Matto, A Smith, ...</div><div class="gs_gray">Haematologica 98 (9), 1397-1406<span class="gs_oph">, 2013</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2013</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:35r97b3x0nAC" class="gsc_a_at">Development of potent inhibitors of DNA-dependent protein kinase (DNA-PK)</a><div class="gs_gray">L Barrett, T Rennison, KM Clapham, S Rodriguez-Aristegui, J Bardos, ...</div><div class="gs_gray">245th ACS National Meeting and Exposition<span class="gs_oph">, 2013</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2013</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:WqliGbK-hY8C" class="gsc_a_at">Functional Intra-Tumour Heterogeneity in Ovarian Cancer: What is a Representative Tumour Sample?</a><div class="gs_gray">R ODonnell, L Woodhouse, A McCormick, A Mukhopadhyay, M Dixon, ...</div><div class="gs_gray">18th International Meeting of the European Society of Gynaecological&nbsp;…<span class="gs_oph">, 2013</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2013</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:NaGl4SEjCO4C" class="gsc_a_at">1308 A ROLE FOR DNA REPAIR PROTEIN KINASE (DNA-PK) IN THE PROGRESSION OF SIMPLE STEATOSIS TO STEATOHEPATITIS (NASH)?</a><div class="gs_gray">A Whitehead, GL Patman, L Cornell, D Televantou, N Curtin, CP Day, ...</div><div class="gs_gray">Journal of Hepatology, S528<span class="gs_oph">, 2013</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2013</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:TQgYirikUcIC" class="gsc_a_at">The Characterisation and Functional Assessment of Epithelial Ovarian Cancer Cells Derived from Ascitic Fluid using Imagestream</a><div class="gs_gray">M Moat, R ODonnell, B Dent, L Ogle, NJ Curtin, D Jamieson, ...</div><div class="gs_gray">18th International Meeting of the European Society of Gynaecological&nbsp;…<span class="gs_oph">, 2013</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2013</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:_xSYboBqXhAC" class="gsc_a_at">Non homologous end joining assessment in ovarian cancer</a><div class="gs_gray">A McCormick, N Curtin, R Edmondson</div><div class="gs_gray">Bjog: An International Journal of Obstetrics and Gynaecology 119 (6)<span class="gs_oph">, 2012</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2012</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:4OULZ7Gr8RgC" class="gsc_a_at">The DNA-PK inhibitor NU7441 inhibits non-homologous end joining, enhances radio-and chemosensitivity and increases dependence on homologous recombination in hepatocellular&nbsp;…</a><div class="gs_gray">L Cornell, JM Munck, HL Reeves, NJ Curtin</div><div class="gs_gray">Cancer Research 72 (8 Supplement), 3122-3122<span class="gs_oph">, 2012</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2012</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:i2xiXl-TujoC" class="gsc_a_at">194 Targeting the S and G2 checkpoint to treat cancer</a><div class="gs_gray">T Chen, PA Stephens, FK Middleton, NJ Curtin, NO Carragher, ...</div><div class="gs_gray"></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2012</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:u9iWguZQMMsC" class="gsc_a_at">278 Chemosensitisation By, and Single Agent Activity of, ATR Inhibitor VE-821 in Human Breast Cancer Cells</a><div class="gs_gray">FK Middleton, T Chen, JR Pollard, NJ Curtin</div><div class="gs_gray">European Journal of Cancer, 85-86<span class="gs_oph">, 2012</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2012</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:_kc_bZDykSQC" class="gsc_a_at">Abstract A77: Efficacy of PARP inhibitor AG014699 in orthotopic GBM xenografts is limited by ineffective drug penetration into the central nervous system.</a><div class="gs_gray">L Cen, BL Carlson, MA Schroeder, J Murray, J Sludden, AV Boddy, ...</div><div class="gs_gray">Molecular Cancer Therapeutics 10 (11 Supplement), A77-A77<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:u-x6o8ySG0sC" class="gsc_a_at">Poly (ADP ribose) polymerase (PARP) inhibition in peripheral blood lymphocytes (PBLs): Does it reflect PARP inhibition in tumor?</a><div class="gs_gray">DR Shalinsky, DD Wang, KA Kern, P English, NJ Curtin, R Plummer</div><div class="gs_gray">Journal of Clinical Oncology 29 (15_suppl), 3054-3054<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:mNrWkgRL2YcC" class="gsc_a_at">Combined cdk1 and PARP inhibition results in tumor regression in a KrasG12D p53L/L murine lung adenocarcinoma model</a><div class="gs_gray">N Johnson, YC Li, Z Walton, D Li, L Moreau, SJ Rodig, AD D'Andrea, ...</div><div class="gs_gray">Cancer Research 71 (8 Supplement), 2979-2979<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:abG-DnoFyZgC" class="gsc_a_at">Chemosensitization of cancer cells by KU-0060648: A dual inhibitor of DNA-PK and PI-3K</a><div class="gs_gray">MA Batey, JM Munck, Y Zhao, C Cano, M Tavecchio, J Bardos, RJ Griffin, ...</div><div class="gs_gray">Cancer Research 71 (8 Supplement), 2548-2548<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:XvxMoLDsR5gC" class="gsc_a_at">Implications of homologous recombination defectiveness in ovarian cancer</a><div class="gs_gray">RJ Edmondson, A Mukhopadhyay, A Cerbinskaite, NJ Curtin</div><div class="gs_gray">Gynaecological Cancers: Biology and Therapeutics, 75<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:D03iK_w7-QYC" class="gsc_a_at">Dna-pk inhibitors</a><div class="gs_gray">GCM Smith, NMB Martin, KA Menear, MG Hummersone, LJM Rigoreau, ...</div><div class="gs_gray">US Patent 7,732,483<span class="gs_oph">, 2010</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2010</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:q3CdL3IzO_QC" class="gsc_a_at">Development of potent inhibitors of the DNA-dependent protein kinase (DNA-PK)</a><div class="gs_gray">C Cano, C Bailey, J Bardos, N Curtin, M Frigerio, B Golding, I Hardcastle, ...</div><div class="gs_gray">Cancer Research 70 (8 Supplement), 5780-5780<span class="gs_oph">, 2010</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2010</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:q3oQSFYPqjQC" class="gsc_a_at">KU-0060019, a novel small molecule inhibitor of ATM</a><div class="gs_gray">KF Shea, M Albertella, J Bárdos, MA Batey, A Cranston, N Curtin, R Griffin, ...</div><div class="gs_gray">Cancer Research 70 (8 Supplement), 3928-3928<span class="gs_oph">, 2010</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2010</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:LI9QrySNdTsC" class="gsc_a_at">Synthetic lethality in liver cancer cell lines treated with inhibitors of DNA double strand break repair</a><div class="gs_gray">L Cornell, JM Munck, F Budhisetiawan, DR Newell, JI Bardos, D Manas, ...</div><div class="gs_gray">61st Annual Meeting of the American Association for the Study of Liver Diseases<span class="gs_oph">, 2010</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2010</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:evX43VCCuoAC" class="gsc_a_at">Sensitisation of paediatric solid tumours to DNA-damaging chemotherapy by inhibition of DNA-dependent protein kinase (PRKDC)</a><div class="gs_gray">B Vormoor, KE Foy, N Curtin, SC Clifford</div><div class="gs_gray">EJC Supplements: 22nd EORTC-NCI-AACR Symposium on Molecular Targets and&nbsp;…<span class="gs_oph">, 2010</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2010</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:ldfaerwXgEUC" class="gsc_a_at">Daayana, S 1129 Dahl, E 1736 Dahlman, I 1541 Dahlman-Wright, K 1541 Dai, Y 1549</a><div class="gs_gray">A Carracedo, BM Carrington, C Cartier, L Carvajal-Carmona, ...</div><div class="gs_gray">British Journal of Cancer 102 (12), 1794-1801<span class="gs_oph">, 2010</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2010</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:d1gkVwhDpl0C" class="gsc_a_at">443 Development of potent inhibitors of DNA-dependent protein kinase (DNA-PK)</a><div class="gs_gray">KM Clapham, T Rennison, S Rodriguez-Aristegui, J Bardos, NJ Curtin, ...</div><div class="gs_gray">Ejc Supplements 7 (8), 140<span class="gs_oph">, 2010</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2010</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:ILKRHgRFtOwC" class="gsc_a_at">Abstract A138: Development of potent inhibitors of the DNA‐dependent protein kinase (DNA‐PK)</a><div class="gs_gray">C Cano, N Curtin, I Hardcastle, B Golding, G Smith, H Newell, R Griffin</div><div class="gs_gray">Molecular Cancer Therapeutics 8 (12 Supplement), A138-A138<span class="gs_oph">, 2009</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2009</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:XD-gHx7UXLsC" class="gsc_a_at">Exploiting Homologous Recombination Repair Defects in Cancer Cells.: S37</a><div class="gs_gray">N Issaeva, H Thomas, N Pedley, T Djurenovic, C Lundin, E Gubanova, ...</div><div class="gs_gray">Environmental &amp; Molecular Mutagenesis 50 (7)<span class="gs_oph">, 2009</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2009</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:08ZZubdj9fEC" class="gsc_a_at">Abstract# 3019: Validated sensitive immunological determination of PARP-1 protein levels and activity in cultured cells and human lymphocytes</a><div class="gs_gray">E Mulligan, T Zaremba, Y Drew, Z Hostomsky, E Plummer, N Curtin</div><div class="gs_gray">Cancer Research 69 (9 Supplement), 3019-3019<span class="gs_oph">, 2009</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2009</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:K3LRdlH-MEoC" class="gsc_a_at">Abstract# 3312: Transient treatment with CDK inhibitors eliminates proliferative potential even when their abilities to evoke apoptosis and DNA damage are blocked</a><div class="gs_gray">S Scrace, P Kierstan, J Borgognoni, LZ Wang, S Denny, J Wayne, ...</div><div class="gs_gray">Cancer Research 69 (9 Supplement), 3312-3312<span class="gs_oph">, 2009</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2009</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:p2g8aNsByqUC" class="gsc_a_at">Abstract# LB-47: Central nervous system (CNS) penetration, poly-ADP ribose polymerase (PARP) inhibition and enhancement of temozolomide activity against childhood&nbsp;…</a><div class="gs_gray">R Daniel, A Rozanska, E Mulligan, Y Drew, H Thomas, D Castelbuono, ...</div><div class="gs_gray">Cancer Research 69 (9 Supplement), LB-47-LB-47<span class="gs_oph">, 2009</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2009</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:hqOjcs7Dif8C" class="gsc_a_at">Abstract# 521: Poly (ADP-ribose) polymerase-1 polymorphisms, expression and activity in a panel of human tumor cell lines</a><div class="gs_gray">T Zaremba, P Ketzer, E Plummer, S Coulthard, M Cole, N Curtin</div><div class="gs_gray">Cancer Research 69 (9 Supplement), 521-521<span class="gs_oph">, 2009</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2009</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:_5tno0g5mFcC" class="gsc_a_at">Effective sensitization of temozolomide by ABT-888 is lost with development of temozolomide resistance in glioblastoma</a><div class="gs_gray">X Lines, MJ Clarke, EA Mulligan, PT Grogan, AC Mladek, BL Carlson, ...</div><div class="gs_gray">Molecular cancer therapeutics 8 (2), 407-414<span class="gs_oph">, 2009</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2009</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:wbdj-CoPYUoC" class="gsc_a_at">Validated sensitive immunological determination of PARP-1 protein levels and activity in cultured cells and human lymphocytes</a><div class="gs_gray">EA Mulligan, T Zaremba, Y Drew, Z Hostomsky, ER Plummer, NJ Curtin</div><div class="gs_gray">Proceedings of the 100th Annual Meeting of the American Association for&nbsp;…<span class="gs_oph">, 2009</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2009</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:CHSYGLWDkRkC" class="gsc_a_at">Central nervous system (CNS) penetration, poly-ADP ribose polymerase (PARP) inhibition and enhancement of temozolomide activity against childhood medulloblastoma by AG-014699</a><div class="gs_gray">RA Daniel, A Rozanska, EA Mulligan, E Drew, HD Thomas, ...</div><div class="gs_gray">Proceedings of the 100th Annual Meeting of the American Association for&nbsp;…<span class="gs_oph">, 2009</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2009</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:0N-VGjzr574C" class="gsc_a_at">Potent <i>in vitro</i> and <i>in vivo</i> radiosensitisation by the selective DNA-dependent protein kinase inhibitor KU-0060648</a><div class="gs_gray">M Albertella, A Slade, K Shea, J Bardos, C Richardson, M Batey, ...</div><div class="gs_gray">Cancer Research 68 (9 Supplement), 406-406<span class="gs_oph">, 2008</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2008</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:ZfRJV9d4-WMC" class="gsc_a_at">Chemosensitisation of cancer cells by KU-0060648, a potent and selective inhibitor of DNA-PK</a><div class="gs_gray">M Batey, Y Zhao, K Shea, J Bardos, C Richardson, H Jenkins, A Slade, ...</div><div class="gs_gray">Cancer Research 68 (9 Supplement), 4080-4080<span class="gs_oph">, 2008</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2008</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:LjlpjdlvIbIC" class="gsc_a_at">Chemosensitisation by tricyclic poly(ADP-ribose) polymerase (PARP) inhibitors <i>in vivo</i>: More than just DNA repair?</a><div class="gs_gray">K Williams, B Telfer, M Ali, M Kamjoo, H Thomas, M O'Rourke, ...</div><div class="gs_gray">Cancer Research 68 (9 Supplement), 1125-1125<span class="gs_oph">, 2008</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2008</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:uWQEDVKXjbEC" class="gsc_a_at">Preclinical <i>in vitro </i>and <i>in vivo</i> evaluation of the cyclin dependent kinase 2 inhibitor NU6102 and a water pro-drug NU6301</a><div class="gs_gray">D Newell, H Thomas, L Wang, C Roche, J Bentley, Y Cheng, I Hardcastle, ...</div><div class="gs_gray">Cancer Research 68 (9 Supplement), 2413-2413<span class="gs_oph">, 2008</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2008</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:sSrBHYA8nusC" class="gsc_a_at">PARP-1 INHIBITORS IN CANCER</a><div class="gs_gray">H Calvert, R Plummer, N Curtin, R Edmondson, Y Drew</div><div class="gs_gray">CURRENT TREATMENT OPTIONS IN ONCOLOGY 9 (1), 32-32<span class="gs_oph">, 2008</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2008</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:qUcmZB5y_30C" class="gsc_a_at">Rationale for and development of PARP inhibitors for cancer therapy</a><div class="gs_gray">NJ Curtin</div><div class="gs_gray">ANNALS OF ONCOLOGY 19, 19-19<span class="gs_oph">, 2008</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2008</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:LkGwnXOMwfcC" class="gsc_a_at">127 POSTER Development of potent water-soluble inhibitors of the DNA-dependent protein kinase (DNA-PK)</a><div class="gs_gray">C Cano, NJ Curtin, BT Golding, K Haggerty, IR Hardcastle, ...</div><div class="gs_gray">Ejc Supplements 12 (6), 41-42<span class="gs_oph">, 2008</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2008</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:7PzlFSSx8tAC" class="gsc_a_at">Design and synthesis of inhibitors of cyclin-dependent kinases as potential antitumor agents</a><div class="gs_gray">F Marchetti, N Curtin, B Golding, R Griffin, I Hardcastle, D Newell, L Wang</div><div class="gs_gray">Molecular Cancer Therapeutics 6 (11 Supplement), B245-B245<span class="gs_oph">, 2007</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2007</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:kh2fBNsKQNwC" class="gsc_a_at">PRECLINICAL EVALUATION OF THE POLY-ADP RIBOSE POLYMERASE 1 (PARP-1) INHIBITOR AG014699 IN COMBINATION WITH TOPOTECAN AND TEMOZOLOMIDE FOR THE TREATMENT OF MEDULLOBLASTOMA AND&nbsp;…</a><div class="gs_gray">S Clifford, R Daniel, A Rozanska, H Thomas, A Boddy, D Tweddle, ...</div><div class="gs_gray">Pediatric Blood &amp; Cancer 49 (4), 434-435<span class="gs_oph">, 2007</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2007</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:O3NaXMp0MMsC" class="gsc_a_at">Molecular bases of cancer metastasis: H-prune-nm23 protein complex in cancer</a><div class="gs_gray">M Zollo Sr, L Garzia, P Carotenuto, N Marino, C Roma, N Tata, A Bello, ...</div><div class="gs_gray">Cancer Research 66 (8 Supplement), 1008-1008<span class="gs_oph">, 2006</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2006</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:iH-uZ7U-co4C" class="gsc_a_at">Activation of Poly (ADP-ribose) polymerase-1 and DNA-dependent protein kinase by blunt and overhanging DNA double strand termini and their role in DNA double strand break repair</a><div class="gs_gray">J Mitchell, GC Smith, N Curtin</div><div class="gs_gray">Cancer Research 66 (8 Supplement), 124-124<span class="gs_oph">, 2006</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2006</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:u5HHmVD_uO8C" class="gsc_a_at">Chemo-sensitization by the novel ATM inhibitor (KU-55933) is p53 independent</a><div class="gs_gray">Y Zhao, Y Lu, DR Newell, A Lau, N Harris, GCM Smith, NJ Curtin</div><div class="gs_gray">Cancer Research 66 (8 Supplement), 486-486<span class="gs_oph">, 2006</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2006</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:PYBJJbyH-FwC" class="gsc_a_at">PARP inhibitors and cancer therapy</a><div class="gs_gray">NJ Curtin</div><div class="gs_gray">Poly (ADP-ribosyl)ation edited by A Burkle 1, 218-233<span class="gs_oph">, 2006</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2006</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:1sJd4Hv_s6UC" class="gsc_a_at">42 ATM and DNA-PK inhibitors: Functional significance, mechanism of action and clinical application</a><div class="gs_gray">A Slade, M Batey, N Curtin, M Frigerio, M Hummersone, S Jackson, ...</div><div class="gs_gray">Radiotherapy and Oncology, S15<span class="gs_oph">, 2006</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2006</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:OU6Ihb5iCvQC" class="gsc_a_at">Comparative activity of the potent selective CDK2 inhibitor NU6102 in CDK2 wild-type and knock-out mouse embryo fibroblasts</a><div class="gs_gray">Y Cheng, LZ Wang, NJ Curtin, DR Newell</div><div class="gs_gray">Cancer Research 65 (9 Supplement), 1043-1044<span class="gs_oph">, 2005</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2005</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:43bX7VzcjpAC" class="gsc_a_at">Tricyclic parp inhibitors</a><div class="gs_gray">T Helleday, N Curtin</div><div class="gs_gray"></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2005</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:kz9GbA2Ns4gC" class="gsc_a_at">The role of PARP-1 and DNA-PK in the repair of DNA double strand breaks</a><div class="gs_gray">JR Mitchell, H Newell, GC Smith, NJ Curtin</div><div class="gs_gray">AACR/NCI/EORTC International Conference on Molecular Targets and Cancer&nbsp;…<span class="gs_oph">, 2005</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2005</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:W5xh706n7nkC" class="gsc_a_at">Searching for potent CDK2 inhibitors using a variant of the Cope elimination</a><div class="gs_gray">A Henderson, YZ Cheng, NJ Curtin, JA Endicott, BT Golding, RJ Griffin, ...</div><div class="gs_gray">230th National Meeting of the American Chemical Society<span class="gs_oph">, 2005</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2005</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:eQOLeE2rZwMC" class="gsc_a_at">Potent CDK2 inhibitors generated using a variant of the cope elimination</a><div class="gs_gray">RJ Griffin, AJ Henderson, YZ Cheng, NJ Curtin, JA Endicott, BT Golding, ...</div><div class="gs_gray">AACR/NCI/EORTC International Conference on Molecular Targets and Cancer&nbsp;…<span class="gs_oph">, 2005</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2005</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:fbc8zXXH2BUC" class="gsc_a_at">Identification and <i>in vitro</i> characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM</a><div class="gs_gray">I Hickson, Y Zhao, X Cockcroft, NJ Curtin, SJ Green, M Hummersone, ...</div><div class="gs_gray">Cancer Research 64 (7 Supplement), 1236-1236<span class="gs_oph">, 2004</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2004</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:LO7wyVUgiFcC" class="gsc_a_at">A phase II mechanistic study of temozolomide in metastatic melanoma involving development of a PARP-1 activity assay suitable for clinical samples.</a><div class="gs_gray">R Plummer, M Middleton, N Curtin, A Olsen, C Jones, A Clark, A Boddy, ...</div><div class="gs_gray">Cancer Research 64 (7 Supplement), 705-705<span class="gs_oph">, 2004</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2004</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:5Ul4iDaHHb8C" class="gsc_a_at">The use of novel CDK inhibitors in the treatment of hormone refractory breast cancer</a><div class="gs_gray">N Johnson, NJ Curtin</div><div class="gs_gray">Cancer Research 64 (7 Supplement), 190-190<span class="gs_oph">, 2004</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2004</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:Se3iqnhoufwC" class="gsc_a_at">Cyclin dependent kinase inhibitors</a><div class="gs_gray">RJ Griffin, AH Calvert, NJ Curtin, DR Newell, BT Golding, JA Endicott, ...</div><div class="gs_gray">US Patent 6,677,345<span class="gs_oph">, 2004</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2004</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:Y5dfb0dijaUC" class="gsc_a_at">478 Preclinical investigation of novel inhibitors of DNA dependent protein kinase</a><div class="gs_gray">MA Batey, Y Zhao, HD Thomas, GCM Smith, DR Newell, NJ Curtin</div><div class="gs_gray">EJC Supplements 8 (2), 146<span class="gs_oph">, 2004</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2004</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:WA5NYHcadZ8C" class="gsc_a_at">Experimental Therapeutics, Preclinical Pharmacology-Novel Poly (ADP-ribose) Polymerase-1 Inhibitor, AG14361, Restores Sensitivity to Temozolomide in Mismatch Repair-Deficient&nbsp;…</a><div class="gs_gray">NJ Curtin, LZ Wang, A Yiakouvaki, S Kyle, CA Arris, S Canan-Koch, ...</div><div class="gs_gray">Clinical Cancer Research 10 (3), 881-889<span class="gs_oph">, 2004</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2004</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:pyW8ca7W8N0C" class="gsc_a_at">Therapeutic Compounds.</a><div class="gs_gray">T Helleday, NJ Curtin</div><div class="gs_gray"></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2004</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:zYLM7Y9cAGgC" class="gsc_a_at">The effects of a novel CDK inhibitor on tamoxifen sensitive and resistant breast cancer cell lines</a><div class="gs_gray">NL Johnson, NJ Curtin</div><div class="gs_gray">British Cancer Research Meeting<span class="gs_oph">, 2004</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2004</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:1taIhTC69MYC" class="gsc_a_at">DNA-binding specificity of wild type and two mutant forms of human poly (ADP-ribosyl) ated-p53</a><div class="gs_gray">R Alvarez-Gonzalez, H Zentgraf, M Frey, H Mendoza-Alvarez</div><div class="gs_gray">Medical Science Monitor 9 (1), 1-0<span class="gs_oph">, 2003</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2003</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:oNZyr7d5Mn4C" class="gsc_a_at">Competition and co-operation of PARP-1 and DNA-PK in the repair of DNA strand breaks</a><div class="gs_gray">S Veuger, N Curtin, A Calvert, D Newell, R Griffin, G Smith, Z Hostomsky, ...</div><div class="gs_gray">Medical Science Monitor 9 (1), 74<span class="gs_oph">, 2003</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2003</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:vRqMK49ujn8C" class="gsc_a_at">Pre-clinical development of PARP-1 inhibitors for cancer therapy</a><div class="gs_gray">N Curtin, M Batey, T Boritzki, C Calabrese, S Canan-Koch, R Griffin, ...</div><div class="gs_gray">Medical Science Monitor 9 (1), 18<span class="gs_oph">, 2003</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2003</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:rHJHxKgnXwkC" class="gsc_a_at">Thiopyrane-4-ones as dna protein kinase inhibitors</a><div class="gs_gray">RJ Griffin, BT Golding, DR Newell, HA Calvert, NJ Curtin, IR Hardcastle, ...</div><div class="gs_gray"></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2003</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:AHdEip9mkN0C" class="gsc_a_at">Experimental Therapeutics, Preclinical Pharmacology-Identification of Potent Nontoxic Poly (ADP-Ribose) Polymerase-1 Inhibitors: Chemopotentiation and Pharmacological Studies.</a><div class="gs_gray">CR Calabrese, MA Batey, HD Thomas, BW Durkacz, LZ Wang, S Kyle, ...</div><div class="gs_gray">Clinical Cancer Research 9 (7), 2711-2718<span class="gs_oph">, 2003</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2003</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:eq2jaN3J8jMC" class="gsc_a_at">Experimental Therapeutics, Molecular Targets, and Chemical Biology-Radiosensitization and DNA Repair Inhibition by the Combined Use of Novel Inhibitors of DNA-dependent Protein&nbsp;…</a><div class="gs_gray">SJ Veuger, NJ Curtin, CJ Richardson, GCM Smith, BW Durkacz</div><div class="gs_gray">Cancer Research 63 (18), 6008-6015<span class="gs_oph">, 2003</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2003</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:ubry08Y2EpUC" class="gsc_a_at">PUBLICATIONS: W. CLEGG 2002</a><div class="gs_gray">W Clegg, DG Watson, JS Northen, FT Boyle, NJ Curtin, AJ Edwards, ...</div><div class="gs_gray">Acta Cryst 58, m121-m122<span class="gs_oph">, 2002</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2002</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:-_dYPAW6P2MC" class="gsc_a_at">Pyrimidopyrimidine compounds</a><div class="gs_gray">RJ Griffin, NJ Curtin, BT Golding, AH Calvert, DR Newell</div><div class="gs_gray">US Patent 6,297,250<span class="gs_oph">, 2001</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2001</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:OTTXONDVkokC" class="gsc_a_at">Tumour radiosensitisation using TBI-361, an inhibitor of poly (ADP-reibose) polymerase (PARP).</a><div class="gs_gray">KJ Williams, L Wang, B Telfer, N Curtin, DR Newell, Z Hostomski, ...</div><div class="gs_gray">Proc. EORTC Int. Conference: Molecular Targets and Cancer Therapeutics<span class="gs_oph">, 2001</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2001</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:URolC5Kub84C" class="gsc_a_at">Inhibiting the MDM2-p53 interaction using low molecular weight compounds</a><div class="gs_gray">G Farnie, H Atkins, AH Calvert, NJ Curtin, BT Golding, RJ Griffin, ...</div><div class="gs_gray">BRIT J CANCER 85, 81-81<span class="gs_oph">, 2001</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2001</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:1qzjygNMrQYC" class="gsc_a_at">Structure based design of a potent inhibitor of CDK2</a><div class="gs_gray">TG Davies, JA Endicott, LN Johnson, MEM Noble, CE Arris, J Bentley, ...</div><div class="gs_gray">Cellular and Molecular Biology Letters 6 (2B)<span class="gs_oph">, 2001</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2001</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:r0BpntZqJG4C" class="gsc_a_at">Regular Articles-Experimental Therapeutics, Preclinical Pharmacology-In Vitro and in Vivo Properties of Novel Nucleoside Transport Inhibitors with Improved Pharmacological&nbsp;…</a><div class="gs_gray">PG Smith, HD Thomas, HC Barlow, RJ Griffin, BT Golding, AH Calvert, ...</div><div class="gs_gray">Clinical Cancer Research 7 (7), 2105-2113<span class="gs_oph">, 2001</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2001</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:0KyAp5RtaNEC" class="gsc_a_at">Structure activity relationship, crystal structure, and biological evaluation of potent poly (ADP-ribose) polymerase-1 inhibitors.</a><div class="gs_gray">SSC Koch, LH Thoresen, JG Tikhe, KA Maegley, J Li, XH Yu, RJ Almassy, ...</div><div class="gs_gray">ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 220, U538-U538<span class="gs_oph">, 2000</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2000</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:DBa1UEJaJKAC" class="gsc_a_at">O6-substituted guanines and 4-substituted pyrimidines: a novel class of antiproliferative cyclin dependent kinase inhibitors with distinct molecular interactions and tumor cell&nbsp;…</a><div class="gs_gray">CE Arris, FT Boyle, AH Calvert, NJ Curtin, P Jewsbury, JA Endicott, ...</div><div class="gs_gray">Journal of Medicinal Chemistry<span class="gs_oph">, 2000</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2000</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:rmuvC79q63oC" class="gsc_a_at">Design, synthesis, and biological evaluation of O-6-alkylguanine and O-4-alkylpyrimidine cyclin-dependent kinase inhibitors</a><div class="gs_gray">RJ Griffin, CE Arris, AH Calvert, NJ Curtin, P Jewsbury, JA Endicott, ...</div><div class="gs_gray">Abstracts of Papers of the American Chemical Society<span class="gs_oph">, 2000</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2000</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:FPJr55Dyh1AC" class="gsc_a_at">Chemopotentiation studies with two classes of potent (polyADP-ribose) polymerase (PARP) inhibitors in human lung and colon carcinoma cell lines</a><div class="gs_gray">NJ Curtin, AH Calvert, S Canan-Koch, BW Durkacz, RJ Griffin, BT Golding, ...</div><div class="gs_gray">Clinical Cancer Research 6, 205-<span class="gs_oph">, 2000</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2000</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:XoXfffV-tXoC" class="gsc_a_at">Experimental Therapeutics, Preclinical Pharmacology-Potentiation of Temozolomide and Topotecan Growth Inhibition and Cytotoxicity by Novel Poly (adenosine Diphosphoribose&nbsp;…</a><div class="gs_gray">CA Delaney, LZ Wang, S Kyle, AW White, AH Calvert, NJ Curtin, ...</div><div class="gs_gray">Clinical Cancer Research 6 (7), 2860-2867<span class="gs_oph">, 2000</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2000</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:PoWvk5oyLR8C" class="gsc_a_at">Experimental Therapeutics, Preclinical Pharmacology-Cellular ATP Depletion by LY309887 as a Predictor of Growth Inhibition in Human Tumor Cell Lines</a><div class="gs_gray">X Lu, J Errington, VJ Chen, NJ Curtin, AV Boddy, DR Newell</div><div class="gs_gray">Clinical Cancer Research 6 (1), 271-277<span class="gs_oph">, 2000</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2000</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:p__nRnzSRKYC" class="gsc_a_at">EXPERIMENTAL THERAPEUTICS-Cellular glutathione as a determinant of the sensitivity of colorectal tumour cell-lines to ZD2767 anti-body-directed enzyme prodrug therapy (ADEPT)</a><div class="gs_gray">NR Monks, JA Calvete, NJ Curtin, DC Blakey, SJ East, DR Newell</div><div class="gs_gray">British Journal of Cancer 83 (2), 267-269<span class="gs_oph">, 2000</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2000</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:BrmTIyaxlBUC" class="gsc_a_at"><i>In vitro</i> activity and <i>in vivo</i> pharmacology of two novel nucleoside transport inhibitors, NU3108 and NU3121</a><div class="gs_gray">PG Smith, HD Thomas, HC Barlow, RJ Griffin, BT Golding, AH Calvert, ...</div><div class="gs_gray">Clinical Cancer Research<span class="gs_oph">, 2000</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2000</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:NhqRSupF_l8C" class="gsc_a_at">Structure-activity relationships and cellular effects of novel purine-and pyrimidine-based cyclin dependent kinase inhibitors</a><div class="gs_gray">BT Golding, RJ Griffin, CE Arris, AE Gibson, J Bentley, AH Calvert, ...</div><div class="gs_gray">Clinical Cancer Research<span class="gs_oph">, 2000</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2000</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:UeHWp8X0CEIC" class="gsc_a_at">Design and evaluation of novel potent inhibitors of poly (ADP-ribose) polymerase.</a><div class="gs_gray">CR Calabrese, NJ Curtin, SS Canan-Koch, MA Batey, HD Thomas, S Kyle, ...</div><div class="gs_gray">CLIN CANCER RES 6, 4496S-4496S<span class="gs_oph">, 2000</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2000</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:2VqYfGB8ITEC" class="gsc_a_at">Graft inhibitor LY309887 cytotoxicity correlates with ATP depletion but not with p53 status in human tumour cell lines</a><div class="gs_gray">X Lu, J Errington, J Lunec, VJ Chen, NJ Curtin, AV Boddy, DR Newell</div><div class="gs_gray">BRITISH JOURNAL OF CANCER 80, 49-49<span class="gs_oph">, 1999</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1999</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:PVgj2kMGcgYC" class="gsc_a_at">EXPERIMENTAL ONCOLOGY-Potentiation of the cytotoxicity of thymidylate synthase (TS) inhibitors by dipyridamole analogues with reduced a 1)-acid glycoprotein binding</a><div class="gs_gray">NJ Curtin, KJ Bowman, RN Turner, B Huang, PJ Loughlin, AH Calvert, ...</div><div class="gs_gray">British Journal of Cancer 80 (11), 1738-1746<span class="gs_oph">, 1999</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1999</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:IRz6iEL74y4C" class="gsc_a_at">Potentiation of temozolomide and topotecan cytotoxicity by PARP inhibitors in a panel of human cancer cell lines.</a><div class="gs_gray">CA Delaney, LZ Wang, LZ Kyle, S Srinivasan, AW White, NJ Curtin, ...</div><div class="gs_gray">BRIT J CANCER 80, 44-44<span class="gs_oph">, 1999</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1999</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:GtLg2Ama23sC" class="gsc_a_at">2, 6-Disubstituted-4, 8-dibenzylaminopyrimido [5, 4-d] pyrimidines as nucleoside transport inhibitors: Structure-activity relationships for binding to alpha (1)-acid&nbsp;…</a><div class="gs_gray">RJ Griffin, HC Barlow, NJ Curtin, AH Calvert, BT Golding, DR Newell, ...</div><div class="gs_gray">CLIN CANCER RES 5, 3843S-3843S<span class="gs_oph">, 1999</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1999</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:hMsQuOkrut0C" class="gsc_a_at">MTA (LY231514) induced intracellular dNTP pool pertubations are alleviated by salvage of pre-formed purines and pyrimidines</a><div class="gs_gray">PG Smith, J Bewley, JA Gogel, AH Calvert, DR Newell, NJ Curtin, ...</div><div class="gs_gray">British Journal of Cancer 80, 83-<span class="gs_oph">, 1999</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1999</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:XiVPGOgt02cC" class="gsc_a_at">Potentiation of temozolomide and topotecan growth inhibition by novel potent benzimidazole poly (ADP-ribose) polymerase (PARP) inhibitors</a><div class="gs_gray">NJ Curtin, S Kyle, LZ Wang, BW Durkacz, AJ White, S Srinivasan, ...</div><div class="gs_gray">Clinical Cancer Research 5, 520-<span class="gs_oph">, 1999</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1999</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:_Qo2XoVZTnwC" class="gsc_a_at">Novel dipyridamole analogues potentiate the in vitro activity of MTA (LY231514) in the presence of alpha (1)-acid glycoprotein</a><div class="gs_gray">PG Smith, HC Barlow, P Loughlin, B Huang, KJ Bowman, AH Calvert, ...</div><div class="gs_gray">British Journal of Cancer 80, 82-<span class="gs_oph">, 1999</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1999</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:HDshCWvjkbEC" class="gsc_a_at">Preclinical pharmacology of novel substituted benzimidazoles-potent inhibitors of poly (ADP-ribose) polymerase</a><div class="gs_gray">CR Calabrese, HD Thomas, MA Batey, T Boritzki, K Zhang, AW White, ...</div><div class="gs_gray">Clinical Cancer Research 5, 543-<span class="gs_oph">, 1999</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1999</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:GFxP56DSvIMC" class="gsc_a_at">2-phenylbenzimidazole-4-carboxamides are potent inhibitors of the DNA repair enzyme poly (ADP-ribose)-polymerase (PARP)</a><div class="gs_gray">R Almassy, K Bowman, AH Calvert, NJ Curtin, BT Golding, Z Hostomska, ...</div><div class="gs_gray">Annals of Oncology 9, 116-<span class="gs_oph">, 1998</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1998</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:F9fV5C73w3QC" class="gsc_a_at">Induction of apoptosis in LoVo colorectal cells by the ADEPT system ZD2767: A comparison with chlorambucil and a mono-functional ZD2767 analogue</a><div class="gs_gray">NR Monks, DR Newell, NJ Curtin, DC Blakey, SJ East, A Heuze</div><div class="gs_gray">10th NCI-EORTC Symposium on New Drugs in Cancer Therapy<span class="gs_oph">, 1998</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1998</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:mlAyqtXpCwEC" class="gsc_a_at">Insights into CDK inhibitor design from X-ray crystallographic studies</a><div class="gs_gray">J Endicott, M Noble, A Lawrie, P Tunnah, N Brown, L Johnson, A Calvert, ...</div><div class="gs_gray">ANN ONCOL 9, 3-3<span class="gs_oph">, 1998</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1998</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:SdhP9T11ey4C" class="gsc_a_at">Potentiation of the in vitro activity of the multi-targeted antifolate MTA (LY231514) by dipyridamole</a><div class="gs_gray">PG Smith, DR Newell, MJ Barnes, AH Calvert, NJ Curtin</div><div class="gs_gray">Annals of Oncology 9, 588-<span class="gs_oph">, 1998</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1998</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:RGFaLdJalmkC" class="gsc_a_at">Dipyridamole selectively potentiates antipurine antifolates in human tumour cell lines but not normal tissue targets of dose-limiting toxicity</a><div class="gs_gray">E Marshman, AH Calvert, DR Newell, NJ Curtin</div><div class="gs_gray">Annals of Oncology 9, 589-<span class="gs_oph">, 1998</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1998</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:4TOpqqG69KYC" class="gsc_a_at">O-6-alkylguanines as selective inhibitors of cyclin dependent kinases</a><div class="gs_gray">S Grant, F Boyle, AH Calvert, NJ Curtin, J Endicott, BT Golding, RJ Griffin, ...</div><div class="gs_gray">Annals of Oncology 9, 523-<span class="gs_oph">, 1998</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1998</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:yqoGN6RLRZoC" class="gsc_a_at">Mechanism-based inhibition of O-6-methylguanine-DNA methyltransferase.</a><div class="gs_gray">CE Arris, C Bleasdale, FT Boyle, AH Calvert, NJ Curtin, C Dalby, ...</div><div class="gs_gray">ABSTR PAP AM CHEM S 212, 99-TOXI<span class="gs_oph">, 1996</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1996</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:foquWX3nUaYC" class="gsc_a_at">Novel potent inhibitors of the DNA repair enzyme poly (ADP-ribose) polymerase</a><div class="gs_gray">RJ Griffin, K Bowman, AH Calvert, NJ Curtin, BT Golding, DR Newell, ...</div><div class="gs_gray">Journal of Pharmacy and Pharmacology 47 (12), 1074-1074<span class="gs_oph">, 1995</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1995</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:YsMSGLbcyi4C" class="gsc_a_at">DIPYRIDAMOLE ENHANCES INCREASED INTRACELLULAR DUTP AND DNA STRAND BREAKAGE IN A549 (HUMAN LUNG-CARCINOMA) CELLS TREATED WITH CB3717</a><div class="gs_gray">NJ CURTIN, GW AHERNE, AL HARRIS</div><div class="gs_gray">BRITISH JOURNAL OF CANCER 62 (3), 508-508<span class="gs_oph">, 1990</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1990</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:HoB7MX3m0LUC" class="gsc_a_at">INCREASED 2'-DEOXYURIDINE 5'-TRIPHOSPHATE LEVELS ARE RELATED TO CYTOTOXICITY IN HUMAN LUNG-CARCINOMA CELLS EXPOSED TO THE THYMIDYLATE SYNTHASE INHIBITOR N-10-PROPARGYL-5, 8&nbsp;…</a><div class="gs_gray">NJ CURTIN, E PIALL, W AHERNE, S AIKENHEAD, AL HARRIS</div><div class="gs_gray">MUTAGENESIS 5 (1), 99-99<span class="gs_oph">, 1990</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1990</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:tKAzc9rXhukC" class="gsc_a_at">POTENTIATION OF CB3717 TOXICITY BY DIPYRIDAMOLE IN A549 CELLS</a><div class="gs_gray">NJ CURTIN, AL HARRIS</div><div class="gs_gray">BRITISH JOURNAL OF CANCER 56 (2), 196-196<span class="gs_oph">, 1987</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1987</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:V3AGJWp-ZtQC" class="gsc_a_at">THE QUANTIFICATION OF 2'-DEOXYURIDINE 5'-TRIPHOSPHATE IN ANTIFOLATE TREATED-CELLS USING A SENSITIVE RADIOIMMUNOASSAY</a><div class="gs_gray">E PIALL, N CURTIN, W AHERNE, A HARRIS, V MARKS</div><div class="gs_gray">CLINICAL SCIENCE 73, P18-P18<span class="gs_oph">, 1987</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1987</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:tS2w5q8j5-wC" class="gsc_a_at">INDUCTION OF REMISSION IN PRIMARY LIVER-CELL CANCER (PLC) WITH A NEW THYMIDYLATE SYNTHASE INHIBITOR, CB3717-A PHASE-II STUDY</a><div class="gs_gray">MF BASSENDINE, NJ CURTIN, AL HARRIS, OFW JAMES</div><div class="gs_gray">GUT 27 (10), 1249-1250<span class="gs_oph">, 1986</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1986</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:hCrLmN-GePgC" class="gsc_a_at">Primary Hepatocellular Carcinoma Localisation using A Radiolabelled Monoclonal Antibody</a><div class="gs_gray">NI Markham, OFW James, K Sikora, MF Bassendine, N Curtin, A Ritson, ...</div><div class="gs_gray">Clinical Science 69 (s12), 24P-24P<span class="gs_oph">, 1985</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1985</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:P7Ujq4OLJYoC" class="gsc_a_at">LOCALIZATION OF PRIMARY HEPATOCELLULAR-CARCINOMA USING A RADIOLABELED MONOCLONAL-ANTIBODY</a><div class="gs_gray">NI MARKHAM, A RITSON, MF BASSENDINE, OFW JAMES, NJ CURTIN, ...</div><div class="gs_gray">BRITISH JOURNAL OF SURGERY 71 (11), 906-906<span class="gs_oph">, 1984</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1984</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:bz8QjSJIRt4C" class="gsc_a_at">A NEW QUINAZOLINE ANTIFOLATE DRUG CB3717 WHICH INHIBITS THE GROWTH OF HUMAN-LIVER CANCER-CELLS IN ATHYMIC MICE, CELL-CULTURE AND PATIENTS</a><div class="gs_gray">N CURTIN, AL HARRIS, OFW JAMES, MF BASSENDINE</div><div class="gs_gray">BRITISH JOURNAL OF CANCER 50 (2), 265-265<span class="gs_oph">, 1984</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1984</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:JQOojiI6XY0C" class="gsc_a_at">SUCCESSFUL TREATMENT OF HUMAN PRIMARY LIVER-CANCER XENOGRAFT BY NEW QUINAZOLINE ANTI-FOLATE AGENT CB-3717</a><div class="gs_gray">MF BASSENDINE, NJ CURTIN, K WOODHOUSE, AL HARRIS, ...</div><div class="gs_gray">GUT 24 (10), A984-A984<span class="gs_oph">, 1983</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1983</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:q-HalDI95KYC" class="gsc_a_at">Ovary: Oral Abstract</a><div class="gs_gray">A Mukhopadhyay, N Curtin, R Edmondson</div><div class="gs_gray"></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl"></span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:CdxZDUztZiMC" class="gsc_a_at">PARP and PARP Inhibitor</a><div class="gs_gray">NJ Curtin</div><div class="gs_gray"></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl"></span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:1yWc8FF-_SYC" class="gsc_a_at">Investigating BRCAness in Epithelial Ovarian Cancer (EOC) in India to Develop Stratified Surgical and Chemotherapy Options</a><div class="gs_gray">CM Siddikuzzaman, S Moulik, H Smith, S Johnson, A Mukherjee, ...</div><div class="gs_gray"></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl"></span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:LdasjJ6CEcoC" class="gsc_a_at">PMC2374405.</a><div class="gs_gray">BT Golding, S Grant, RJ Griffin, P Jewsbury, LN Johnson, V Mesguiche, ...</div><div class="gs_gray"></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl"></span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:SpbeaW3--B0C" class="gsc_a_at">Ewing’s sarcoma cells can be sensitized to temozolomide and to a lesser extent to radiotherapy by co-treatment with a PARP-inhibitor (Rucaparib, AG014699)</a><div class="gs_gray">B Vormoor, S Wilkinson, Y Schlosser, F Harvey, R Plummer, N Curtin</div><div class="gs_gray"></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl"></span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:738O_yMBCRsC" class="gsc_a_at">Targeting apurinic/apyrimidinic endonuclease-redox factor 1 (APE1/REF-1) as a therapeutic strategy in acute myeloid leukemia (AML)</a><div class="gs_gray">M Nahari, J Allan, N Curtin</div><div class="gs_gray"></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl"></span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:EUQCXRtRnyEC" class="gsc_a_at">Phase II trial of the Poly (ADP-ribose) polymerase (PARP) inhibitor AG-014699 in BRCA 1 and 2 mutated advanced ovarian and breast cancer</a><div class="gs_gray">Y Drew, J Ledermann, A Jones, G Hall, G Jayson, M Highley, D Rea, ...</div><div class="gs_gray"></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl"></span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=FhFQsc8AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=FhFQsc8AAAAJ:cFHS6HbyZ2cC" class="gsc_a_at">Acknowledgement to Reviewers of Cancers in 2014</a><div class="gs_gray">K Abdelmohsen, K Akimoto, L Albiges, F Al-Ejeh, V Alexeev, M Alison, ...</div><div class="gs_gray"></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl"></span></td></tr></tbody></table><div id="gsc_a_sp" class=""></div><div id="gsc_a_err" class="gs_alrt">The system can't perform the operation now. Try again later.</div></div><div id="gsc_lwp"><span id="gsc_a_nn">Articles 1–396</span><div id="gsc_bpf"><button type="button" id="gsc_bpf_more" class="gs_btnPD gs_in_ib gs_btn_flat gs_btn_lrge gs_btn_lsu" disabled=""><span class="gs_wr"><span class="gs_ico"></span><span class="gs_lbl">Show more</span></span></button></div></div></form></div></div></div></div><div id="gs_ftr_sp" role="presentation"></div><div id="gs_ftr" role="contentinfo"><div id="gs_ftr_rt"><a href="/intl/en/scholar/about.html">Help</a><a href="//www.google.com/intl/en/policies/privacy/">Privacy</a><a href="//www.google.com/intl/en/policies/terms/">Terms</a></div></div></div></body></html>